Organic compounds

ABSTRACT

There are described cyclohexyl amide derivatives useful as corticotropin releasing factor (CRF 1 ) receptor antagonists.

FIELD OF THE INVENTION

The present invention relates to cyclohexyl amide derivatives, theirpreparation, their use as pharmaceuticals and pharmaceuticalcompositions containing them. More particularly the present inventionrelates to their use as corticotropin releasing factor (CRF-1) receptorantagonists.

SUMMARY OF THE INVENTION

In a first aspect of the invention we provide a compound of formula I;

in which R¹ is —(CH₂)_(n)(SO₂)_(m)R^(x);

R^(x) is phenyl, biphenyl, naphthyl or heteroaryl, each of which may beoptionally substituted by one or more substituents selected from thegroup alkyl C1 to 10, alkoxy C1 to 10, hydroxyalkyl C1 to 10, halogen,haloalkyl C1 to 10, haloalkoxy C1 to 10, nitrile, —CO₂R²⁵,—(CH₂)_(p)NR²⁹R³⁰, —SO₂NR³¹R³², alkoxy(C1 to 6)alkyl(C1 to 6)-, a 5- or6-membered heterocycle, a 5- or 6- membered heteroaryl, phenyl,phenylalkyl(C1 to 6)-aryloxy, each of the 5- or 6- membered heterocycle,5- or 6-membered heteroaryl, phenyl and aryloxy being optionallysubstituted by one or more substituents selected from the group,carboxy, alkyl C1 to 6, halogen and hydroxy;

R² is hydrogen or alkyl C1 to 6 or R¹ and R², together with the nitrogento which they are attached, form a 5- or 6-membered heteroarylcontaining 2, 3 or 4 heteroatoms, the heteroaryl being optionallysubstituted by one or more substituents selected from the group alkyl C1to 10, alkoxy C1 to 10, halogen, haloalkyl C1 to 10, haloalkoxy C1 to10, phenyl or a 5- or 6-membered heterocycle, said heterocycle beingoptionally substituted by carboxy;

R³, R⁴, R⁵, R⁶, R⁷, R⁹, R¹⁰, R¹⁷, R²², R²⁵, R²⁹, R³⁰, R³¹ and R³², whichmay be the same or different, are each hydrogen or alkyl C1 to 6;

R³⁰ is hydrogen, alkyl C1 to 6 or R³³CO—;

R³³ is alkyl C1 to 6;

R⁸ is phenyl or a heteroaryl, each of which may be optionallysubstituted by one or more substituents selected from the group alkyl C1to 6, haloalkyl C1 to 6, halogen, alkoxy C1 to 6, nitrile or dialkylamino C1 to 6 or two adjacent substituents may together form a saturatedor unsaturated carbocyclic or heterocyclic ring;

m is an integer 0 or 1;

n is an integer, 0, 1 or 2;

p is an integer from 0 to 6;

and isomers thereof;

in free form or in salt form.

For purposes of interpreting this specification, the followingdefinitions will apply and whenever appropriate, terms used in thesingular will also include the plural and vice versa.

As used herein, the term “alkyl” refers to a fully saturated, branchedor unbranched hydrocarbon moiety, i.e. primary, secondary or tertiaryalkyl or, where appropriate, cycloalkyl or alkyl substituted bycycloalkyl, they may also be saturated or unsaturated alkyl groups.Where not otherwise identified, preferably the alkyl comprises 1 to 20carbon atoms, more preferably 1 to 16 carbon atoms, 1 to 10 carbonatoms, 1 to 7 carbon atoms, or 1 to 4 carbon atoms. Representativeexamples of alkyl include, but are not limited to, methyl, ethyl,n-propyl, iso-propyl, n-butyl, sec-butyl, isobutyl, tert-butyl,n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl,2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl,n-decyl and the like.

As used herein, the term “haloalkyl” refers to an alkyl as definedherein, that is substituted by one or more halo groups as definedherein. Preferably the haloalkyl can be monohaloalkyl, dihaloalkyl orpolyhaloalkyl including perhaloalkyl. A monohaloalkyl can have one iodo,bromo, chloro or fluoro within the alkyl group. Dihaloalkyl andpolyhaloalkyl groups can have two or more of the same halo atoms or acombination of different halo groups within the alkyl. Preferably, thepolyhaloalkyl contains up to 12, or 10, or 8, or 6, or 4, or 3, or 2halo groups. Non-limiting examples of haloalkyl include fluoromethyl,difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl,trichloromethyl, pentafluoroethyl, heptafluoropropyl,difluorochloromethyl, dichlorofluoromethyl, difluoroethyl,difluoropropyl, dichloroethyl and dichloropropyl. A perhaloalkyl refersto an alkyl having all hydrogen atoms replaced with halo atoms.

As used herein, the term “alkoxy” refers to alkyl-O—, wherein alkyl isdefined herein above. Representative examples of alkoxy include, but arenot limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy,tert-butoxy, pentyloxy, hexyloxy, cyclopropyloxy-, cyclohexyloxy- andthe like. Preferably, alkoxy groups have about 1-7, more preferablyabout 1-4 carbons.

As used herein, the term “sulphonyl” refers to R—SO₂—, wherein R ishydrogen, alkyl, aryl, heteroaryl, aryl-alkyl, heteroaryl-alkyl, alkoxy,aryloxy, cycloalkyl, or heterocyclyl. As used herein, the term“heterocyclyl” or “heterocyclo” refers to an optionally substituted,saturated or unsaturated non-aromatic ring or ring system, e.g., whichis a 4-, 5-, 6-, or 7-membered monocyclic, 7-, 8-, 9-, 10-, 11-, or12-membered bicyclic or 10-, 11-, 12-, 13-, 14- or 15-membered tricyclicring system and contains at least one heteroatom selected from O, S andN, where the N and S can also optionally be oxidized to variousoxidation states. The heterocyclic group can be attached at a heteroatomor a carbon atom. The heterocyclyl can include fused or bridged rings aswell as spirocyclic rings. Examples of heterocycles includetetrahydrofuran (THF), dihydrofuran, 1,4-dioxane, morpholine,1,4-dithiane, piperazine, piperidine, 1,3-dioxolane, imidazolidine,imidazoline, pyrroline, pyrrolidine, tetrahydropyran, dihydropyran,oxathiolane, dithiolane, 1,3-dioxane, 1,3-dithiane, oxathiane,thiomorpholine, and the like.

The term “heterocyclyl” further refers to heterocyclic groups as definedherein substituted with 1, 2 or 3 substituents selected from the groupsconsisting of the following:

-   -   (a) alkyl;    -   (b) hydroxy (or protected hydroxy);    -   (c) halo;    -   (d) haloalkyl;    -   (e) oxo, i.e., ═O;    -   (f) amino, alkylamino or dialkylamino;    -   (g) alkoxy;    -   (h) cycloalkyl;    -   (i) carboxyl;    -   (j) heterocyclooxy, wherein heterocyclooxy denotes a        heterocyclic group bonded through an oxygen bridge;    -   (k) alkyl-O—C(O)—;    -   (l) mercapto;    -   (m) nitro;    -   (n) cyano;    -   (o) sulfamoyl or sulfonamido;    -   (p) aryl;    -   (q) alkyl-C(O)—O—;    -   (r) aryl-C(O)—O—;    -   (s) aryl-S—;    -   (t) aryloxy;    -   (u) alkyl-S—;    -   (v) formyl, i.e., HC(O)—;    -   (w) carbamoyl;    -   (x) aryl-alkyl-; and    -   (y) aryl substituted with alkyl, cycloalkyl, alkoxy, hydroxy,        amino, alkyl-C(O)—NH—, alkylamino, dialkylamino or halogen.

As used herein, the term “cycloalkyl” refers to saturated or unsaturatedmonocyclic, bicyclic or tricyclic hydrocarbon groups of 3-12 carbonatoms, preferably 3-9, or 3-7 carbon atoms, each of which can beoptionally substituted by one, or two, or three, or more substituents,such as alkyl, halo, oxo, hydroxy, alkoxy, alkyl-C(O)—, acylamino,carbamoyl, alkyl-NH—, (alkyl)₂N—, thiol, alkyl-S—, nitro, cyano,carboxy, alkyl-O—C(O)—, sulfonyl, sulfonamido, sulfamoyl, heterocyclyland the like. Exemplary monocyclic hydrocarbon groups include, but arenot limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl,cyclohexyl and cyclohexenyl and the like. Exemplary bicyclic hydrocarbongroups include bornyl, indyl, hexahydroindyl, tetrahydronaphthyl,decahydronaphthyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl,bicyclo[2.2.1]heptenyl, 6,6-dimethylbicyclo[3.1.1]heptyl,2,6,6-trimethylbicyclo[3.1.1]heptyl, bicyclo[2.2.2]octyl and the like.Exemplary tricyclic hydrocarbon groups include adamantyl and the like.

As used herein, the term “aryl” refers to an aromatic carbocyclic ringsystem containing 6 to 14 ring carbon atoms, which may be unsubstitutedor substituted as defined.

As used herein, the term “aryloxy” refers to both an —O-aryl and an—O-heteroaryl group, wherein aryl and heteroaryl are defined herein.

As used herein, the term “heteroaryl” refers to a 5-14 memberedmonocyclic- or bicyclic- or polycyclic-aromatic ring system, having 1 to8 heteroatoms selected from N, O or S. Preferably, the heteroaryl is a5-10 or 5-7 membered ring system. Typical heteroaryl groups include 2-or 3-thienyl, 2- or 3-furyl, 2- or 3-pyrrolyl, 2-, 4-, or 5-imidazolyl,3-, 4-, or 5-pyrazolyl, 2-, 4-, or 5-thiazolyl, 3-, 4-, or5-isothiazolyl, 2-, 4-, or 5-oxazolyl, 3-, 4-, or 5-isoxazolyl, 3- or5-1,2,4-triazolyl, 4- or 5-1,2,3-triazolyl, tetrazolyl, 2-, 3-, or4-pyridyl, 3- or 4-pyridazinyl, 3-, 4-, or 5-pyrazinyl, 2-pyrazinyl, 2-,4-, or 5-pyrimidinyl.

The term “heteroaryl” also refers to a group in which a heteroaromaticring is fused to one or more aryl, cycloaliphatic, or heterocyclylrings, where the radical or point of attachment is on the heteroaromaticring. Nonlimiting examples include but are not limited to 1-, 2-, 3-,5-, 6-, 7-, or 8-indolizinyl, 1-, 3-, 4-, 5-, 6-, or 7-isoindolyl, 2-,3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-indazolyl, 2-,4-, 5-, 6-, 7-, or 8-purinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, or9-quinolizinyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, 1-, 3-, 4-, 5-,6-, 7-, or 8-isoquinolinyl, 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl, 2-,3-, 4-, 5-, or 6-, naphthyridinyl, 2-, 3-, 5-, 6-, 7-, or8-quinazolinyl, 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl, 2-, 4-, 6-, or7-pteridinyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, or 8-4aH carbazolyl, 1-, 2-,3-, 4-, 5-, 6-, 7-, or 8-carbazolyl, 1-, 3-, 4-, 5-, 6-, 7-, 8-, or9-carbolinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or 10-phenanthridinyl, 1-,2-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-acridinyl, 1-, 2-, 4-, 5-, 6-, 7-, 8-,or 9-perimidinyl, 2-, 3-, 4-, 5-, 6-, 8-, 9-, or 10-phenathrolinyl, 1-,2-, 3-, 4-, 6-, 7-, 8-, or 9-phenazinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-,or 10-phenothiazinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or10-phenoxazinyl, 2-, 3-, 4-, 5-, 6-, or 1-, 3-, 4-, 5-, 6-, 7-, 8-, 9-,or 10-benzisoqinolinyl, 2-, 3-, 4-, or thieno[2,3-b]furanyl, 2-, 3-, 5-,6-, 7-, 8-, 9-, 10-, or 11-7H-pyrazino[2,3-c]carbazolyl, 2-, 3-, 5-, 6-,or 7-2H-furo[3,2-b]-pyranyl, 2-, 3-, 4-, 5-, 7-, or8-5H-pyrido[2,3-d]-o-oxazinyl, 1-, 3-, or 5-1H-pyrazolo[4,3-d]-oxazolyl,2-, 4-, or 54H-imidazo[4,5-d]thiazolyl, 3-, 5-, or8-pyrazino[2,3-d]pyridazinyl, 2-, 3-, 5-, or 6-imidazo[2,1-b]thiazolyl,1-, 3-, 6-, 7-, 8-, or 9-furo[3,4c]cinnolinyl, 1-, 2-, 3-, 4-, 5-, 6-,8-, 9-, 10, or 11-4H-pyrido[2,3-c]carbazolyl, 2-, 3-, 6-, or7-imidazo[1,2-b][1,2,4]triazinyl, 7-benzo[b]thienyl, 2-, 4-, 5-, 6-, or7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, 2-, 4-, 4-, 5-, 6-,or 7-benzothiazolyl, 1-, 2-, 4-, 5-, 6-, 7-, 8-, or 9-benzoxapinyl, 2-,4-, 5-, 6-, 7-, or 8-benzoxazinyl, 1-, 2-, 3-, 5-, 6-, 7-, 8-, 9-, 10-,or 11-1H-pyrrolo[1,2-b][2]benzazapinyl. Typical fused heteroaryl groupsinclude, but are not limited to 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl,1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl, 2-, 3-, 4-, 5-, 6-, or7-indolyl, 2-, 3-, 4-, 5-, 6-, 7-benzofuranyl, 2-, 4-, 5-, 6-, or7-benzo[b]thienyl, 2-, 4-, 5-, 6-, or 7-benzoxazolyl, 2-, 4-, 5-,6-benzimidazolyl, 2-, 4,5-, 6-, or 7-benzothiazolyl.

A heteroaryl group may be mono-, bi-, tri-, or polycyclic, preferablymono-, bi-, or tricyclic, more preferably mono- or bicyclic.

As used herein, the term “halogen” or “halo” refers to fluoro, chloro,bromo, and iodo.

The trans arrangement of the 1,4-cyclohexyl substituents —N(R⁷)C═OR⁸ and—CR³R⁴NR¹R² is preferred.

The term alkyl includes straight chain, branched or cyclic alkyl groups.The term haloalkyl includes mono- and poly-substituted e.g. mono-, di-or tri-halo substituted alkyl groups.

When R^(x) is a heteroaryl examples of such heteroaryls include,pyridine, pyrazole, thiazole, imidazole, pyrazine, pyrimidine,imidazole, triazole, thiadiazole, isoxazole, oxadiazole, quinoline,isoquinoline, indole, benzothiazole, isobenzofuran, benzoimidazole andbenzoxazole.

R² may be hydrogen.

R³ and R⁴ may each be hydrogen

R⁵ and R⁶, which may be the same or different, are each preferablyhydrogen or methyl.

R⁷ may be preferably hydrogen

R⁸ is preferably phenyl or 3-pyridyl and more preferably substitutedphenyl or 3-pyridyl, and especially disubstituted phenyl ordisubstituted 3-pyridyl, such as 2,5-disubstituted. Preferredsubstituents are halogen, such as Cl, or haloalkyl C1 to 10, such asCF₃, alkyl C1 to 6, alkoxy C1 to 6, trifluoralkoxy C1 to 6 anddimethylamino.

Specific compounds of formula I which may be mentioned include:

-   trans-3-methyl-N-(4-phenylaminomethyl-cyclohexyl)-benzamide;-   trans-3-chloro-N-(4-phenylaminomethyl-cyclohexyl)-benzamide;-   trans-N-(4-Phenylaminomethyl-cyclohexyl)-2-trifluoromethyl-benzamide;-   trans-3-cyano-N-(4-phenylaminomethyl-cyclohexyl)-benzamide;-   trans-3-methoxy-N-(4-phenylaminomethyl-cyclohexyl)-benzamide;-   trans-3-chloro-2-fluoro-N-(4-phenylaminomethyl-cyclohexyl)-6-trifluoromethyl-benzamide;-   trans-N-{4-[(4-chloro-phenylamino)-methyl]-cyclohexyl}-3-trifluoromethyl-benzamide;-   trans-N-[4-(p-tolylamino-methyl)-cyclohexyl]-3-trifluoromethyl-benzamide;-   trans-N-{4-[(3-chloro-4-methoxy-phenylamino)-methyl]-cyclohexyl}-3-trifluoromethyl-benzamide;-   trans-N-{4-[(4-isopropyl-phenylamino)-methyl]-cyclohexyl}-3-trifluoromethyl-benzamide;-   trans-N-{4-[(4-fluoro-phenylamino)-methyl]-cyclohexyl}-3-trifluoromethyl-benzamide;-   trans-3-trifluoromethyl-N-{4-[(4-trifluoromethyl-phenylamino)-methyl]-cyclohexyl}-benzamide;-   trans-N-{4-[(4-cyano-phenylamino)-methyl]-cyclohexyl}-3-trifluoromethyl-benzamide;-   trans-N-{4-[(3-chloro-cyano-phenylamino)-methyl]-cyclohexyl}-3-trifluoromethyl-benzamide;-   trans-N-[4-(naphthalen-1-ylaminomethyl)-cyclohexyl]-3-trifluoromethyl-benzamide;-   trans-N-{4-[(3-cyano-phenylamino)-methyl]-cyclohexyl}-3-trifluoromethyl-benzamide;-   trans-N-{4-[(3-methoxy-phenylamino)-methyl]-cyclohexyl}-3-trifluoromethyl-benzamide;-   trans-N-[4-(quinolin-5-ylaminomethyl)-cyclohexyl]-3-trifluoromethyl-benzamide;-   trans-N-[4-(quinolin-6-ylaminomethyl)-cyclohexyl]-3-trifluoromethyl-benzamide;-   trans-N-{4-[(4-cyano-3-trifluoromethyl-phenylamino)-methyl]-cyclohexyl}-3-trifluoro    methyl-benzamide;-   trans-N-{4-[(4-morpholin-4-yl-phenylamino)-methyl]-cyclohexyl}-3-trifluoromethyl-benzamide;-   trans-2-chloro-N-(4-phenylaminomethyl-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-[4-([1,3,4]thiadiazol-2-ylaminomethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(5-methyl-1H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(4-methyl-thiazol-2-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(1H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(2-methyl-1H-indol-5-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-5-trifluoromethyl-N-{4-[(1,3,5-trimethyl-1H-pyrazol-4-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-N-[4-(benzothiazol-2-ylaminomethyl)-cyclohexyl]-2-chloro-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-(4-{[(5-phenyl-4H-[1,2,4]triazol-3-ylmethyl)-amino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(1,3-dihydro-isobenzofuran-5-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-(4-{[(2-phenyl-2H-[1,2,3]triazol-4-ylmethyl)-amino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide;    trans-2-chloro-N-(4-{[5-(4-fluoro-phenyl)-2H-pyrazol-3-ylamino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(2-methyl-3H-benzoimidazol-5-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(1-methyl-1H-benzoimidazol-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(1-methyl-1H-[1,2,4]triazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(5-propyl-1H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(5-isopropyl-1H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(5-cyclopropyl-2H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(5,6-dimethyl-1H-benzoimidazol-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-N-(4-{[(benzooxazol-2-ylmethyl)-amino]-methyl}-cyclohexyl)-2-chloro-5-trifluoromethyl-benzamide;-   trans-N-{4-[(1H-benzoimidazol-2-ylamino)-methyl]-cyclohexyl}-2-chloro-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-[4-(pyridin-3-ylaminomethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-N-{4-[(4-tert-butyl-phenylamino)-methyl]-cyclohexyl}-2-chloro-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(3,4-dimethoxy-phenylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-N-{4-[(3-bromo-4-methyl-phenylamino)-methyl]-cyclohexyl}-2-chloro-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-(4-{[methyl-(3-phenyl-[1,2,4]oxadiazol-5-ylmethyl)-amino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-(4-{[methyl-(4-methyl-thiazol-2-ylmethyl)-amino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(methyl-phenyl-amino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-(4-{[methyl-(5-phenyl-1H-pyrazol-3-ylmethyl)-amino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-(4-{[methyl-(2-methyl-thiazol-4-ylmethyl)-amino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-(4-{[methyl-(3-phenyl-isoxazol-5-ylmethyl)-amino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(3-methoxy-4-methyl-phenylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(6-methyl-quinolin-5-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(2,6-dimethyl-quinolin-5-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-(4-{[(2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-amino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-[4-(quinolin-8-ylaminomethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-[4-(quinolin-6-ylaminomethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(2-sulfamoyl-phenylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(4-methyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-[4-(isoquinolin-1-ylaminomethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(6-chloro-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(5-ethyl-[1,3,4]thiadiazol-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(5-methyl-thiazol-2-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(4,6-dimethyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(6-methoxy-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(3-methyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(5-methyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(6-methyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(4,6-dimethoxy-pyrimidin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-[4-(thiazol-2-ylaminomethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(5-cyclopropyl-[1,3,4]thiadiazol-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(2-fluoro-phenylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(2,4-difluoro-phenylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(2-fluoro-5-methyl-phenylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(2-chloro-5-methyl-phenylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(2-methoxy-phenylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(3-cyano-phenylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(3-fluoro-phenylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(3-chloro-phenylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-5-trifluoromethyl-N-{4-[(3-trifluoromethyl-phenylamino)-methyl]-cyclohexyl}-benzamide;-   trans-2-chloro-N-{4-[(3,4-dimethyl-phenylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(3,5-dimethyl-phenylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(4-methoxy-phenylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(4-ethoxy-phenylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(2-chloro-phenylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(3-isopropoxy-phenylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(1H-indol-5-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-N-[4-(benzo[1,3]dioxol-5-ylaminomethyl)-cyclohexyl]-2-chloro-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-[4-(quinolin-6-ylaminomethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(4-trifluoromethoxy-phenylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(3-trifluoromethoxy-phenylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(4,5-dimethyl-thiazol-2-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-N-{4-[(2-benzenesulfonyl-ethylamino)-methyl]-cyclohexyl}-2-chloro-5-trifluoro    methyl-benzamide;-   trans-N-{4-[(5-tert-butyl-isoxazol-3-ylamino)-methyl]-cyclohexyl}-2-chloro-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-(4-{[(5-phenyl-isoxazol-3-ylmethyl)-amino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-(4-{[(3-phenyl-[1,2,4]oxadiazol-5-ylmethyl)-amino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-(4-{[(3-phenyl-isoxazol-5-ylmethyl)-amino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(3,5-dimethyl-isoxazol-4-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(4-fluoro-3-trifluoromethyl-phenylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(6-phenoxy-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(8-methyl-quinolin-5-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   2-chloro-N-(2-methyl-4-phenylaminomethyl-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-N-{4-[3-(2-oxo-imidazolidin-1-yl)-pyrazol-1-ylmethyl]-cyclohexyl}-3-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[3-(2-oxo-imidazolidin-1-yl)-pyrazol-1-ylmethyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-methyl-N-(4-phenylaminomethyl-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2,5-dichloro-N-[4-(pyridin-3-ylaminomethyl)-cyclohexyl]-benzamide;-   trans-2,5-dichloro-N-{4-[(6-trifluoromethyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-2,5-dichloro-N-{4-[(6-cyano-pyridin-3-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-N-{4-[(6-acetylamino-pyridin-3-ylamino)-methyl]-cyclohexyl}-2,5-dichloro-benzamide;-   trans-2,5-dichloro-N-{4-[(6-methoxy-pyridin-3-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-2,5-dichloro-N-{4-[(6-chloro-pyridin-3-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-2,5-dichloro-N-{4-[(6-morpholin-4-yl-pyridin-3-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-2,5-dichloro-N-(4-{[5-(4-fluoro-phenyl)-2H-pyrazol-3-ylamino]-methyl}-cyclohexyl)-benzamide;-   trans-2-chloro-N-{4-[(4,5-dimethyl-thiazol-2-ylamino)-methyl]-cyclohexyl}-5-methyl-benzamide;-   trans-N-[4-(benzothiazol-2-ylaminomethyl)-cyclohexyl]-2,5-Dichloro-benzamide;-   trans-2,5-dichloro-N-{4-[(1-methyl-1H-benzoimidazol-2-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-2-chloro-N-{4-[(2-methyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(6-methyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(5-methyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(4-methyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2,5-dichloro-N-{4-[(5-cyclopropyl-2H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-2,5-dichloro-N-{4-[(4,5-dimethyl-thiazol-2-ylamino)-methyl]-cyclohexyl}-nicotinamide;-   trans-2,5-dichloro-N-(4-{[methyl-(5-phenyl-2H-pyrazol-3-ylmethyl)-amino]-methyl}-cyclohexyl)-benzamide;-   trans-2-chloro-N-{4-[(4,5-dimethyl-thiazol-2-ylamino)-methyl]-cyclohexyl}-5-methoxy-benzamide;-   trans-2-chloro-N-[4-(pyridin-2-ylaminomethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(5-chloro-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-5-trifluoromethyl-N-{4-[(5-trifluoromethyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-2,5-dichloro-N-{4-[(5-propyl-2H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-2-chloro-5-trifluoromethyl-N-{4-[(6-trifluoromethyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-2,5-dichloro-N-{4-[(6-trifluoromethyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-2,5-dichloro-N-{4-[(6-methyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-2,5-dichloro-N-{4-[(5-methyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-2,5-dichloro-N-{4-[(4,6-dimethyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-2-chloro-N-{4-[(6-methoxy-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2,5-dichloro-N-[4-(pyrazin-2-ylaminomethyl)-cyclohexyl]-benzamide;-   trans-2-chloro-6-methyl-N-(4-phenylaminomethyl-cyclohexyl)-nicotinamide;-   trans-5-methyl-N-(4-phenylaminomethyl-cyclohexyl)-nicotinamide;-   trans-3H-indole-5-carboxylic acid    (4-phenylaminomethyl-cyclohexyl)-amide;-   trans-2-methyl-N-(4-phenylaminomethyl-cyclohexyl)-benzamide;-   trans-2,3-dimethyl-N-(4-phenylaminomethyl-cyclohexyl)-benzamide;-   trans-3-chloro-4-methyl-N-(4-phenylaminomethyl-cyclohexyl)-benzamide;-   trans-2,5-dichloro-N-(4-phenylaminomethyl-cyclohexyl)-benzamide;-   trans-4-fluoro-N-(4-phenylaminomethyl-cyclohexyl)-3-trifluoromethyl-benzamide;-   trans-5-fluoro-N-(4-phenylaminomethyl-cyclohexyl)-2-trifluoromethyl-benzamide;-   trans-2,5-dichloro-N-(4-phenylaminomethyl-cyclohexyl)-isonicotinamide;-   trans-benzofuran-5-carboxylic acid    (4-phenylaminomethyl-cylcohexyl)-amide;-   trans-3-fluoro-N-(4-phenylaminomethyl-cyclohexyl)-benzamide;-   trans-N-{4-[(4-Methoxy-phenylamino)-methyl]-cyclohexyl}-3-trifluoromethyl-benzamide;-   trans-N-(4-phenylaminomethyl-cyclohexyl)-3-trifluoromethyl-benzamide;-   trans-2,5-dichloro-N-{4-[3-(2-oxo-imidazolidin-1-yl)-pyrazol-1-ylmethyl]-cyclohexyl}-benzamide;-   trans-2-chloro-N-{4-[(5-ethyl-2H-pyrazol-3-ylamino)-methyl]cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-5-chloro-N-{4-[(4,5-dimethyl-thiazol-2-ylamino)-methyl]-cyclohexyl}-2-methoxy-nicotinamide;-   trans-5-chloro-N-{4-[(4,5-dimethyl-thiazol-2-ylamino)-methyl]-cyclohexyl}-2-methyl-nicotinamide;-   trans-2-chloro-N-[4-(pyrimidin-2-ylaminomethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-2,5-dichloro-N-{4-[(5-trifluoromethyl-1H-indazol-3-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-5-chloro-2-dimethylamino-N-{4-[(4,5-dimethyl-thiazol-2-ylamino)-methyl]-cyclohexyl}-nicotinamide;-   cis-2-chloro-N-(4-{[5-(4-fluoro-phenyl)-2H-pyrazol-3-ylamino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-6-chloro-benzofuran-5-carboxylic acid    {4-[(4,5-dimethyl-thiazol-2-ylamino)-methyl]-cyclohexyl}-amide;-   trans-N-{4-[(4,5-dimethyl-thiazol-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-nicotinamide;-   trans-2,5-dichloro-N-{4-[5-methyl-3-(2-oxo-imidazolidin-1-yl)-pyrazol-1-ylmethyl]-cyclohexyl}-benzamide;-   cis-2-chloro-N-{4-[(4-methyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-N-{4-[(4,5-dimethyl-thiazol-2-ylamino)-methyl]-cyclohexyl}-2-fluoro-5-trifluoro    methyl-benzamide;-   trans-5-chloro-N-{4-[(4,5-dimethyl-thiazol-2-ylamino)-methyl]-cyclohexyl}-2-fluoro-benzamide;-   trans-2-chloro-N-[4-(1-phenylamino-ethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(5-fluoro-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(5-fluoro-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(3,5-difluoro-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-5-trifluoromethyl-N-{4-[(4-trifluoromethyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-2-chloro-5-trifluoromethyl-N-{4-[(5-trifluoromethyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-2-chloro-N-{4-[(2-methoxy-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(5-chloro-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(4-methyl-pyrimidin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(4,6-dimethyl-pyrimidin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2,5-dichloro-N-{4-[(5-fluoro-pyridin-3-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-2,5-dichloro-N-{4-[(5-fluoro-pyridin-2-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-2,5-dichloro-N-{4-[(3,5-difluoro-pyridin-2-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-2-chloro-N-{4-[(6-dimethylamino-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(5-dimethylamino-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-6-{[4-(2-chloro-5-trifluoromethyl-benzoylamino)-cyclohexylmethyl]-amino}-nicotinic    acid methyl ester;-   trans-2-chloro-N-(4-{[5-(4-fluoro-phenyl)-1H-pyrazol-3-ylamino]-methyl}-3-methyl-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-[4-((S)-1-phenylamino-ethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-[4-((R)-1-phenylamino-ethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(3,5-dimethyl-pyrazin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-5-chloro-2-dimethylamino-N-{4-[(4,5-dimethyl-thiazol-2-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-chloro-N-{4-[(5-hydroxymethyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-dimethylamino-N-{4-[(4,5-dimethyl-thiazol-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-nicotinamide;-   trans-6-{[4-(2-chloro-5-trifluoromethyl-benzoylamino)-cyclohexylmethyl]-amino}-nicotinic    acid;-   trans-5-chloro-N-{4-[(5-cyclopropyl-2H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-2-methyl-nicotinamide;-   trans-2-chloro-N-{4-[(5-dimethylaminomethyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2,5-dichloro-N-{4-[(3,5-dimethyl-1H-pyrazol-4-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-2,5-dichloro-N-{4-[(5-cyclopropyl-2-methyl-2H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-2,5-dichloro-N-{4-[(1-propyl-1H-pyrazol-4-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-N-{4-[(6-bromo-pyridin-2-ylamino)-methyl]-cyclohexyl}-2-chloro-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(5-fluoro-4-methyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-5-chloro-2-methyl-N-{4-[(5-methyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-nicotinamide;-   trans-5-chloro-N-{4-[(4,6-dimethyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-2-methyl-nicotinamide;-   trans-5-chloro-N-{4-[(5-fluoro-pyridin-3-ylamino)-methyl]-cyclohexyl}-2-methyl-nicotinamide;-   trans-5-chloro-2-methyl-N-{4-[(3-methyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-nicotinamide;-   trans-5-chloro-2-methyl-N-{4-[(1-methyl-1H-benzoimidazol-2-ylamino)-methyl]-cyclohexyl}-nicotinamide;-   trans-5-chloro-2-methyl-N-[4-(pyrimidin-2-ylaminomethyl)-cyclohexyl]-nicotinamide;-   trans-5-chloro-2-dimethylamino-N-{4-[(5-methyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-nicotinamide;-   trans-2-methyl-N-{4-[(5-methyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-nicotinamide;-   trans-2,5-dimethyl-N-{4-[(5-methyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-nicotinamide;-   trans-5-chloro-2-dimethylamino-N-{1,4-[(4,6-dimethyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-nicotinamide;-   trans-N-{4-[(4,6-dimethyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-2-methyl-5-trifluoro    methyl-nicotinamide;-   trans-5-chloro-2-dimethylamino-N-{4-[(5-fluoro-pyridin-3-ylamino)-methyl]-cyclohexyl}-nicotinamide;-   trans-N-{4-[(5-fluoro-pyridin-3-ylamino)-methyl]-cyclohexyl}-2-methyl-5-trifluoro    methyl-nicotinamide;-   trans-N-{4-[(5-fluoro-pyridin-3-ylamino)-methyl]-cyclohexyl}-2,5-dimethyl-nicotinamide;-   trans-2,5-dichloro-N-{4-[(5-propyl-2H-[1,2,4]triazol-3-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-2-chloro-N-{4-[5-methyl-3-(2-oxo-imidazolidin-1-yl)-pyrazol-1-ylmethyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[2-(4,6-dimethyl-pyridin-2-ylamino)-ethyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(5-fluoro-6-methyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(2,6-dimethyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   2-dimethylamino-N-{4-[(4,6-dimethyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-nicotinamide;-   trans-2-chloro-N-{4-[(5-hydroxymethyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(2,4-dimethyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(4,6-dimethyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-(4-{[5-(4-fluoro-phenyl)-1H-pyrazol-3-ylamino]-methyl}-3-methyl-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(5-fluoromethyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(4,5,6,7-tetrahydro-1H-indazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(5-ethyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(1H-pyrazol-4-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(1H-indazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(5-ethyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-5-chloro-N-{4-[(5-fluoro-4-methyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-2-methyl-nicotinamide;-   trans-5-chloro-2-methyl-N-{4-[(4,5,6,7-tetrahydro-1H-indazol-3-ylamino)-methyl]-cyclohexyl}-nicotinamide;-   trans-2-chloro-N-{4-[(2-methoxy-5-methyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(1H-pyrazolo[3,4-b]pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-5-trifluoromethyl-N-{4-[(5-trifluoromethyl-1H-indazol-3-ylamino)-methyl]-cyclohexyl}-benzamide;-   trans-2-chloro-N-{4-[(5-methyl-1H-indazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(5,5-dimethyl-4,5,6,7-tetrahydro-1H-indazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(6-methyl-1H-indazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(5-fluoro-1H-indazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(4-fluoro-1H-indazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(4,6-dimethyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-isopropyl-nicotinamide;-   trans-2-chloro-N-{4-[(4-methyl-1H-indazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(5-chloro-1H-indazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(5,6-dimethoxy-1H-indazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(6-methoxy-1H-indazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(5-chloro-4-methyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(1-methyl-1H-indazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(5-methyl-4-phenyl-2H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-N-{4-[(5-benzyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-ylamino)-methyl]-cyclohexyl}2-chloro-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-(4-indazol-1-ylmethyl-cyclohexyl)-5-trifluoromethyl-benzamide-   trans-2-chloro-N-(4-indazol-2-ylmethyl-cyclohexyl)-5-trifluoromethyl-benzamide-   trans-2-chloro-N-{4-[(5-chloro-2-methyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(6-methyl-1H-pyrazolo[3,4-b]pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(5-chloro-6-methyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   N-{4-[(4-bromo-5-propyl-1H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-2-chloro-5-trifluoromethyl-benzamide;-   N-[4-(3-amino-4-chloro-indazol-1-ylmethyl)-cyclohexyl]-2-chloro-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-[4-(imidazo[1,2-b]pyridazin-3-ylaminomethyl)-cyclohexyl]-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(4,6-dihydro-1H-thieno[3,4c]pyrazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(4-methyl-5-phenyl-1H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-(4-{[4-(4-chloro-phenyl)-1H-pyrazol-3-ylamino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide;-   N-{4-[(7-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-methyl]-cyclohexyl}-2-chloro-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(1-methyl-1H-pyrazolo[3,4-b]pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-5-chloro-N-{4-[(5-chloro-4-methyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-2-methyl-nicotinamide;-   trans-2-chloro-N-[4-(pyrazolo[1,5-a]pyridin-3-ylaminomethyl)-cyclohexyl]-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-(4-{[4-(2,4-dichloro-phenyl)-1H-pyrazol-3-ylamino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-5-chloro-2-methyl-N-{4-[(4-trifluoromethyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-nicotinamide;-   trans-5-chloro-2-methyl-N-{4-[(5-trifluoromethyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-nicotinamide;-   trans-2-chloro-N-{4-[(5-phenyl-4-propyl-2H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-[4-(3,5-dimethyl-[1,2,4]triazol-1-ylmethyl)-cyclohexyl]-5-trifluoro    methyl-benzamide;-   N-{4-[(6-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-methyl]-cyclohexyl}-2-chloro-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(4,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-5-chloro-N-{4-[(1H-indazol-3-ylamino)-methyl]-cyclohexyl}-2-methyl-nicotinamide;-   trans-2-chloro-N-[4-(3,5-dimethyl-pyrazol-1-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-5-chloro-2-methyl-N-{4-[(1H-pyrazolo[3,4-b]pyridin-3-ylamino)-methyl]-cyclohexyl}-nicotinamide;-   trans-2-chloro-N-(4-{[4-(4-chloro-phenyl)-5-methyl-1H-pyrazol-3-ylamino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-(4-{[5-chloro-3-(4-hydroxy-cyclohexyl)-3H-imidazo[4,5-b]pyridin-2-ylamino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(1H-pyrazolo[4,3-b]pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(4-phenyl-1H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(6-fluoro-1H-pyrazolo[4,3-b]pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-5-chloro-2-methyl-N-{4-[(5-methyl-4-phenyl-2H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-nicotinamide;-   trans-2-chloro-N-{4-[(5-pyridin-3-yl-2H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(3-chloro-6-methoxy-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(5-chloro-6-methoxy-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(1-phenyl-1H-tetrazol-5-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(1-methyl-4-phenyl-1H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-[4-(5-methyl-tetrazol-2-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-[4-(5-cyclopropyl-tetrazol-2-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(3,4-dimethyl-isoxazol-5-ylamino)-methyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[(4-pyridin-3-yl-2H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(5-chloro-6-d3-methyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-[4-(3-phenyl-pyrazol-1-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-5-chloro-N-[4-(3,5-dimethyl-pyrazol-1-ylmethyl)-cyclohexyl]-2-methyl-nicotinamide;-   trans-2-chloro-N-(4-{[4-(4-fluoro-phenyl)-5-methyl-1H-pyrazol-3-ylamino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-[4-(4-phenyl-pyrazol-1-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(1H-pyrazolo[3,4-b]pyrazin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-5-chloro-2-methyl-N-{4-[(5-trifluoromethyl-2H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-nicotinamide;-   trans-2-chloro-N-[4-(4-chloro-3,5-dimethyl-pyrazol-1-ylmethyl)-cyclohexyl]-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-[4-(3-ethoxy-5-methyl-[1,2,4]triazol-1-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-[4-(5-ethoxy-3-methyl-[1,2,4]triazol-1-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-2-chloro-5-trifluoromethyl-N-[4-(3,4,5-trimethyl-pyrazol-1-ylmethyl)-cyclohexyl]-benzamide;-   trans-5-chloro-N-{4-[(5-fluoro-pyridin-2-ylamino)-methyl]-cyclohexyl}-2-methyl-nicotinamide;-   trans-2-chloro-N-{4-[(5-chloro-6-methoxy-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-5-chloro-2-methyl-N-{4-[(5-propyl-1H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-nicotinamide;-   trans-2-chloro-5-trifluoromethyl-N-[4-(3-trifluoromethyl-pyrazol-1-ylmethyl)-cyclohexyl]-benzamide;-   trans-2-chloro-N-(4-{[4-(4-chloro-phenyl)-3-methyl-isoxazol-5-ylamino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(5-methoxymethyl-4H-[1,2,4]triazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(trans-5-chloro-2-methoxy-pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(4-chloro-5-methyl-2H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(4-cyano-5-methyl-2H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-(4-{[2-(4-chloro-phenyl)-5-methyl-2H-pyrazol-3-ylamino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-[4-(3-methyl-5-trifluoromethyl-pyrazol-1-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-[4-(5-methyl-3-trifluoromethyl-pyrazol-1-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(5-ethyl-4-methyl-1H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-(4-imidazol-1-ylmethyl-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-[4-(2-methyl-4-trifluoromethyl-imidazol-1-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(1-methyl-1H-pyrazolo[4,3-b]pyridin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-[4-([1,2,4]triazolo[4,3-a]pyridin-3-ylaminomethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-(4-{[4-(4-chloro-phenyl)-isoxazol-3-ylamino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-5-chloro-N-[4-(4-chloro-3,5-dimethyl-pyrazol-1-ylmethyl)-cyclohexyl]-2-methyl-nicotinamide;-   trans-2-chloro-N-[4-(2-methyl-imidazol-1-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-5-chloro-N-{4-[(5-chloro-2-methoxy-pyridin-3-ylamino)-methyl]-cyclohexyl}-2-methyl-nicotinamide;-   trans-5-chloro-2-methyl-N-[4-(3,4,5-trimethyl-pyrazol-1-ylmethyl)-cyclohexyl]-nicotinamide;-   trans-2-chloro-N-(4-{[4-(3,4-dimethoxy-phenyl)-2,5-dimethyl-2H-pyrazol-3-ylamino]-methyl}cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-(4-{[4-(2-chloro-phenyl)-1H-pyrazol-3-ylamino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-[4-(3,5-di-(d3)-methyl-pyrazol-1-ylmethyl)-cyclohexyl]-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-[4-(5-methyl-pyrazol-1-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-[4-(3-methyl-pyrazol-1-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[5-(4-methoxy-phenyl)-pyrazol-1-ylmethyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-{4-[3-(4-methoxy-phenyl)-pyrazol-1-ylmethyl]-cyclohexyl}-5-trifluoro    methyl-benzamide;-   trans-2-chloro-N-(4-{[1-(4-chloro-benzyl)-1H-tetrazol-5-ylamino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide;-   trans-2-chloro-N-{4-[(4-chloro-5-methoxy-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide;-   trans-5-chloro-2-methyl-N-[4-(3-methyl-5-trifluoromethyl-pyrazol-1-ylmethyl)-cyclohexyl]-nicotinamide;    and-   trans-5-chloro-2-methyl-N-[4-(5-methyl-3-trifluoromethyl-pyrazol-1-ylmethyl)-cyclohexyl]-nicotinamide;

and isomers thereof;

in free or in salt form.

Therefore, according to a further aspect of the invention we provide acompound of formula I as hereinbefore described as a medicament. Moreparticularly, we provide a compound of formula I as hereinbeforedescribed as a corticotropin releasing factor (CRF-1) receptorantagonist.

According to a further aspect of the invention we provide the use of acompound of formula I as hereinbefore described in the manufacture of amedicament. More particularly, we provide the use as hereinbeforedescribed in the manufacture of a medicament for a corticotropinreleasing factor (CRF-1) receptor antagonist.

Furthermore it has now been found that the compounds of formula I, or asalt thereof, behave as CRF-1 receptor antagonists. Representativecompounds of the invention have no significant agonist or antagonistactivity at melanin concentrating hormone receptor 1 (MCH-1) or MCH-2.

The activity of a compound according to the present invention can beassessed by the following in vitro & in vivo methods.

The CRF-1 or CRF-2α receptor antagonistic activity of the agents of theinvention has been determined in vitro in the following assay:

Chinese hamster ovary (CHO) cells expressing either the humanrecombinant CRF-1 or CRF-2a receptors (Chen et al., Proc Natl Acad SciUSA 90, 8967-8971, 1993; Liaw et al., Endocrinology 137, 72-77, 1996)are propagated in Dulbecco's modified Eagle medium supplemented with 10%foetal calf serum, non-essential amino acids, 100 U/ml penicillin, 100mg/l streptomycin and 1 g/l geneticin (G418). For cyclic AMPdeterminations the Homogeneous Time-Resolved Fluoresce (HTRF) cAMPdynamic 2 kit (Cisbio International, France) was used as permanufacturers' instructions. CHO cells, previously cryopreserved, werethawed, centrifuged for 7 mins at 1200 rpm and resuspended in serum freemedia, then pipetted out onto clear bottomed black tissue culturetreated 384-well microtitre plates (Corning Inc, US) at 2,000 cells perwell. Compounds of the invention, prepared in DMSO, and subsequentlydiluted 50 fold in assay buffer (1× Hanks balanced salt solution, 0.2%(w/v) bovine serum albumin, 1.7 mM isobutylmethylxanthine and 10 mMHepes, pH 7.4) are then added onto the cell containing plate where afurther 2 fold dilution is performed and incubated for 15 min. Followingincubation, buffer containing a 5 times final concentration of agonistis added to the plate and incubated for 30 min. Finally, d2 dye labelledcAMP and cryptate labeled anti-cAMP antibody, both made in lysis buffer,are added to the plate followed by a settling period of 1 hour. Duringthe settling period cAMP produced by the cells competes with the d2labelled cAMP for the anti-cAMP cryptate. The plate is read on thePherastar (BMG, Germany). Increasing levels of endogenous cAMP producedby cells can be followed by a decrease of fluorescent signal and viceversa. Values represented by a change in arbitrary fluorescence unitsare converted into cAMP concentrations by use of a standard curve thereagents for which are supplied with the kit. Antagonist dose responsecurves (1 nM-30 μM) are constructed in the presence of 1 nM CRF. IC50values of antagonists are calculated by fitting the percent inhibitionof the effect of CRF by increasing concentrations of the antagonists.The fit is performed using the nonlinear logistic function of theActivitybase software package v 5.4.5.27 (IDBS, UK).

In this test, the agents of the invention show CRF, antagonisticactivity with IC50 CRF, values of about 1 nM to 10 μM, preferably about1 to 500 nM. Specific data are provided in Table 1 herein.

Compounds of the invention are useful for the treatment of any statewith increased endogenous levels of CRF (corticotropin releasing factor)or in which the HPA (hypothalamic pituitary axis) is disregulated, or ofvarious diseases induced or facilitated by CRF.

Compounds of the invention are in particular useful for the treatment orprevention of gastrointestinal disorders including irritable bowelsyndrome with or without diarrhea, inflammatory bowel diseases,post-operative ileus, reflux disease and infectious diarrhea.

Compounds of the invention are also in particular useful for thetreatment or prevention of major depressive disorders including bipolardepression, unipolar depression, single or recurrent major depressiveepisodes with or without psychotic features, catatonic features,melancholic features, atypical features or postpartum onset, thetreatment of anxiety and the treatment of panic disorders. Other mooddisorders encompassed within the term major depressive disorders includefatigue syndrome and dysthymic disorder with early or late onset andwith or without atypical features, neurotic depression, post traumaticstress disorders, post operative stress and social phobia; dementia ofthe Alzheimer's type, with early or late onset, with depressed mood;vascular dementia with depressed mood; mood disorders induced byalcohol, amphetamines, cocaine, hallucinogens, inhalants, opioids,phencyclidine, sedatives, hypnotics, anxiolytics and other substances;schizoaffective disorder of the depressed type; and adjustment disorderwith depressed mood. Major depressive disorders may also result from ageneral medical condition including, but not limited to, myocardialinfarction, diabetes, miscarriage or abortion, etc.

Compounds of the invention are also useful in the treatment orprevention of schizophrenic disorders including paranoid schizophrenia,disorganized schizophrenia, catatonic schizophrenia, undifferentiatedschizophrenia, residual schizophrenia.

Compounds of the invention are also useful in the treatment orprevention of neurodegenerative diseases such as Alzheimer's disease,Parkinson's disease, Huntington's disease, senile dementia of theAlzheimer's type, and multiinfarct dementia.

Compounds of the invention are useful as analgesics. In particular theyare useful in the treatment of traumatic pain such as postoperativepain; traumatic avulsion pain such as brachial plexus; chronic pain suchas arthritic pain such as occurring in osteo-, rheumatoid or psoriaticarthritis; neuropathic pain such as post-herpetic neuralgia, trigeminalneuralgia, segmental or intercostal neuralgia, fibromyalgia, causalgia,peripheral neuropathy, diabetic neuropathy, chemotherapy-inducedneuropathy, AIDS related neuropathy, occipital neuralgia, geniculateneuralgia, glossopharyngeal neuralgia, reflex sympathetic dystrophy,phantom limb pain; various forms of headache such as migraine, acute orchronic tension headache, temporomandibular pain, maxillary sinus pain,cluster headache; odontalgia; cancer pain; pain of visceral origin;gastrointestinal pain; nerve entrapment pain; sport's injury pain;dysmennorrhoea; menstrual pain; meningitis; arachnoiditis;musculoskeletal pain; low back pain e.g. spinal stenosis; prolapseddisc; sciatica; angina; ankylosing spondyolitis; gout; burns; scar pain;itch; and thalamic pain such as post stroke thalamic pain.

Compounds of the invention are also useful for the treatment ofdysfunction of appetite and food intake and in circumstances such asanorexia, anorexia nervosa, bulimia, obesity and metabolic syndrome.

Compounds of the invention are also useful in the treatment of sleepdisorders including dysomnia, insomnia, sleep apnea, narcolepsy, andcircadian rhythmic disorders.

Compounds of the invention are also useful in the treatment orprevention of cognitive disorders. Cognitive disorders include dementia,amnestic disorders and cognitive disorders not otherwise specified.

Furthermore compounds of the invention are also useful as memory and/orcognition enhancers in healthy humans with no cognitive and/or memorydeficit.

Compounds of the invention are also useful in the treatment of toleranceto and dependence on a number of substances. For example, they areuseful in the treatment of dependence on nicotine, alcohol, caffeine,phencyclidine (phencyclidine like compounds), or in the treatment oftolerance to and dependence on opiates (e.g. cannabis, heroin, morphine)or benzodiazepines; in the treatment of cocaine, sedative ipnotic,amphetamine or amphetamine-related drugs (e.g. dextroamphetamine,methylamphetamine) addiction or a combination thereof.

Compounds of the invention are also useful as anti-inflammatory agents.In particular they are useful in the treatment of inflammation inasthma, influenza, chronic bronchitis and rheumatoid arthritis; in thetreatment of inflammatory diseases of the gastrointestinal tract such asCrohn's disease, ulcerative colitis, postoperative gastric ileus (POI),inflammatory bowel disease (IBD) and non-steroidal anti-inflammatorydrug induced damage; inflammatory diseases of the skin such as herpesand eczema; inflammatory diseases of the bladder such as cystitis andurge incontinence; and eye and dental inflammation.

Compounds of the invention are also useful in the treatment of fertilityproblems, sexual dysfunctions and pre-term birth and non-inflammatoryurogenital disorders such as overactive bladder and related urinaryincontinence.

Compounds of the invention are also useful in the treatment of allergicdisorders, in particular allergic disorders of the skin such asurticaria, and allergic disorders of the airways such as rhinitis.

Compounds of the invention are also useful in the treatment of mast cellactivation disorders such as mastocytosis.

Compounds of the invention are also useful the treatment of Cushing'ssyndrome induced by drugs such as steroids or cancer such as pituitaryadenoma.

Compounds of the invention are also useful in the treatment of emesis,i.e. nausea, retching and vomiting. Emesis includes acute emesis,delayed emesis and anticipatory emesis. The compounds of the inventionare useful in the treatment of emesis however induced. For example,emesis may be induced by drugs such as cancer chemotherapeutic agentssuch as alkylating agents, e.g. cyclophosphamide, carmustine, lomustineand chlorambucil; cytotoxic antibiotics, e.g. dactinomycin, doxorubicin,mitomycin-C and bleomycin; anti-metabolites, e.g. cytarabine,methotrexate and 5-fluorouracil; vinca alkaloids, e.g. etoposide,vinblastine and vincristine; and others such as cisplatin, dacarbazine,procarbazine and hydroxyurea; and combinations thereof; radiationsickness; radiation therapy, e.g. irradiation of the thorax or abdomen,such as in the treatment of cancer; poisons; toxins such as toxinscaused by metabolic disorders or by infection, e.g. gastritis, orreleased during bacterial or viral gastrointestinal infection;pregnancy; vestibular disorders, such as motion sickness, vertigo,dizziness and Meniere's disease; post-operative sickness;gastrointestinal obstruction; reduced gastrointestinal motility;visceral pain, e.g. myocardial infarction or peritonitis; migraine;increased intercranial pressure; decreased intercranial pressure (e.g.altitude sickness); opioid analgesics, such as morphine; andgastro-oesophageal reflux disease, acid indigestion, over-indulgence offood or drink, acid stomach, sour stomach, regurgitation, heartburn,such as episodic heartburn, nocturnal heartburn, and meal-inducedheartburn and dyspepsia.

Compounds of the invention are of particular use in the treatment ofgastrointestinal disorders such as irritable bowel syndrome; skindisorders such as psoriasis, pruritis and sunburn; vasospastic diseasessuch as angina, vascular headache and Reynaud's disease; cerebralischeamia such as cerebral vasospasm following subarachnoid haemorrhage;fibrosing and collagen diseases such as scleroderma and eosinophilicfascioliasis; disorders related to immune enhancement or suppressionsuch as systemic lupus erythematosus and rheumatic diseases such asfibrositis; and cough.

Compounds of the invention are useful for the treatment of neurotoxicinjury which follows cerebral stroke, thromboembolic stroke, hemorrhagicstroke, cerebral ischemia, cerebral vasospam, hypoglycemia, hypoxia,anoxia, perinatal asphyxia cardiac arrest.

The utility of the agents of the invention in the above indicateddiseases can be confirmed in a range of standard tests. (1) Theanxiolytic activity of the agents of the invention can be confirmed inthe mouse elevated plus-maze [see for example Rodgers R. J., BehaviouralPharmacology 8: 477-496 (1997) where the relevance of the elevatedplus-maze is discussed on p. 486; for the method, see Rodgers R. J. etal. Ethology and Psychopharmacology (Eds S J Cooper and C A Hendrie), pp9-44 (1994), J. Wiley, Chichester]. (2) The analgesic activity of theagents of the invention can be confirmed in rat visceral hyperalgesiamodels following colorectal distension [see for example Schwetz I, Am JPhysiology 286: G683-G691 (2004); for the method, see Ness T. J., BrainResearch 450:153-169 (1988)]. (3) The anti-diarrheal activity of theagents of the invention can be confirmed in rat defecation models duringstress or CRF challenge [see for example Maillot C., Gastroenterology119:1569-1579 (2002)].

In these tests, the agents of the invention show anxiolytic-like,visceral analgesic and anti-diarrheal effects following oraladministration of 0.1 to 30 mg/kg.

For the above-mentioned indications, the appropriate dosage will ofcourse vary depending upon, for example, the compound employed, thehost, the mode of administration and the nature and severity of thecondition being treated. However, in general, satisfactory results inanimals are indicated to be obtained at a daily dosage of from about 0.1to about 100 mg/kg, preferably from about 1 to about 30 mg/kg animalbody weight. In larger mammals, for example humans, an indicated dailydosage is in the range from about 1 to about 500 mg, preferably fromabout 1 to about 100 mg of an agent of the invention, convenientlyadministered, for example, in divided doses up to three times a day orin sustained release form.

The agents of the invention may be administered by any conventionalroute, in particular enterally, preferably orally, for example in theform of tablets or capsules, or parenterally, for example in the form ofinjectable solutions or suspensions.

In accordance with the foregoing, the present invention also provides anagent of the invention, for use as a pharmaceutical, e.g. for thetreatment of diseases induced or facilitated by CRF, such as theseindicated above.

Therefore, according to a further aspect of the invention we provide acompound of formula I, or a salt thereof, for the treatment oralleviation of treatment of any state with increased endogenous level ofCRF or in which the HPA (hypothalamic pituitary axis) is disregulated,or of various diseases induced or facilitated by CRF.

The agents of the invention can be administered in vivo either alone orin combination with other pharmaceutical agents, e.g. agents effectivein the treatment of diseases and conditions in which an increasedendogenous level of CRF plays a role or is implicated. A suitablecombination consists of a compound of the present invention with one ormore compounds selected from the group consisting of dopamine D2receptor antagonists, serotonin 5-HT4 receptor agonists, serotonin 5-HT3receptor agonists, serotonin 5-HT3 receptor antagonists, CCK1 receptorantagonists, motilin receptor agonists, μ-opioid receptor antagonists,opioid receptor agonists and opiates, other CRF-1 receptor antagonists,glutamate receptor antagonists, neurokinin receptor antagonists,histamine H2 receptor antagonists, histamine H4 receptor antagonists,proton pump inhibitors, chloride channel activators, guanylate cyclase-cactivators, muscarinic receptor antagonists, antispasmodics, stimulantlaxatives, osmotic laxatives, faecal softeners, absorbents and fibresupplements, antacids, GI relaxants, bismuth compounds, vanilloidreceptor antagonists, anticonvulsants, NSAIDS, COX-2 inhibitors, GABAbreceptor modulators, CB receptor ligands, calcium channel blockers,sodium channel blockers, tricyclic antidepressants, serotonin andnoradrenaline re-uptake inhibitors, benzodiazepines, alpha-2 receptoragonists and ghrelin receptor agonists.

More specifically, a compound of the present invention may beadministered as a combination with one or more compounds selected fromthe group consisting of dopamine D2 receptor antagonists, such as,chlorpromazine, prochlorperazine, haloperidol, alizapride, domperidone,metoclopramide and itopride; serotonin 5HT4 receptor agonists, such as,cisapride, cinitapride, mosapride, renzapride, prucalopride, tegaserod,velusetrag, ATI-7505 and compounds described in WO 2005068461, US2005228014, WO 2005080389, US 2006100426, US 2006100236, US 2006135764,US 2005277671, WO 2005092882, WO 2005073222, JP 2005104896, JP2005082508, WO 2005021539, JP 2004277319, JP 2004277318, WO 2004026869,EP 1362857, WO 2006108127, US 20060183901, WO 2006127815, US20060276482, WO 2007005951, WO 2007010390, WO 2007005951, WO 2007048643,WO 2007096352, WO 2007068739 and WO 20070117796; serotonin 5-HT3receptor agonists, such as, pumesotrag and compounds described in WO2007004041; serotonin 5-HT3 receptor antagonists, such as, alosetron,cilansetron, ramosetron, azasetron, ondansetron, granisetron,tropisetron, DDP225 and compounds described in WO 2006183769, WO2006105117 and WO 2007004041; CCK1 receptor antagonists, such as,JNJ-17156516, devazepide, loxiglumide and dexloxiglumide; motilinreceptor agonists, such as, motilin, atilmotin, erythromycin, alemcinal,mitemcinal, KOS-2187,1-[4-(3-fluoro-phenylamino)-piperidin-1-yl]-2-[4-((S)-3-methyl-piperazin-1-ylmethyl)-phenyl]-ethanoneand compounds described in WO 2005060693, WO 2006127252, WO 2007007018,WO 2007012479 and WO 2008000729; m-opioid receptor antagonists, such as,naxolone, alvimopan, methylnaltrexone and compounds described in US20050203123, US 2006063792, WO 2007050802, US 2007103187, WO 2009029252,WO 2009029256, WO 2009029257 and WO 2009029253; opioid receptor agonistsand opiates, such as, morphine, buprenorphine, diamorphine,dihydrocodeine, fentanyl, pethidine, asimadoline, loperamide andcodeine; CRF-1 receptor antagonists, such as, GSK876008, pexacerfont andcompounds described in WO 2004069257, WO 9940089, U.S. Pat. No.6,844,351, WO 2005013997, WO 2005014557, WO 2005023806, WO 2005026126,WO 2005028480, WO 005044793, WO 2005051954, WO 2005051954, WO2005115399, WO 2005028480, WO 2005023806, WO 2006044958, WO 2006044821and US 20060211710; glutamate receptor antagonists, such as, AZD9272,AZD2066, AFQ056, ADX-48621 and compounds described in WO 9902497, WO2000020001, WO 200304758 and WO 2005030723, WO 2005077345, US2006009443, EP 1716152, WO 2005080397, US 2006019997, WO 2005066155, WO2005082884, WO 2005044266, WO 2005077373, EP 1713791, EP 1720860, WO2005080379, EP 1716130, US 2006235024, WO 2005080363WO 2006114264, WO2006114260, WO 2006089700, WO 2006114262, WO 2006123257, US 2005272779,WO 2006048771, WO 2006123249, US 2006009477, WO 2006014185, EP 1723144,US 2006025414, US 2006004021, US 2006160857, WO 2006074884, WO2006129199, WO 2006123244, WO 2006123255, WO 2007040982, WO 2007023290,WO 2007023242, WO 2007050050, WO 2007039781, WO 2007039782 and WO2007023245; neurokinin receptor antagonists, such as, taletant,osanetant, casopitant, nepadutrent, saredutant, DNK-333, SLV-317,SLV321, SLV317 and compounds described in EP 96-810237, WO 2006137790,WO 2006137791, WO 2006094934, WO 2007037742 and WO 2007037743; histamineH2 receptor antagonists, such as, famotidine, cimetidine, ranitidine andnizatidine; histamine H4 receptor antagonists, such as, JNJ7777120,JNJ10191584 and compounds described in US 2006111416, WO 2006050965, WO2005092066, WO 2005054239 US 2005070550, US 2005070527, EP 1505064, WO2007090852, WO 2007090853, WO 2007090854, US 20070232616, US20070238771, WO 2007117399, WO 2007031529 and WO2007072163; proton pumpinhibitors, such as, omeprazole, lansoprazole, rabeprazole,tentoprazole, pantoprazole, esomeprazole, revaprazan, soraprazan andAGN201904; chloride channel activators, such as, lubiprostone; guanylatecyclase-2c activators, such as, linaclotide, guanilib, guanylin,uroguanylin and compounds described in WO 2005087797, WO 2005016244, WO2007022531, WO 2007101158, WO 2007101161 and U.S. Pat. No. 7,041,786;muscarinic receptor antagonists, such as, darifenacin, solifenacin,atropine, dicycloverine, hycosine butyl bromide, propantheline,oxybutinin, cimetropium bromide and pinaverium bromide; antispasmodics,such as, mebeverine, octylonium bromide, trimebutine, tiropramide,alverine and peppermint oil; stimulant laxatives, such as, bisacodyl;osmotic laxatives, such as, activated charcoal with sorbitol, lactulose,magnesium hydroxide and phosphate buffered saline; faecal softeners,such as, senna concentrate, liquid paraffin and arachis oil; absorbentsand fibre supplements; bulk fibre laxatives such as bran,methylcellulose, ispaghula husk and sterculia; antacids, such as,aluminum, magnesium and calcium antacids, simeticone and alginatecontaining preparations; GI relaxants, such as, cholestyramine resin;bismuth compounds, such as, bismuth subsalicylate; vanilloid receptorantagonists, such as, SB-705498, ABT-102, AZD1386, GRC-6211, MK-2295 andcompounds described in WO 2002076946, WO 2004033435, WO 2005121116, WO2005120510, WO 2006006740, WO 2006006741, WO 2006010445, WO 2006016218,US 2006058308, WO 2006033620, WO 2006038871, US 2006084640, US2006089360, WO 2006058338, WO 2006063178, US 2006128689, WO 2006062981,WO 2006065646, WO 2006068618, WO 2006068592, WO 2006068593, WO2006076646, US 2006160872, WO 200608082, US 2006183745, WO 2006095263,WO 2006102645, WO 2006100520, US 2006241296, WO 2006122200, WO2006120481, WO 2006122250, DE 102005044814, WO 2006122772, WO2006122777, WO 2006124753, WO 2006122799, WO 2006122770, WO 2006122769,WO 2006136245, WO 2007030761, US 20070088072, US 20070088073, US20070105920, WO 2007042906, WO 2007045462, WO 2007050732;anticonvulsants, such as, carbemazepine, oxcarbemazepine, lamotrigine,gabapentin and pregabalin; NSAIDS, such as, aspirin, acetometaphen,ibuprofen, diclofenac, naproxen, flurbiprofen, indomethacin, piroxicam,ketoprofen, sulindac and diflunisal; COX-2 inhibitors, such as,celecoxib, rofecoxib, lumiracoxib, valdecoxib, etoricoxib and compoundsdescribed in WO 2004048314; GABAb receptor modulators, such as, racemicand (R)-baclofen, AZD3355, XP19986 and compounds described in WO2006001750 and WO 2004000856; CB receptor ligands, such as, dronabinol,nabilone, cannabidiol, rimonabant and compounds described in WO2002042248 and WO 2003066603; calcium channel blockers, such as,ziconotide, AGI0-003, PD-217014 and compounds described in WO2006038594, WO 2006030211 and WO 2005068448; sodium channel blockers,such as, lamotrigine and compounds described in WO 2006023757, WO2005097136, JP 2005206590 and WO 2005047270; tricyclic antidepressants,such as, clomipramine, amoxapine, nortripyline, amitriptyline,imipramine, desipramine, doxepin, trimipramine and protripyline;serotonin and noradrenaline re-uptake inhibitors, such as, milnacipran,desvenlafaxine, sibutramine, duloxetine, fluoxetine, paroxetine,citalopram, sertraline and fluvoxamine; benzodiazepines, such as,levotofisopam, diazepam, lorazepam, clonazepam and alprazolam; alpha-2receptor agonists, such as, clonidine, tizanidine and guanfacine;ghrelin receptor agonists, such as, ghrelin, ibutamoren, capromorelin,tabimorelin, ipamorelin,2-Methylalanyl-N-[1(R)-formamido-2-(1H-indol-3-yl)ethyl]-D-tryptophanamide,TZP-101, TZP-102, LY-444711, EX-1314 and compounds described in U.S.Pat. No. 6,525,203, US 20050154043, WO 2005097788, WO2006036932, WO2006135860, US 20060079562, WO 2006010629, WO 2006009674, WO 2006009645,US 20070021331, WO 2007020013, US 20070037857, WO 2007014258, WO2007113202, WO 2007118852, US 20080194672, US 20080051383 and US20080051383; corticosteroids, such as, hydrocortisone, cortisone,dexamethasone, betamethasone, beclomethasone, prednisolone,6-methylprednisolone, budesonide, mometasone furoate, ciclesonide,fluticasone propionate and fluticasone furoate; aminosalicylates, suchas, mesalazine, ipsalazide, olsalazine and balsalazide;immunomodulators, such as, azathioprine, 6-mercaptopurine, methotrexate,mycophenolate mofetil, ciclosporin and tacrolimus; PDE4 inhibitors, suchas, tetomilast, cilomilast, roflumilast and arofylline; antibiotics,such as, metronidazole, ornidazole and ciprofloxacin; anti-adhesionmolecule agents, such as, natalizumab and MLN02; anti IL-2 agents, suchas, daclizumab and basilixumab; anti CD-3 agents, such as, visilizumab;and anti-TNF agents, such as, infliximab, adalimumab, fontolizumab andcertolizumab pegol; psychiatric medications comprising compoundsselected from the group consisting of agomelatine, azapirones,alprazolam, amitriptyline, aniracetam, acetyl-L-carnitine, aripiprazol,acetophenazine, benzodiazepines, barbiturate, buspirone, bupropione,chlordiazepoxide, chlorazepate, clonazepam, chlorpromazine, clozapine,CX614, CX516, chlorprothixene, diphenhydramine hydroxyzine, demoxepam,diazepam, droperidol, duloxetine, donezepil, doxepine, desipramine,flurazepam, fluphenazine, fluoxetine, flupentixol, gabapentin,melatonin, ginkgo-derived compounds, galantamine, haloperidol, Hydergine(ergoloid mesylates), huperzine, isocarboxazid, imipramine, lorazepam,loxapine, meprobamate, medazepam, moclobemide, molindone, maprotiline,modafinil, memantine, methylphenicate, mesoridazine, methotrimeprazine,nortriptyline, naproxen, oxazepam, oxiracetam, olanzapine, prazepam,paroxetine, phenelzine, pipotiazine, perphenazine, promazine, pimozide,PDE4 inhibitors, quazepam, quetiapine, reboxetine, rivastigmine,prochlorperazine, risperidone, sertraline, sertindole, temazepam,triazolam, tranylcypromine, tomoxetine, thiotixene, trifluoperazine,thioridazine, zolpidem and ziprasidone.

A preferred group of compounds which may be mentioned are compounds offormula II:

in which R²³ is hydrogen, alkyl C1 to 6, haloalkyl C1 to 6, dialkylaminoC1 to 6, alkoxy C1 to 6 or halogen;

R²⁴ is alkyl C1 to 6, haloalkyl C1 to 6 or halogen;

A is —CH— or —N—; and

R¹ and R⁷ are each as hereinbefore described;

and isomers thereof;

in free form or in salt form.

R²³ is preferably halogen, such as Cl or alkyl, such as methyl ordialkylamino C1 to 6, such as dimethylamino.

R²⁴ is preferably haloalkyl C1 to 6, such as CF₃ or halogen, such as Cl.

An alternative preferred group of compounds which may be mentioned arecompounds of formula III;

in which R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹ and R¹⁰ are each as hereinbeforedescribed; and

R¹¹, R¹², R¹³, R¹⁴ and R¹⁵, which may be the same or different, areeach, hydrogen, halogen, alkyl C1 to 6, haloalkyl C1 to 6, alkoxy C1 to6, halogenated alkoxy C1 to 6, nitrile, morpholinyl, sulphamoyl or R¹¹and R¹² or R¹² and R¹³ taken together may form a benzo or heteroarylfused ring;

and isomers thereof;

in free form or in salt form.

An alternative preferred group of compounds which may be mentioned arecompounds of formula IV;

in which R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹ and R¹⁰ are each as hereinbeforedefined; and

R¹⁶ is a heteroaryl ring optionally substituted by one or more of alkylC1 to 10, alkoxy C1 to 10, hydroxyalkyl C1 to 10, halogen, haloalkyl C1to 10, halogenated alkoxy C1 to 10, nitrile, —CO₂R²⁵, alkylamino C1 to6, dialkylamino C1 to 6, morpholinyl, phenyl, substituted phenyl,aryloxy, substituted phenoxy, imidazolinyl or oxoimidazolinyl;

and isomers thereof;

in free form or in salt form.

The heteroaryl ring of R¹⁶ may comprise one or more heteroatoms, ispreferably aromatic and may optionally be substituted. Examples ofheteroaryl rings include, pyridyl, thiazolyl, quinolinyl, thiadiazolyl,pyrimidinyl, oxadiazolyl, indolyl, benzo[1,3]dioxolyl, isoxazolyl,pyrazolyl, oxazolyl, benzimidazolyl, benzothiazolyl, pyrazinyl,triazolyl, benzoxazolyl and imidazolidinyl.

An alternative preferred group of compounds which may be mentioned arecompounds of formula XI;

in which R⁷ and R⁸ are each as hereinbefore defined; and

R¹⁸, R¹⁹ and R²⁰, which may be the same or different, are each hydrogen,alkyl C1 to 10, alkoxy C1 to 10, halogen, haloalkyl C1 to 10,halogenated alkoxy, nitrile, morpholinyl, or, optionally substituted,phenyl, phenoxy, imidazolinyl or oxoimidazolinyl, or R¹⁸ and R¹⁹ or R¹⁹and R²⁰ may together form a saturated or unsaturated carbocyclic orheterocyclic ring;

and isomers thereof;

in free form or in salt form.

An alternative preferred group of compounds which may be mentioned are acompound of formula XII;

in which R², R⁷ and R⁸ are each as hereinbefore defined; and

Het is a 5-membered heteroaryl ring which may optionally be substitutedby one or more of alkyl C1 to 10, alkoxy C1 to 10, halogen, haloalkyl C1to 10, halogenated alkoxy C1 to 10, nitrile, morpholinyl, or optionallysubstituted, phenyl, phenoxy, imidazolinyl or oxoimidazolinyl; or Hetmay optionally be fused to a substituted or unsubstituted benzo orheteroaryl ring;

and isomers thereof;

in free form or in salt form.

In an alternative aspect of the invention we provide a compound offormula IX;

in which R¹ is phenyl, biphenyl, naphthyl, 5- or 6-membered heteroaryl,a bicyclic heteroaryl, each of which may optionally be substituted byone or more of alkyl C1 to 10, alkoxy C1 to 10, halogen, haloalkyl C1 to10, halogenated alkoxy C1 to 10, nitrile, morpholinyl, or optionallysubstituted phenyl, phenoxy, imidazolinyl or oxoimidazolinyl or togetherR¹ and R² form a ring, which may be optionally substituted one or moreof alkyl C1 to 10, alkoxy C1 to 10, halogen, haloalkyl C1 to 10,halogenated alkoxy, nitrile, morpholinyl, or optionally substitutedphenyl, phenoxy, imidazolinyl or oxoimidazolinyl;

R² is hydrogen or alkyl C1 to 6;

R³, R⁴, R⁵, R⁶, R⁷, R⁹ and R¹⁰, which may be the same or different, areeach hydrogen or alkyl C1 to 6;

R⁸ is phenyl, a 5-membered heteroaryl, a 6-membered heteroaryl or abicyclic system, each of which may optionally be substituted, by one ormore of alkyl C1 to 6, halogenated alkyl C1 to 6, halogen, alkylamino C1to 6, dialkylamino C1 to 6, alkoxy C1 to 6 or haloalkoxy C1 to 6;

and isomers thereof;

in free form or in salt form.

In an alternative aspect of the invention we provide a compound offormula X;

in which R¹ is phenyl which may optionally be substituted by one or moreof alkyl C1 to 10, alkoxy C1 to 10, halogen, haloalkyl C1 to 10,halogenated alkoxy C1 to 10, nitrile, morpholinyl, or optionallysubstituted, phenyl, phenoxy, imidazolinyl or oxoimidazolinyl, or R¹ mayoptionally be fused to a substituted or unsubstituted benzo orheteroaryl ring;

R², R³, R⁴, R⁵, R⁶, R⁷, R⁹ and R¹⁰, which may be the same or different,are each hydrogen or alkyl C1 to 6;

R⁸ is phenyl, a 5-membered heteroaryl, a 6-membered heteroaryl or abicyclic system, each of which may optionally be substituted, by one ormore of alkyl C1 to 6, halogenated alkyl C1 to 6, halogen, alkylamino C1to 6, dialkylamino C1 to 6, alkoxy C1 to 6 or haloalkoxy C1 to 6;

and isomers thereof;

in free form or in salt form.

R² is preferably hydrogen.

In an alternative aspect of the invention we provide a compound offormula X;

in which R¹ is 2-pyridyl, 2-pyrimidinyl or 4-pyrazinyl which mayoptionally be substituted by one or more of alkyl C1 to 10, alkoxy C1 to10, halogen, haloalkyl C1 to 10, halogenated alkoxy C1 to 10, nitrile,—CO₂R²⁶, —CH₂NR²⁷R²⁸, morpholinyl, or optionally substituted phenyl,phenoxy, imidazolinyl or oxoimidazolinyl; or R¹ may optionally be fusedto a substituted or unsubstituted benzo or heteroaryl ring;

R², R³, R⁴, R⁵, R⁶, R⁷, R⁹, R¹⁰, R²⁶, R²⁷ and R²⁸, which may be the sameor different, are each hydrogen or alkyl C1 to 6;

R⁸ is phenyl, a 5-membered heteroaryl, a 6-membered heteroaryl or abicyclic system, each of which may optionally be substituted, by one ormore of alkyl C1 to 6, halogenated alkyl C1 to 6, halogen, alkylamino C1to 6, dialkylamino C1 to 6, alkoxy C1 to 6 or haloalkoxy C1 to 6;

and isomers thereof;

in free form or in salt form.

In an alternative aspect of the invention we provide a compound offormula X;

in which R¹ is 3-pyridyl which may optionally be substituted by one ormore of alkyl C1 to 10, alkoxy C1 to 10, halogen, haloalkyl C1 to 10,halogenated alkoxy C1 to 10, nitrile, morpholinyl, or optionallysubstituted, phenyl, phenoxy, imidazolinyl or oxoimidazolinyl; or R¹ mayoptionally be fused to a substituted or unsubstituted benzo orheteroaryl ring;

R², R³, R⁴, R⁵, R⁶, R⁷, R⁹ and R¹⁰, which may be the same or different,are each hydrogen or alkyl C1 to 6;

R⁸ is phenyl, a 5-membered heteroaryl, a 6-membered heteroaryl or abicyclic system, each of which may optionally be substituted, by one ormore of alkyl C1 to 6, halogenated alkyl C1 to 6, halogen, alkylamino C1to 6, dialkylamino C1 to 6, alkoxy C1 to 6 or haloalkoxy C1 to 6;

and isomers thereof;

in free form or in salt form.

In an alternative aspect of the invention we provide a compound offormula X;

in which R¹ is a 5-membered heteroaryl which may optionally besubstituted by one or more of alkyl C1 to 10, alkoxy C1 to 10, halogen,haloalkyl C1 to 10, halogenated alkoxy C1 to 10, nitrile or morpholinyl;or phenyl, phenoxy, imidazolinyl or oxoimidazolinyl each of which may beoptionally substituted, or R¹ may optionally be fused to a substitutedor unsubstituted benzo or heteroaryl ring the substituents beingselected from the group of alkyl C1 to 6, halo. haloalkyl C1 to 6,alkoxy C1 to 6, or carboxy; or together R¹ and R² form a ring, which maybe optionally substituted as hereinbefore described;

R² is hydrogen or alkyl C1 to 6 or together R¹ and R² form a ring, whichmay be optionally be substituted as hereinbefore described;

R³, R⁴, R⁵, R⁶, R⁷, R⁹ and R¹⁰, which may be the same or different, areeach hydrogen or alkyl C1 to 6;

R⁸ is phenyl, a 5-membered heteroaryl, a 6-membered heteroaryl or abicyclic system, each of which may optionally be substituted, by one ormore of alkyl C1 to 6, halogenated alkyl C1 to 6, halogen, alkylamino C1to 6, dialkylamino C1 to 6, alkoxy C1 to 6 or haloalkoxy C1 to 6;

and isomers thereof;

in free form or in salt form.

R¹ may contain from 1 to 3 heteroatoms, selected from one or more of N,O or S, for example R¹ may be pyrrole, pyrazole, oxazole, isozaxole,thiazole, oxadiazole, triazole or thiadiazole.

R² is preferably hydrogen.

In an alternative aspect of the invention we provide a compound offormula X;

in which together R¹ and R² form a heteroaryl ring, which may beoptionally substituted the substituents being selected from the groupalkyl C1 to 10, alkoxy C1 to 10, halogen, haloalkyl C1 to 10,halogenated alkoxy C1 to 10, nitrile or morpholinyl; or phenyl, phenoxy,heteroaryl or R¹ may optionally be fused to a substituted orunsubstituted benzo or heteroaryl ring, the substituents being selectedfrom the group of alkyl C1 to 6, halo. haloalkyl C1 to 6, alkoxy C1 to6, or carboxy;

R³, R⁴, R⁵, R⁶, R⁷, R⁹ and R¹⁰, which may be the same or different, areeach hydrogen or alkyl C1 to 6;

R⁸ is phenyl, a 5-membered heteroaryl, a 6-membered heteroaryl or abicyclic system, each of which may optionally be substituted, by one ormore of alkyl C1 to 6, halogenated alkyl C1 to 6, halogen, alkylamino C1to 6, dialkylamino C1 to 6, alkoxy C1 to 6 or haloalkoxy C1 to 6;

and isomers thereof;

in free form or in salt form.

Together R¹ and R² may form a heteroaryl ring selected from the groupconsisting of pyrrole, pyrazole, oxazole, isoxazole, thiazole,oxadiazole, triazole or thiadiazole, each of which may be optionallysubstituted as hereinbefore described.

In an alternative aspect of the invention we provide a compound offormula X;

in which R¹ is —CH₂R²¹;

R², R³, R⁴, R⁵, R⁶, R⁷, R⁹ and R¹⁰, which may be the same or different,are each hydrogen or alkyl C1 to 6;

R⁸ is phenyl, a 5-membered heteroaryl, a 6-membered heteroaryl or abicyclic system, each of which may optionally be substituted, by one ormore of alkyl C1 to 6, halogenated alkyl C1 to 6, halogen, alkylamino C1to 6, dialkylamino C1 to 6, alkoxy C1 to 6 or haloalkoxy C1 to 6;

R²¹ is a 5-membered heteroaryl which may optionally be substituted byone or more of alkyl C1 to 10, alkoxy C1 to 10, halogen, haloalkyl C1 to10, halogenated alkoxy C1 to 10, nitrile, morpholinyl, or optionallysubstituted, phenyl, phenoxy, imidazolinyl or oxoimidazolinyl; or R²¹may optionally be fused to a substituted or unsubstituted benzo orheteroaryl ring;

and isomers thereof;

in free form or in salt form.

R²¹ may be selected from the group consisting of pyrrole, pyrazole,oxazole, isoxazole, thiazole, oxadiazole, triazole, indole, benzoxazole,benzimidazole, benzothiazole, indazole, oxadiazole or thiadiazole, eachof which may be optionally substituted as hereinbefore described.

Acid addition salts may be produced from the free bases in known manner,and vice-versa. A pharmaceutically acceptable salt is any salt of theparent compound that is suitable for administration to an animal orhuman. A pharmaceutically acceptable salt also refers to any salt whichmay form in vivo as a result of administration of an acid, another salt,or a prodrug which is converted into an acid or salt. A salt comprisesone or more ionic forms of the compound, such as a conjugate acid orbase, associated with one or more corresponding counter-ions. Salts canform from or incorporate one or more deprotonated acidic groups (e.g.carboxylic acids) one or more protonated basic groups (e.g. amines), orboth (e.g. zwitterions).

As used herein, the term “pharmaceutically acceptable salts” refers tosalts that retain the biological effectiveness and properties of thecompounds of this invention and, which are not biologically or otherwiseundesirable. In many cases, the compounds of the present invention arecapable of forming acid and/or base salts by virtue of the presence ofamino and/or carboxyl groups or groups similar thereto. Pharmaceuticallyacceptable acid addition salts can be formed with inorganic acids andorganic acids, e.g., acetate, aspartate, benzoate, besylate,bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate,edisylate, esylate, formate, fumarate, gluceptate, gluconate,glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride,hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate,maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate,nicotinate, nitrate, orotate, oxalate, palmitate, pamoate,phosphate/hydrogen phosphate/dihydrogen phosphate, saccharate, stearate,succinate, tartrate, tosylate and trifluoroacetate salts. Inorganicacids from which salts can be derived include, for example, hydrochloricacid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, andthe like. Organic acids from which salts can be derived include, forexample, acetic acid, propionic acid, glycolic acid, pyruvic acid,oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid,tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid,methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid,salicylic acid, and the like. Pharmaceutically acceptable base additionsalts can be formed with inorganic and organic bases. Inorganic basesfrom which salts can be derived include, for example, sodium, potassium,lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese,aluminum, and the like; particularly preferred are the ammonium,potassium, sodium, calcium and magnesium salts. Organic bases from whichsalts can be derived include, for example, primary, secondary, andtertiary amines, substituted amines including naturally occurringsubstituted amines, cyclic amines, basic ion exchange resins, and thelike, specifically such as isopropylamine, trimethylamine, diethylamine,triethylamine, tripropylamine, and ethanolamine. The pharmaceuticallyacceptable salts of the present invention can be synthesized from aparent compound, a basic or acidic moiety, by conventional chemicalmethods. Generally, such salts can be prepared by reacting free acidforms of these compounds with a stoichiometric amount of the appropriatebase (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or thelike), or by reacting free base forms of these compounds with astoichiometric amount of the appropriate acid. Such reactions aretypically carried out in water or in an organic solvent, or in a mixtureof the two. Generally, non-aqueous media like ether, ethyl acetate,ethanol, isopropanol, or acetonitrile are preferred, where practicable.Lists of additional suitable salts can be found, e.g., in “Remington'sPharmaceutical Sciences”, 20th ed., Mack Publishing Company, Easton,Pa., (1985); and in “Handbook of Pharmaceutical Salts: Properties,Selection, and Use” by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany,2002).

A prodrug is a compound which is converted to a therapeutically activecompound after administration. For example, conversion may occur byhydrolysis of an ester group or some other biologically labile group.Prodrug preparation is well known in the art. For example “Prodrugs andDrug Delivery Systems,” which is a chapter in Richard B. Silverman,Organic Chemistry of Drug Design and Drug Action, 2d Ed., ElsevierAcademic Press: Amsterdam, 2004, pp. 496-557, provides further detail onthe subject.

As used herein, the term “isomers” refers to different compounds thathave the same molecular formula but differ in arrangement andconfiguration of the atoms. Also as used herein, the term “an opticalisomer” or “a stereoisomer” refers to any of the various stereo isomericconfigurations which may exist for a given compound of the presentinvention and includes geometric isomers. It is understood that asubstituent may be attached at a chiral center of a carbon, sulfur orphosphorus atom. Therefore, the invention includes enantiomers,diastereomers or racemates of the compound. “Enantiomers” are a pair ofstereoisomers that are non-superimposable mirror images of each other. A1:1 mixture of a pair of enantiomers is a “racemic” mixture. The term isused to designate a racemic mixture where appropriate.“Diastereoisomers” are stereoisomers that have at least two asymmetricatoms, but which are not mirror-images of each other. The absolutestereochemistry is specified according to the Cahn-Ingold-Prelog R-Ssystem. When a compound is a pure enantiomer the stereochemistry at eachchiral carbon may be specified by either R or S. Resolved compoundswhose absolute configuration is unknown can be designated (+) or (−)depending on the direction (dextro- or levorotatory) which they rotateplane polarized light at the wavelength of the sodium D line. Certain ofthe compounds described herein contain one or more asymmetric centersand may thus give rise to enantiomers, diastereomers, and otherstereoisomeric forms that may be defined, in terms of absolutestereochemistry, as (R)— or (S)—. The present invention is meant toinclude all such possible isomers, including racemic mixtures, opticallypure forms and intermediate mixtures. Optically active (R)— and(S)-isomers may be prepared using chiral synthons or chiral reagents, orresolved using conventional techniques. If the compound contains adouble bond, the substituent may be E or Z configuration. If thecompound contains a disubstituted cycloalkyl, the cycloalkyl substituentmay have a cis- or trans-configuration. All tautomeric forms are alsointended to be included.

Compounds of formula (I) in optically pure form, where appropriate, canbe obtained from the corresponding racemates according to well-knownprocedures, e.g., HPLC with chiral matrix. Alternatively, optically purestarting materials can be used.

Stereoisomeric mixtures, e.g., mixtures of diastereomers, can beseparated into their corresponding isomers in a manner known per se bymeans of suitable separation methods. Diastereomeric mixtures, e.g., maybe separated into their individual diastereomers by means offractionated crystallization, chromatography, solvent distribution andsimilar procedures. This separation may take place either at the levelof a starting compound or in a compound of formula (I) itself.Enantiomers may be separated through the formation of diastereomericsalts, e.g., by salt formation with an enantiomer-pure chiral acid, orby means of chromatography, e.g., by HPLC, using chromatographicsubstrates with chiral ligands.

Any asymmetric atom (e.g., carbon or the like) of the compound(s) of thepresent invention can be present in racemic or enantiomericallyenriched, for example the (R)—, (S)— or (R,S)-configuration. In certainembodiments, each asymmetric atom has at least 50% enantiomeric excess,at least 60% enantiomeric excess, at least 70% enantiomeric excess, atleast 80% enantiomeric excess, at least 90% enantiomeric excess, atleast 95% enantiomeric excess, or at least 99% enantiomeric excess inthe (R)— or (S)-configuration. Substituents at atoms with unsaturatedbonds may, if possible, be present in cis-(Z)— or trans-(E)-form.

Accordingly, as used herein a compound of the present invention can bein the form of one of the possible isomers, rotamers, atropisomers,tautomers or mixtures thereof, for example, as substantially puregeometric (cis or trans) isomers, diastereomers, optical isomers(antipodes), racemates or mixtures thereof.

Any resulting mixtures of isomers can be separated on the basis of thephysicochemical differences of the constituents, into the pure orsubstantially pure geometric or optical isomers, diastereomers,racemates, for example, by chromatography and/or fractionalcrystallization.

Any resulting racemates of final products or intermediates can beresolved into the optical antipodes by known methods, e.g., byseparation of the diastereomeric salts thereof, obtained with anoptically active acid or base, and liberating the optically activeacidic or basic compound. In particular, a basic moiety may thus beemployed to resolve the compounds of the present invention into theiroptical antipodes, e.g., by fractional crystallization of a salt formedwith an optically active acid, e.g., tartaric acid, dibenzoyl tartaricacid, diacetyl tartaric acid, di-O,O′-p-toluoyl tartaric acid, mandelicacid, malic acid or camphor-10-sulfonic acid. Racemic products can alsobe resolved by chiral chromatography, e.g., high pressure liquidchromatography (HPLC) using a chiral adsorbent.

According to a further aspect of the invention we provide a method oftreatment or alleviation of any state with increased endogenous level ofCRF or in which the HPA (hypothalamic pituitary axis) is disregulated,or of various diseases induced or facilitated by CRF which comprisesadministering to a mammal a therapeutically effective amount of acompound of formula I as hereinbefore described, or a salt thereof.

We further provide a pharmaceutical composition comprising a compound offormula I as hereinbefore described, in free form or in pharmaceuticallyacceptable salt form, in association with a pharmaceutically acceptableadjuvant, diluent or carrier.

The pharmaceutical compositions for separate administration of thecombination partners and for the administration in a fixed combination,i.e., a single galenical composition comprising at least two combinationpartners, according to the invention can be prepared in a manner knownper se and are those suitable for enteral, such as oral or rectal, andparenteral administration to mammals, including man, comprising atherapeutically effective amount of at least one pharmacologicallyactive combination partner alone or in combination with one or morepharmaceutically acceptable carriers, especially suitable for enteral orparenteral application.

Pharmaceutical compositions contain, e.g., from about 0.1% to about99.9%, preferably from about 20% to about 60%, of the activeingredients. Pharmaceutical preparations for the combination therapy forenteral or parenteral administration are, e.g., those in unit dosageform, such as tablets including sugar-coated tablets, capsules,suppositories and ampoules. These are prepared in a manner known, perse, e.g., by means of conventional mixing, granulating, sugar-coating,dissolving or lyophilizing processes. It will be appreciated that theunit content of a combination partner contained in an individual dose ofeach dosage form need not in itself constitute an effective amount sincethe necessary effective amount can be reached by administration of aplurality of dosage units.

The pharmaceutical composition can be formulated for particular routesof administration such as oral administration, parenteraladministration, and rectal administration, etc. In addition, thepharmaceutical compositions of the present invention can be made up in asolid form including capsules, tablets, pills, granules, powders orsuppositories, or in a liquid form including solutions, suspensions oremulsions. The pharmaceutical compositions can be subjected toconventional pharmaceutical operations such as sterilization and/or cancontain conventional inert diluents, lubricating agents, or bufferingagents, as well as adjuvants, such as preservatives, stabilizers,wetting agents, emulsifers and buffers etc.

Typically, the pharmaceutical compositions are tablets and gelatincapsules comprising the active ingredient together with

-   -   a) diluents, e.g., lactose, dextrose, sucrose, mannitol,        sorbitol, cellulose and/or glycine;    -   b) lubricants, e.g., silica, talcum, stearic acid, its magnesium        or calcium salt and/or polyethyleneglycol; for tablets also    -   c) binders, e.g., magnesium aluminum silicate, starch paste,        gelatin, tragacanth, methylcellulose, sodium        carboxymethylcellulose and/or polyvinylpyrrolidone; if desired    -   d) disintegrants, e.g., starches, agar, alginic acid or its        sodium salt, or effervescent mixtures; and/or    -   e) absorbents, colorants, flavors and sweeteners.

Tablets may be either film coated or enteric coated according to methodsknown in the art.

Suitable compositions for oral administration include an effectiveamount of a compound of the invention in the form of tablets, lozenges,aqueous or oily suspensions, dispersible powders or granules, emulsion,hard or soft capsules, or syrups or elixirs. Compositions intended fororal use are prepared according to any method known in the art for themanufacture of pharmaceutical compositions and such compositions cancontain one or more agents selected from the group consisting ofsweetening agents, flavoring agents, coloring agents and preservingagents in order to provide pharmaceutically elegant and palatablepreparations. Tablets contain the active ingredient in admixture withnontoxic pharmaceutically acceptable excipients which are suitable forthe manufacture of tablets. These excipients are, for example, inertdiluents, such as calcium carbonate, sodium carbonate, lactose, calciumphosphate or sodium phosphate; granulating and disintegrating agents,for example, corn starch, or alginic acid; binding agents, for example,starch, gelatin or acacia; and lubricating agents, for example magnesiumstearate, stearic acid or talc. The tablets are uncoated or coated byknown techniques to delay disintegration and absorption in thegastrointestinal tract and thereby provide a sustained action over alonger period. For example, a time delay material such as glycerylmonostearate or glyceryl distearate can be employed. Formulations fororal use can be presented as hard gelatin capsules wherein the activeingredient is mixed with an inert solid diluent, for example, calciumcarbonate, calcium phosphate or kaolin, or as soft gelatin capsuleswherein the active ingredient is mixed with water or an oil medium, forexample, peanut oil, liquid paraffin or olive oil.

Certain injectable compositions are aqueous isotonic solutions orsuspensions, and suppositories are advantageously prepared from fattyemulsions or suspensions. Said compositions may be sterilized and/orcontain adjuvants, such as preserving, stabilizing, wetting oremulsifying agents, solution promoters, salts for regulating the osmoticpressure and/or buffers. In addition, they may also contain othertherapeutically valuable substances. Said compositions are preparedaccording to conventional mixing, granulating or coating methods,respectively, and contain about 0.1-75%, or contain about 1-50%, of theactive ingredient.

Suitable compositions for transdermal application include an effectiveamount of a compound of the invention with carrier. Carriers includeabsorbable pharmacologically acceptable solvents to assist passagethrough the skin of the host. For example, transdermal devices are inthe form of a bandage comprising a backing member, a reservoircontaining the compound optionally with carriers, optionally a ratecontrolling barrier to deliver the compound of the skin of the host at acontrolled and predetermined rate over a prolonged period of time, andmeans to secure the device to the skin.

Suitable compositions for topical application, e.g., to the skin andeyes, include aqueous solutions, suspensions, ointments, creams, gels orsprayable formulations, e.g., for delivery by aerosol or the like. Suchtopical delivery systems will in particular be appropriate for dermalapplication, e.g., for the treatment of skin cancer, e.g., forprophylactic use in sun creams, lotions, sprays and the like. They arethus particularly suited for use in topical, including cosmetic,formulations well-known in the art. Such may contain solubilizers,stabilizers, tonicity enhancing agents, buffers and preservatives.

As used herein a topical application may also pertain to an inhalationor to an intranasal application. They are conveniently delivered in theform of a dry powder (either alone, as a mixture, for example a dryblend with lactose, or a mixed component particle, for example withphospholipids) from a dry powder inhaler or an aerosol spraypresentation from a pressurized container, pump, spray, atomizer ornebulizer, with or without the use of a suitable propellant.

The pharmaceutical composition or combination of the present inventioncan be in unit dosage of about 1-1000 mg of active ingredient(s) for asubject of about 50-70 kg, or about 1-500 mg or about 1-250 mg or about1-150 mg or about 0.5-100 mg, or about 1-50 mg of active ingredients.The therapeutically effective dosage of a compound, the pharmaceuticalcomposition, or the combinations thereof, is dependent on the species ofthe subject, the body weight, age and individual condition, the disorderor disease or the severity thereof being treated. A physician, clinicianor veterinarian of ordinary skill can readily determine the effectiveamount of each of the active ingredients necessary to prevent, treat orinhibit the progress of the disorder or disease.

The above-cited dosage properties are demonstrable in vitro and in vivotests using advantageously mammals, e.g., mice, rats, dogs, monkeys orisolated organs, tissues and preparations thereof. The compounds of thepresent invention can be applied in vitro in the form of solutions,e.g., preferably aqueous solutions, and in vivo either enterally,parenterally, advantageously intravenously, e.g., as a suspension or inaqueous solution. The dosage in vitro may range between about 10⁻³ molarand 10⁻⁹ molar concentrations. A therapeutically effective amount invivo may range depending on the route of administration, between about0.1-500 mg/kg, or between about 1-100 mg/kg.

As used herein, the term “pharmaceutically acceptable carrier” includesany and all solvents, dispersion media, coatings, surfactants,antioxidants, preservatives (e.g., antibacterial agents, antifungalagents), isotonic agents, absorption delaying agents, salts,preservatives, drugs, drug stabilizers, binders, excipients,disintegration agents, lubricants, sweetening agents, flavoring agents,dyes, such like materials and combinations thereof, as would be known toone of ordinary skill in the art (see, for example, Remington'sPharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp.1289-1329). Except insofar as any conventional carrier is incompatiblewith the active ingredient, its use in the therapeutic or pharmaceuticalcompositions is contemplated.

The term “a therapeutically effective amount” of a compound of thepresent invention refers to an amount of the compound of the presentinvention that will elicit the biological or medical response of asubject, for example, reduction or inhibition of an enzyme or a proteinactivity, or ameliorate symptoms, alleviate conditions, slow or delaydisease progression, or prevent a disease, etc. In one non-limitingembodiment, the term “a therapeutically effective amount” refers to theamount of the compound of the present invention that, when administeredto a subject, is effective to (1) at least partially alleviating,inhibiting, preventing and/or ameliorating a condition, or a disorder ora disease (i) mediated by CRF, or (ii) associated with CRF activity, or(iii) characterized by abnormal activity of CRF; or (2) reducing orinhibiting the activity of CRF; or (3) reducing or inhibiting theexpression of CRF. In another non-limiting embodiment, the term “atherapeutically effective amount” refers to the amount of the compoundof the present invention that, when administered to a cell, or a tissue,or a non-cellular biological material, or a medium, is effective to atleast partially reducing or inhibiting the activity of CRF; or at leastpartially reducing or inhibiting the expression of CRF. The meaning ofthe term “a therapeutically effective amount” as illustrated in theabove embodiment for CRF also applies by the same means to any otherrelevant proteins/peptides/enzymes.

As used herein, the term “subject” refers to an animal. Preferably, theanimal is a mammal. A subject also refers to for example, primates(e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats,mice, fish, birds and the like. In a preferred embodiment, the subjectis a human.

As used herein, the term “inhibition” or “inhibiting” refers to thereduction or suppression of a given condition, symptom, or disorder, ordisease, or a significant decrease in the baseline activity of abiological activity or process.

As used herein, the term “treating” or “treatment” of any disease ordisorder refers in one embodiment, to ameliorating the disease ordisorder (i.e., slowing or arresting or reducing the development of thedisease or at least one of the clinical symptoms thereof. In anotherembodiment “treating” or “treatment” refers to alleviating orameliorating at least one physical parameter including those which maynot be discernible by the patient. In yet another embodiment, “treating”or “treatment” refers to modulating the disease or disorder, eitherphysically, (e.g., stabilization of a discernible symptom),physiologically, (e.g., stabilization of a physical parameter), or both.In yet another embodiment, “treating” or “treatment” refers topreventing or delaying the onset or development or progression of thedisease or disorder.

As used herein, the term “a,” “an,” “the” and similar terms used in thecontext of the present invention (especially in the context of theclaims) are to be construed to cover both the singular and plural unlessotherwise indicated herein or clearly contradicted by the context.

All methods described herein can be performed in any suitable orderunless otherwise indicated herein or otherwise clearly contradicted bycontext. The use of any and all examples, or exemplary language (e.g.“such as”) provided herein is intended merely to better illuminate theinvention and does not pose a limitation on the scope of the inventionotherwise claimed.

Compounds of the present invention are either obtained in the free form,as a salt thereof, or as prodrug derivatives thereof.

When both a basic group and an acid group are present in the samemolecule, the compounds of the present invention may also form internalsalts, e.g., zwitterionic molecules.

The present invention also provides pro-drugs of the compounds of thepresent invention that converts in vivo to the compounds of the presentinvention. A pro-drug is an active or inactive compound that is modifiedchemically through in vivo physiological action, such as hydrolysis,metabolism and the like, into a compound of this invention followingadministration of the prodrug to a subject. The suitability andtechniques involved in making and using pro-drugs are well known bythose skilled in the art. Prodrugs can be conceptually divided into twonon-exclusive categories, bioprecursor prodrugs and carrier prodrugs.See The Practice of Medicinal Chemistry, Ch. 31-32 (Ed. Wermuth,Academic Press, San Diego, Calif., 2001). Generally, bioprecursorprodrugs are compounds, which are inactive or have low activity comparedto the corresponding active drug compound, that contain one or moreprotective groups and are converted to an active form by metabolism orsolvolysis. Both the active drug form and any released metabolicproducts should have acceptably low toxicity.

Carrier prodrugs are drug compounds that contain a transport moiety,e.g., that improve uptake and/or localized delivery to a site(s) ofaction. Desirably for such a carrier prodrug, the linkage between thedrug moiety and the transport moiety is a covalent bond, the prodrug isinactive or less active than the drug compound, and any releasedtransport moiety is acceptably non-toxic. For prodrugs where thetransport moiety is intended to enhance uptake, typically the release ofthe transport moiety should be rapid. In other cases, it is desirable toutilize a moiety that provides slow release, e.g., certain polymers orother moieties, such as cyclodextrins. Carrier prodrugs can, forexample, be used to improve one or more of the following properties:increased lipophilicity, increased duration of pharmacological effects,increased site-specificity, decreased toxicity and adverse reactions,and/or improvement in drug formulation (e.g., stability, watersolubility, suppression of an undesirable organoleptic or physiochemicalproperty). For example, lipophilicity can be increased by esterificationof (a) hydroxyl groups with lipophilic carboxylic acids (e.g., acarboxylic acid having at least one lipophilic moiety), or (b)carboxylic acid groups with lipophilic alcohols (e.g., an alcohol havingat least one lipophilic moiety, for example aliphatic alcohols).

Exemplary prodrugs are, e.g., esters of free carboxylic acids and Sacylderivatives of thiols and O-acyl derivatives of alcohols or phenols,wherein acyl has a meaning as defined herein. Preferred arepharmaceutically acceptable ester derivatives convertible by solvolysisunder physiological conditions to the parent carboxylic acid, e.g.,lower alkyl esters, cycloalkyl esters, lower alkenyl esters, benzylesters, mono- or di-substituted lower alkyl esters, such as theα-(amino, mono- or di-lower alkylamino, carboxy, loweralkoxycarbonyl)-lower alkyl esters, the α-(lower alkanoyloxy, loweralkoxycarbonyl or di-lower alkylaminocarbonyl)-lower alkyl esters, suchas the pivaloyloxymethyl ester and the like conventionally used in theart. In addition, amines have been masked as arylcarbonyloxymethylsubstituted derivatives which are cleaved by esterases in vivo releasingthe free drug and formaldehyde (Bundgaard, J. Med. Chem. 2503 (1989)).Moreover, drugs containing an acidic NH group, such as imidazole, imide,indole and the like, have been masked with N-acyloxymethyl groups(Bundgaard, Design of Prodrugs, Elsevier (1985)). Hydroxy groups havebeen masked as esters and ethers. EP 039,051 (Sloan and Little)discloses Mannich-base hydroxamic acid prodrugs, their preparation anduse.

Furthermore, the compounds of the present invention, including theirsalts, can also be obtained in the form of their hydrates, or includeother solvents used for their crystallization.

The present invention includes all pharmaceutically acceptableisotopically-labeled compounds of the invention, i.e. compounds offormula (I), wherein (1) one or more atoms are replaced by atoms havingthe same atomic number, but an atomic mass or mass number different fromthe atomic mass or mass number usually found in nature, and/or (2) theisotopic ratio of one or more atoms is different from the naturallyoccurring ratio.

Examples of isotopes suitable for inclusion in the compounds of theinvention comprises isotopes of hydrogen, such as ²H and ³H, carbon,such as ¹¹C, ¹³C and ¹⁴C, chlorine, such as ³⁶Cl, fluorine, such as ¹⁸F,iodine, such as ¹²³I and ¹²⁵I, nitrogen, such as ¹³N and ¹⁵N, oxygen,such as ¹⁵O, ¹⁷O and ¹⁸O, phosphorus, such as ³²P, and sulphur, such as³⁵S.

Certain isotopically-labeled compounds of formula (I), for example,those incorporating a radioactive isotope, are useful in drug and/orsubstrate tissue distribution studies. The radioactive isotopes tritium,i.e. ³H, and carbon-14, i.e. ¹⁴C, are particularly useful for thispurpose in view of their ease of incorporation and ready means ofdetection.

Substitution with heavier isotopes such as deuterium, i.e. ²H, mayafford certain therapeutic advantages resulting from greater metabolicstability, for example, increased in vivo half-life or reduced dosagerequirements, and hence may be preferred in some circumstances.

Substitution with positron emitting isotopes, such as ¹¹C, ¹⁸F, ¹⁵O and¹³N, can be useful in Positron Emission Topography (PET) studies forexamining substrate receptor occupancy.

Isotopically-labeled compounds of formula (I) can generally be preparedby conventional techniques known to those skilled in the art or byprocesses analogous to those described in the accompanying Examples andPreparations using an appropriate isotopically-labeled reagents in placeof the non-labeled reagent previously employed.

Pharmaceutically acceptable solvates in accordance with the inventioninclude those wherein the solvent of crystallization may be isotopicallysubstituted, e.g. D₂O, d₆-acetone, d₆-DMSO.

Compounds of the invention, i.e. compounds of formula I that containgroups capable of acting as donors and/or acceptors for hydrogen bondsmay be capable of forming co-crystals with suitable co-crystal formers.These co-crystals may be prepared from compounds of formula I by knownco-crystal forming procedures. Such procedures include grinding,heating, co-subliming, co-melting, or contacting in solution compoundsof formula I with the co-crystal former under crystallization conditionsand isolating co-crystals thereby formed. Suitable co-crystal formersinclude those described in WO 2004/078163. Hence the invention furtherprovides co-crystals comprising a compound of formula I.

According to an additional aspect of the invention we provide a processfor the manufacture of a compound of formula I as hereinbefore describedwhich comprises one or more of the following steps;

(i) reacting a compound of formula V;

in which R⁵, R⁶, R⁷ and R⁸, are each as hereinbefore defined;

with a compound of formula VI;R¹NH₂  VI

in which R¹ is as hereinbefore defined; or

(ii) reacting a compound of formula VII;

in which R^(8a) is R⁸ or a protecting group;

R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹⁷ and R²², are each as hereinbefore defined;and

R^(y) is a leaving group;

with a compound of formula VIII;R¹R²NH  VIII

in which R¹ and R² are each as hereinbefore defined.

The invention further includes any variant of the present processes, inwhich an intermediate product obtainable at any stage thereof is used asstarting material and the remaining steps are carried out, or in whichthe starting materials are formed in situ under the reaction conditions,or in which the reaction components are used in the form of their saltsor optically pure antipodes.

Compounds of the invention and intermediates can also be converted intoeach other according to methods generally known per se.

Other process schemes which may be utilized include:

The leaving group R^(y) may be any conventionally known leaving group,examples of which include, -Ts (tosylate), -Tf (triflate) or Ms(mesylate).

Within the scope of this text, only a readily removable group that isnot a constituent of the particular desired end product of the compoundsof the present invention is designated a “protecting group”, unless thecontext indicates otherwise. The protection of functional groups by suchprotecting groups, the protecting groups themselves, and their cleavagereactions are described for example in standard reference works, such asJ. F. W. McOmie, “Protective Groups in Organic Chemistry”, Plenum Press,London and New York 1973, in T. W. Greene and P. G. M. Wuts, “ProtectiveGroups in Organic Synthesis”, Third edition, Wiley, New York 1999, in“The Peptides”; Volume 3 (editors: E. Gross and J. Meienhofer), AcademicPress, London and New York 1981, in “Methoden der organischen Chemie”(Methods of Organic Chemistry), Houben Weyl, 4th edition, Volume 15/l,Georg Thieme Verlag, Stuttgart 1974, in H.-D. Jakubke and H. Jeschkeit,“Aminosäuren, Peptide, Proteine” (Amino acids, Peptides, Proteins),Verlag Chemie, Weinheim, Deerfield Beach, and Basel 1982, and in JochenLehmann, “Chemie der Kohlenhydrate: Monosaccharide und Derivate”(Chemistry of Carbohydrates: Monosaccharides and Derivatives), GeorgThieme Verlag, Stuttgart 1974. A characteristic of protecting groups isthat they can be removed readily (i.e. without the occurrence ofundesired secondary reactions) for example by solvolysis, reduction,photolysis or alternatively under physiological conditions (e.g. byenzymatic cleavage).

Salts of compounds of the present invention having at least onesalt-forming group may be prepared in a manner known per se. Forexample, salts of compounds of the present invention having acid groupsmay be formed, for example, by treating the compounds with metalcompounds, such as alkali metal salts of suitable organic carboxylicacids, e.g. the sodium salt of 2-ethylhexanoic acid, with organic alkalimetal or alkaline earth metal compounds, such as the correspondinghydroxides, carbonates or hydrogen carbonates, such as sodium orpotassium hydroxide, carbonate or hydrogen carbonate, with correspondingcalcium compounds or with ammonia or a suitable organic amine,stoichiometric amounts or only a small excess of the salt-forming agentpreferably being used. Acid addition salts of compounds of the presentinvention are obtained in customary manner, e.g. by treating thecompounds with an acid or a suitable anion exchange reagent. Internalsalts of compounds of the present invention containing acid and basicsalt-forming groups, e.g. a free carboxy group and a free amino group,may be formed, e.g. by the neutralization of salts, such as acidaddition salts, to the isoelectric point, e.g. with weak bases, or bytreatment with ion exchangers.

Salts can be converted in customary manner into the free compounds;metal and ammonium salts can be converted, for example, by treatmentwith suitable acids, and acid addition salts, for example, by treatmentwith a suitable basic agent.

Mixtures of isomers obtainable according to the invention can beseparated in a manner known per se into the individual isomers;diastereoisomers can be separated, for example, by partitioning betweenpolyphasic solvent mixtures, recrystallization and/or chromatographicseparation, for example over silica gel or by e.g. medium pressureliquid chromatography over a reversed phase column, and racemates can beseparated, for example, by the formation of salts with optically puresalt-forming reagents and separation of the mixture of diastereoisomersso obtainable, for example by means of fractional crystallization, or bychromatography over optically active column materials.

Intermediates and final products can be worked up and/or purifiedaccording to standard methods, e.g. using chromatographic methods,distribution methods, (re-) crystallization, and the like.

The following applies in general to all processes mentioned hereinbefore and hereinafter.

All the above-mentioned process steps can be carried out under reactionconditions that are known per se, including those mentionedspecifically, in the absence or, customarily, in the presence ofsolvents or diluents, including, for example, solvents or diluents thatare inert towards the reagents used and dissolve them, in the absence orpresence of catalysts, condensation or neutralizing agents, for exampleion exchangers, such as cation exchangers, e.g. in the H+ form,depending on the nature of the reaction and/or of the reactants atreduced, normal or elevated temperature, for example in a temperaturerange of from about −100° C. to about 190° C., including, for example,from approximately −80° C. to approximately 150° C., for example at from−80 to −60° C., at room temperature, at from −20 to 40° C. or at refluxtemperature, under atmospheric pressure or in a closed vessel, whereappropriate under pressure, and/or in an inert atmosphere, for exampleunder an argon or nitrogen atmosphere.

At all stages of the reactions, mixtures of isomers that are formed canbe separated into the individual isomers, for example diastereoisomersor enantiomers, or into any desired mixtures of isomers, for exampleracemates or mixtures of diastereoisomers, for example analogously tothe methods described under “Additional process steps”.

The solvents from which those solvents that are suitable for anyparticular reaction may be selected include those mentioned specificallyor, for example, water, esters, such as lower alkyl-lower alkanoates,for example ethyl acetate, ethers, such as aliphatic ethers, for examplediethyl ether, or cyclic ethers, for example tetrahydrofuran or dioxane,liquid aromatic hydrocarbons, such as benzene or toluene, alcohols, suchas methanol, ethanol or 1- or 2-propanol, nitrites, such asacetonitrile, halogenated hydrocarbons, such as methylene chloride orchloroform, acid amides, such as dimethylformamide or dimethylacetamide, bases, such as heterocyclic nitrogen bases, for examplepyridine or N-methylpyrrolidin-2-one, carboxylic acid anhydrides, suchas lower alkanoic acid anhydrides, for example acetic anhydride, cyclic,linear or branched hydrocarbons, such as cyclohexane, hexane orisopentane, methycyclohexane, or mixtures of those solvents, for exampleaqueous solutions, unless otherwise indicated in the description of theprocesses. Such solvent mixtures may also be used in working up, forexample by chromatography or partitioning.

The compounds, including their salts, may also be obtained in the formof hydrates, or their crystals may, for example, include the solventused for crystallization. Different crystalline forms may be present.

The invention relates also to those forms of the process in which acompound obtainable as an intermediate at any stage of the process isused as starting material and the remaining process steps are carriedout, or in which a starting material is formed under the reactionconditions or is used in the form of a derivative, for example in aprotected form or in the form of a salt, or a compound obtainable by theprocess according to the invention is produced under the processconditions and processed further in situ.

All starting materials, building blocks, reagents, acids, bases,dehydrating agents, solvents and catalysts utilized to synthesize thecompounds of the present invention are either commercially available orcan be produced by organic synthesis methods known to one of ordinaryskill in the art (Houben-Weyl 4^(th) Ed. 1952, Methods of OrganicSynthesis, Thieme, Volume 21).

Certain of the intermediates used in the processes as hereinbeforedescribed are novel per se. Therefore, according to a further aspect ofthe invention we provide a compound of formula V;

in which R⁵, R⁶, R⁷ and R⁸, are each as hereinbefore defined.

We also provide a compound of formula VII;

in which R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹⁷, R²² and R^(y), are each ashereinbefore defined.

R^(y) may be for example, tosylate, triflate or halo.

Compounds of formula I may be prepared by the general reactions (itshould be noted that the numbered R groups referred to in the reactionsequences below are for illustrative purposes only and do not preciselycorrespond to the R groups hereinbefore defined):

Referring to the examples that follow, compounds of the preferredembodiments are synthesized using the methods described herein, or othermethods, which are known in the art.

It should be understood that the organic compounds according to thepreferred embodiments may exhibit the phenomenon of tautomerism. As thechemical structures within this specification can only represent one ofthe possible tautomeric forms, it should be understood that thepreferred embodiments encompasses any tautomeric form of the drawnstructure.

The following examples are intended to illustrate the invention and arenot to be construed as being limitations thereon. Temperatures are givenin degrees centrigrade. If not mentioned otherwise, all evaporations areperformed under reduced pressure, preferably between about 15 mm Hg and100 mm Hg (=20-133 mbar). The structure of final products, intermediatesand starting materials is confirmed by standard analytical methods,e.g., microanalysis and spectroscopic characteristics, e.g., MS, IR,NMR. Abbreviations used are those conventional in the art.

All starting materials, building blocks, reagents, acids, bases,dehydrating agents, solvents, and catalysts utilized to synthesis thecompounds of the present invention are either commercially available orcan be produced by organic synthesis methods known to one of ordinaryskill in the art (Houben-Weyl 4th Ed. 1952, Methods of OrganicSynthesis, Thieme, Volume 21). Further, the compounds of the presentinvention can be produced by organic synthesis methods known to one ofordinary skill in the art as shown in the following examples.

General Conditions:

1H-NMR: Spectra are run on either a Bruker Ultrashield™ 400 (400 MHz)spectrometer or on a Bruker AVANCE 400 NMR spectrometer using ICON-NMR.Spectra are measured at 298K and are referenced using the solvent peak,chemical shifts (□-values) are reported in ppm, coupling constants (J)are given in Hz, spectra splitting pattern are designated as singlet(s), doublet (d), triplet (t), quadruplet (q), multiplet or moreoverlapping signals (m), broad signal (br), solvent is given inparentheses.

MS: These are either Agilent 1100 HPLC/Micromass Platform MassSpectrometer combinations or Waters Acquity UPLC with SQD MassSpectrometer or Waters Alliance HT HPLC system equipped with a MSdetector Waters MicromassZQ or Waters Micromass Plattform LCZ system.Mass spectra are run on LCMS systems using electrospray ionization.[M+H]+ refers to mono-isotopic molecular weights.

The various starting materials, intermediates, and compounds of thepreferred embodiments may be isolated and purified, where appropriate,using conventional techniques such as precipitation, filtration,crystallization, evaporation, distillation, catch and release, andchromatography. Unless otherwise stated, all starting materials areobtained from commercial suppliers and used without furtherpurification. Salts may be prepared from compounds by known salt-formingprocedures.

It should be understood that the organic compounds according to thepreferred embodiments may exhibit the phenomenon of tautomerism. As thechemical structures within this specification can only represent one ofthe possible tautomeric forms, it should be understood that thepreferred embodiments encompasses any tautomeric form of the drawnstructure.

In addition various trade reagents and materials available from havebeen utilized. Such reagents and materials include IST PE-AX/SCX-2 andSCX-2 cartridges and can be readily obtained from the suppliersindicated.

For the examples below as well as throughout the application, thefollowing abbreviations have the following meanings. If not defined, theterms have their generally accepted meanings.

Abbreviations: RT room temperature DMF N,N-dimethylformamide DIPEAN,N-diisopropylethylamine MeOH methanol MeCN acetonitrile ^(t)BuOHtert-butanol DCM dichloromethane EtOAc ethyl acetate HATU2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uroniumhexafluorophosphate PS-NCO Polymer-supported isocyanate PS-DIEAPolymer-supported diisopropylethylamine

PREPARATION OF FINAL COMPOUNDS Example 1Trans-2-Chloro-N-{4-[(3-methyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamideStep 1 Trans-4-(2-Chloro-5-trifluoromethyl-benzoylamino)-cyclohexanecarboxylic acid methyl ester

To a stirred suspension of trans-4-amino-cyclohexylcarboxylic acidmethyl ester hydrochloride (6.7 g, 34.7 mmol) in dry THF (90 mL) undernitrogen atmosphere is added triethylamine (12 mL, 86.8 mmol). Thesuspension is cooled to 0° C. and 2-chloro-5-(trifluoromethyl)benzoylchloride (8.85 g, 36.4 mmol) in dry THF (40 mL) is added dropwise over20 minutes. The resulting thick, colourless slurry is stirred at 0-5° C.for 30 minutes and then allowed to warm to room temp and stirred at roomtemp for 1 hour. The reaction is quenched by the dropwise addition ofwater (5 mL) in THF (45 mL) to give a clear solution. This is dilutedwith water (100 mL) and ethyl acetate (300 mL). The biphasic mixture isstirred for 5 minutes then the organic phase is separated and washedsuccessively with water (100 mL), saturated sodium bicarbonate (100 mL)and saturated brine (100 mL), dried (MgSO₄), filtered and evaporated togive a colourless solid.; [MH+ 364].

Step 2Trans-2-Chloro-N-(4-hydroxymethyl-cyclohexyl)-5-trifluoromethyl-benzamide

To a solution oftrans-4-(2-chloro-5-trifluoromethyl-benzoylamino)-cyclohexane carboxylicacid methyl ester (step 1)(95.2 g, 0.26 mol) in dry THF (1 L) undernitrogen at 0° C. is added lithium aluminum hydride pellets (20 g, 0.53mol) portion wise over 3 hours. The reaction mixture is stirred at 0° C.for a further 2 hours and then carefully quenched at 0° C. by theaddition of water (40 mL) in THF (60 mL) followed by further THF (500mL) to maintain a mobile suspension. Finally, 1M sodium hydroxidesolution (80 mL) is added at 0° C. resulting in a yellow solutioncontaining a colourless suspension. The reaction is filtered through aCelite® pad (filter material) to remove inorganic salts. The Celite®pad/salts are washed with EtOAc (500 mL) then with EtOAc:THF (1:1; 300mL). The organics are combined and diluted with further EtOAc (600 mL)and then washed with saturated brine (600 mL). The organic layer isdried (Na₂SO₄), filtered and concentrated under reduced pressure until aslurry is obtained. Et₂O is added to the slurry, which is then stirredfor 5 minutes before being filtered to recover a colourless solid. Thesolid is washed with isohexane and then dried at 35° C. under vacuum togive the required product.

Step 3Trans-2-Chloro-N-(4-formyl-cyclohexyl)-5-trifluoromethyl-benzamide

To a stirred suspension oftrans-2-chloro-N-(4-hydroxymethyl-cyclohexyl)-5-trifluoromethyl-benzamide(step 2)(24 g, 71.5 mmol) in DCM (72 mL) under N₂ supply at RT, is addedtriethylamine (29.7 mL, 214 mmol) followed by DMSO (24 mL), giving analmost homogenous solution. The mixture is cooled to 0° C. (ice/saltbath), and to this is added dropwise a solution/suspension of sulfurtrioxide-pyridine complex (34.1 g, 214 mmol) in DMSO (30 mL): DCM (20mL) over a period of ˜90 min. The mixture is stirred at 0-5° C. over a 1h period then allowed to warm to RT over 2 h. The mixture is cooled to0° C. in an ice bath and is quenched by the addition of 1M HCl (aq) (40mL) dropwise over 30 min. The mixture is then diluted with water (60 mL)and DCM (150 mL). 2 M HCl is added to give pH˜1-2. The organic phase isseparated, washed again with 2 M HCl (100 mL), followed by sat. NaHCO₃(100 mL). The organic layer is diluted with EtOAc (800 mL) and isvigourously stirred at RT. The mixture is then filtered removing someinsoluble material in the process. The now clear two phase mixture isseparated, the organic (EtOAc) layer is dried over over MgSO₄ and isfiltered and concentrated to give an off white solid. The crude solid issuspended in diethylether (500 mL) and is triturated, removing somebrown/yellow colour. The solid is allowed to settle, and the liquors aredecanted off. The solid is then triturated in iso-hexane (300 mL), usingthe same procedure twice, then the solid is transferred to a small flaskin iso-hexane slurry and is dried in vacuo to give an off-white solid;[MH+ 334]

Step 4Trans-2-chloro-N-{4-[(3-methyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide

To a 100 mL round-bottomed flask containingtrans-2-chloro-N-(4-formyl-cyclohexyl)-5-trifluoromethyl-benzamide (step3) (900 mg, 2.70 mmol) and 2-amino-3-picoline (306 mg, 2.83 mmol) in dryDCM (30 mL) is added sodium triacetoxyborohydride (857 mg, 4.05 mmol) inone portion. The suspension is stirred at RT overnight. 1N sodiumhydroxide (10 mL) is added and the mixture is stirred at RT for 10 min.The mixture is then extracted with DCM (3×75 mL). DCM extracts arecombined, washed with sat. brine (50 mL), dried (MgSO₄), filtered andevaporated to give a colourless solid. The crude product is redissolvedin DCM, absorbed directly onto silica gel and columned on silica gelusing a 40 g pre-packed column and isohexane/EtOAc gradient elution (0%to 100% EtOAc). Product is isolated as a colourless solid and isrecrystallised from minimum amount of EtOAc containing isohexane (approx10:1 iHex:EtOAc) to give 487 mg colourless crystals.

The compounds of the following tabulated Examples (Table 1) are preparedby a similar method to that of Example 1 using the appropriate benzamideor pyrazole starting materials (prepared analogously totrans-2-chloro-N-(4-formyl-cyclohexyl)-5-trifluoromethyl-benzamide fromtrans-4-amino-cyclohexylcarboxylic acid methyl ester hydrochloride andthe appropriate benzoly chloride) and the appropriate amine.

TABLE 1 Ex. Structure Name [M + H]⁺ 1.1

Trans-2-Chloro-N-methyl- N-(4-phenylaminomethyl- cyclohexyl)-5-trifluoromethyl-benzamide 425.36 1.2

Trans-2,5-Dichloro-N-[4- (pyridin-3-ylaminomethyl)-cyclohexyl]-benzamide 378.19 1.3

Trans-2,5-Dichloro-N-{4-[(6- trifluoromethyl-pyridin-3-ylamino)-methyl]- cyclohexyl}-benzamide 446.23 1.4

Trans-2,5-Dichloro-N-{4-{(6- cyano-pyridin-3-ylamino)-methyl]-cyclohexyl}- benzamide 403.23 1.5

Trans-N-{4-[(6- Acetylamino-pyridin-3- ylamino)-methyl]-cyclohexyl}-2,5-dichloro- benzamide 435.28 1.6

Trans-2,5-Dichloro-N-{4-[(6- methoxy-pyridin-3-ylamino)-methyl]-cyclohexyl}- benzamide 408.26 1.7

Trans-2,5-Dichloro-N-{4-[(6- chloro-pyridin-3-ylamino)-methyl]-cyclohexyl}- benzamide 412.23 1.8

Trans-2,5-Dichloro-N-{4-[(6- morpholin-4-yl-pyridin-3- ylamino)-methyl]-cyclohexyl}-benzamide 463.27 1.9

Trans-2,5-Dichloro-N-(4-{[5- (4-fluoro-phenyl)-2H-pyrazol-3-ylamino]-methyl}- cyclohexyl)-benzamide 461.3 1.10

Trans-2-Chloro-N-{4-[(4,5- dimethyl-thiazol-2-ylamino)-methyl]-cyclohexyl}-5- methyl-benzamide 392.32 1.11

Trans-N-[4-(Benzothiazol-2- ylaminomethyl)-cyclohexyl]-2,5-dichloro-benzamide 434.29 1.12

Trans-2,5-Dichloro-N-{4-[(1- methyl-1H-benzoimidazol-2-ylamino)-methyl]- cyclohexyl}-benzamide 431.35 1.13

Trans-2-Chloro-N-{4-[(2- methyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-5- trifluoromethyl-benzamide 426.4 1.14

Trans-2-Chloro-N-{4-[(6- methyl-pyridin-3-ylamino)-methyl]-cyclohexyl}-5- trifluoromethyl-benzamide 426.42 1.15

Trans-2,5-Dichloro-N-[4- (pyrazin-2-ylaminomethyl)-cyclohexyl]-benzamide 379.21 1.16

Trans-2-Chloro-N-{4-[(4- methyl-pyridin-3-ylamino)-methyl]-cyclohexyl)-5- trifluoromethyl-benzamide 426.42 1.17

Trans-2,5-Dichloro-N-{4-[(5- cyclopropyl-2H-pyrazol-3- ylamino)-methyl]-cyclohexyl}-benzamide 407.32 1.18

Trans-2,5-Dichloro-N-{4- [(4,5-dimethyl-thiazol-2- ylamino)-methyl]-cyclohexyl}-nicotinamide 413.37 1.19

Trans-2-Chloro-N-{4-[(6- methoxy-pyridin-2-ylamino)-methyl]-cyclohexyl}-5- trifluoromethyl-benzamide 442.32 1.20

Trans-2-Chloro-N-{4-[(4,5- dimethyl-thiazol-2-ylamino)-methyl]-cyclohexyl}-5- methoxy-benzamide 408.33 1.21

Trans-2-Chloro-N-[4- (pyridin-2-ylaminomethyl)- cyclohexyl]-5-trifluoromethyl-benzamide 412.33 1.22

Trans-2-Chloro-N-{4-[(5- chloro-pyridin-2-ylamino)-methyl]-cyclohexyl}-5- trifluoromethyl-benzamide 446.28 1.23

Trans-2-Chloro-5- trifluoromethyl-N-{4-[(5- trifluoromethyl-pyridin-2-ylamino)-methyl]- cyclohexyl}-benzamide 480.23 1.24

Trans-2,5-Dichloro-N-{4-[(5- propyl-2H-pyrazol-3- ylamino)-methyl]-cyclohexyl}-benzamide 409.34 1.25

Trans-2-Chloro-5- trifluoromethyl-N-{4-[(6- trifluoromethyl-pyridin-2-ylamino)-methyl]- cyclohexyl}-benzamide 480.21 1.26

Trans-2,5-Dichloro-N-{4-[(6- trifluoromethyl-pyridin-2-ylamino)-methyl]- cyclohexyl}-benzamide 446.25 1.27

Trans-2,5-Dichloro-N-{4-[(6- methyl-pyridin-2-ylamino)-methyl]-cyclohexyl}- benzamide 392.25 1.28

Trans-2,5-Dichloro-N-{4-[(5- methyl-pyridin-2-ylamino)-methyl]-cyclohexyl}- benzamide 392.27 1.29

Trans-2 ,5-Dichloro-N-{4- [(4,6-dimethyl-pyridin-2- ylamino)-methyl]-cyclohexyl}-benzamide 406.3 1.30

Trans-2-Chloro-N-{4-[(5- ethyl-2H-pyrazol-3- ylamino)-methyl]cyclohexyl}-5- trifluoromethyl-benzamide 429.39 1.31

Trans-2-Chloro-N-[4- (pyrimidin-2- ylaminomethyl)-cyclohexyl]-5-trifluoromethyl-benzamide 413.34 1.32

Trans-2,5-Dichloro-N-{4-[(5- trifluoromethyl-1H-indazol-3-ylamino)-methyl]- cyclohexyl}-benzamide 485.25

Example 1.33Trans-6-{[4-(2-Chloro-5-trifluoromethyl-benzoylamino)-cyclohexylmethyl]-amino}-nicotinicacid

Trans-6-{[4-(2-Chloro-5-trifluoromethyl-benzoylamino)-cyclohexylmethyl]-amino}-nicotinicacid methyl ester (Example 19.15) (30 mg, 0.06 mmol) is placed in a vialwith MeOH (2 mL). 1M NaOH (1 mL) is added and the reaction mixture isstirred at RT for 3 days. The reaction mixture is acidified and theresulting precipitate in the aqueous layer which was filtered and driedto afford the title compound. [MH+ 456.31], NMR: δH (400 MHz, DMSO);12.29 (1H, s), 8.53 (1H, d), 8.48 (1H, d), 7.78 (4H, m) 7.35 (1H, m),6.50 (1H, d), 3.71 (1H, m), 3.19 (2H, m), 1.96 (2H, m), 1.83 (2H, m),1.52 (1H, m), 1.23 (2H, m), 1.08 (2H, m).

Example 1.34Trans-2-Chloro-N-{4-[(5-dimethylaminomethyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamidehydrochloride

Step 1Trans-2-Chloro-N-{4-[(5-formyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide

Trans-2-Chloro-N-{4-[(5-hydroxymethyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide(Example 19.20) (100 mg, 0.23 mmol) is placed in a flask with DCM (10mL) and manganese (IV) oxide (297 mg, 3.4 mmol). The reaction mixture isstirred at RT for 4 hours and manganese (IV) oxide is removed byfiltration. The solvent was removed in vacuo to afford the titlecompound; NMR (400 MHz, DMSO-d₆) δ 9.66 (1H, s), 8.49 (2H, m), 7.77 (5H,m), 6.58 (1H, d), 3.70 (1H, m), 3.23 (2H, m), 1.93 (2H, m), 1.81 (2H,m),1.53 (1H, m), 1.23 (2H, m), 1.09 (2H, m).

Step 2Trans-2-Chloro-N-{4-[(5-dimethylaminomethyl-pyridin-2-ylamino)-methyl]-cyclohexyl}5-trifluoromethyl-benzamide hydrochloride

The title compound is prepared fromTrans-2-Chloro-N-{4-[(5-formyl-pyridin-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamideand dimethylamine hydrochloride analogously to Example 1.

[MH]⁺ 469.30. NMR: δH (400 MHz, DMSO); 11.75 (1H, s), 8.51 (1H, d), 8.10(1H, s), 7.92 (1H, br), 7.80 (1H, m), 7.81 (1H, m), 7.74 (2H, m), 7.05(1H, br s), 4.20 (2H, m), 3.71 (1H, m), 3.27 (2H, m), 2.70 (6H, d), 1.92(4H, m), 1.59 (1H, m), 1.28 (2H, m), 1.12 (2H, m).

Example 1.35 1.35a(+/−)-2-Chloro-N-(1S,3R,4S)-4-{[5-(4-fluoro-phenyl)-1H-pyrazol-3-ylamino]-methyl}-3-methyl-cyclohexyl)-5-trifluoromethyl-benzamideand 1.35b(+/−)-2-Chloro-N-((1S,3S,4S)-4-{[5-(4-fluoro-phenyl)-1H-pyrazol-3-ylamino]-methyl}-3-methylcyclohexyl)-5-trifluoromethyl-benzamide

Step 1 Ethyl 4-amino-2-methylcyclohexanecarboxylate

Ethyl 2-methyl-4-oxocyclohex-2-enecarboxylate (2.0 g, 10.98 mmol) isdissolved in MeOH (40 ml) and water (4.0 ml) to give a yellow solution.Ammonium formate (8.31 g, 132 mmol) is added and stirred at RT until thesuspension dissolves to form a solution. Palladium on carbon (0.117 g,1.098 mmol) is added and the reaction mixture is stirred at 70° C. for 1hour. The mixture is filtered through Celite® (filter material) andwashed with MeOH. The filtrate is concentrated in vacuo and the residueis partitioned between EtOAc and water. The aqueous portion is dilutedwith sat. sodium bicarbonate and washed with EtOAc. The pH is adjustedto pH 14 using 1M NaOH and the aqueous is extracted with EtOAc. Thecombined organic extracts are dried MgSO₄, filtered and concentrated invacuo to afford the title compound; [MH]⁺ 186.24.

Step 2 Ethyl4-(2-chloro-5-(trifluoromethyl)benzamido)-2-methylcyclohexanecarboxylate

Ethyl 4-amino-2-methylcyclohexanecarboxylate (780 mg, 4.21 mmol) in THF(10 ml) is treated with TEA (1.174 ml, 8.42 mmol) and the reactionmixture is cooled to 0° C. 2-Chloro-5-(trifluoromethyl)benzoyl chloride(921 mg, 3.79 mmol) is added dropwise and the reaction mixture isstirred and allowed to warm to RT. After 3 hours, the reaction isquenched with water and partitioned between EtOAc and sat. sodiumbicarbonate. The organic portion is separated and dried over MgSO₄ andconcentrated in vacuo to afford the title compound which is used withoutfurther purification. [MH]⁺ 392.26.

Step 32-Chloro-N-(4-{[5-(4-fluoro-phenyl)-1H-pyrazol-3-ylamino]-methyl}-3-methyl-cyclohexyl)-5-trifluoromethyl-benzamide

The title compound is prepared analogously to Example 1 by replacingtrans-4-(2-chloro-5-trifluoromethyl-benzoylamino)-cyclohexane carboxylicacid methyl ester (Ex. 1 Step 2) with ethyl4-(2-chloro-5-(trifluoromethyl)benzamido)-2-methyl cyclohexanecarboxylate (Ex. 1.35 step 2) and by replacing 2-amino-3-picoline (Ex. 1step 4) with 5-(4-fluorophenyl)-1H-pyrazol-3-amine. [MH]⁺ 509.40.

Separation and isolation of 1.35a(+/−)-2-Chloro-N-((1S,3R,4S)-4-{[5-(4-fluoro-phenyl)-1H-pyrazol-3-ylamino]-methyl}-3-methyl-cyclohexyl)-5-trifluoromethyl-benzamideand 1.35b(+/−)-2-Chloro-N-((1S,3S,4S)-4-{[5-(4-fluoro-phenyl)-1H-pyrazol-3-ylamino]-methyl}-3-methylcyclohexyl)-5-trifluoromethyl-benzamidefrom a 90 mg sample of the crude reaction mixture was carried out bySupercritical Fluid Chromatography followed by preparative mass directedreverse phase HPLC, using the following methods:

(1) Supercritical Fluid Chromatography

Mobile Phase: 36% 2-propanol/0.1% DEA/64% CO₂

Column: Chiralpak AD-H, 250×10 mm id, 5 μm

Detection: UV @220 nm

Flow rate: 10 ml/min

Sample concentration: 90 mg in 3.0 ml EtOH

Injection volume: 200 μl

7 mg of 1.35a(+/−)-2-Chloro-N-((1S,3R,4S)-4-{[5-(4-fluoro-phenyl)-1H-pyrazol-3-ylamino]-methyl}-3-methyl-cyclohexyl)-5-trifluoromethyl-benzamidewas isolated with a retention time of 10.48 min.

Impure fractions centered around retention time 9.15 min were combinedand purified by preparative mass directed reverse phase HPLC

(2) Preparative Mass Directed Reverse Phase HPLC

The impure fractions from the SFC purification above were purified bythe following method

Column: Sunfire C18, 19×50 mm, 5 um column

Mobile phase: A=Water+0.1% TFA

-   -   B=MeCN+0.1% TFA

Gradient: 0-1.0 min 35% B (flow rate 10 ml/min)

-   -   1.0-9.0 min 35-42% B (flow rate 30 ml/min)

Detection: single quad electrospray MS

Injection volume: 100 μl

Sample concentration: 20 mg in 2 ml

11 mg of(+/−)-2-Chloro-N-((1S,3S,4S)-4-{[5-(4-fluoro-phenyl)-1H-pyrazol-3-ylamino]-methyl}-3-methyl-cyclohexyl)-5-trifluoromethyl-benzamidewas isolated with retention time 7.70 min

Example 1.36Trans-2-Chloro-N-(4-{[4-(4-chloro-phenyl)-isoxazol-3-ylamino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide

A mixture oftrans-2-chloro-N-(4-formyl-cyclohexyl)-5-trifluoromethyl-benzamide(Example 1 Step 3) (100 mg, 0.30 mmol) and4-(4-chlorophenyl)isoxazol-3-amine (this compound can be preparedaccording to method described in ‘Chemistry of Heterocyclic Compounds’(New York, N.Y., United States) (2007), 43(1), 118-119) (58 mg, 0.300mmol) is stirred in titanium(IV) isopropoxide (1 ml, 3.4 mmol) for 3 h.A thick slurry results. After 3 h, methanol (5 ml) is added followed byslow addition of sodium borohydride (18 mg, 0.5 mmol). after 5 minutes,sodium hydroxide solution 91 ml, 0.1M) is added to the reaction followedby dilution with ethyl acetate and brine. The organic extract is washedwith brine, dried over MgSO4 and the solvent removed in vacuo.Purification by chromatography on silica, eluting withchloroform-ethanol (10:1) affords a sample of product containing minoramounts of starting materials. Trituation with methanol yields a puresample or the title compound. MS m/z 512.3 [M+H]+; ¹H NMR (400 MHz,CDCl3) δ 1.25 8H, m), 1.75 (1H, m), 1.95 (2H, m), 2.22 (2H, m), 3.20(2H, d), 4.00 (1H, m), 5.97 (1H, d), 7.35 (2H, d), 7.45 (2H, d), 7.55(1H, d), 7.62 (1H, d), 7.90 (1H, s), 8.15 (1H, s).

Examples 2.1 to 2.46

The compounds of the following tabulated Examples are prepared using thefollowing general procedure:

A stock solution oftrans-2-chloro-N-(4-formyl-cyclohexyl)-5-trifluoromethyl-benzamide(Example 1 Step 3) is made up in dry THF (5.5 g in 88 mL). 800 ul ofaldehyde solution is pipetted into each vial of pre-weighed amine (1.2eq, 0.18 mmol). A stock solution of acetic acid is made up in dry THF(2.56 mL in 22 mL THF). Acetic acid stock solution (200 μl) is pipettedinto each vial. MP-triacetoxyborohydride resin (>2.5 eq, >0.374 mmol,˜200 mg) is added to each vial. Vials are sealed and shaken at RT for 16hours. Crude reaction mixtures are passed onto a 1 g SCX-2 cartridge(Biotage) under gravity, which had been pre-wetted with 1 mL MeOH. Thecartridges are washed with 2×2 mL MeOH, then compounds eluted with 2×2mL 2M ammonia in MeOH. Compounds are analyzed and evaporated in vacuo.Crude mixtures are purified further by prep HPLC (Waters Sunfire C18 5micron column, 19×50 mm, mobile phases 0.1% TFA in water, 0.1% TFA inacetonitrile, 6 minute gradient dependant on retention time fromanalytics). Successful purifications are turned into free-based aminesby passing prep fraction through a SCX-2 cartridge pre-wetted with MeOH,washed with 5 mL MeOH, and eluted with 2×2 mL 3.5M ammonia in MeOH.Finally, compounds are evaporated in vacuo.

TABLE 2 Ex. Structure Name [M + H]⁺ 2.1

Trans-2-Chloro-N- {4-[(4-methyl-pyridin- 2-ylamino)-methyl]-cyclohexyl}-5- trifluoromethyl- benzamide 426.34 2.2

Trans-2-Chloro-N-[4- (isoquinolin-1- ylaminomethyl)- cyclohexyl]-5-trifluoromethyl- benzamide 462.36 2.3

Trans-2-Chloro-N- {4-[(6-chloro-pyridin- 3-ylamino)-methyl]-cyclohexyl}-5- trifluoromethyl- benzamide 446.29 2.4

Trans-2-Chloro-N- {4-[(5-ethyl- [1,3,4]thiadiazol-2- ylamino)-methyl]-cyclohexyl}-5- trifluoromethyl- benzamide 447.3  2.5

Trans-2-Chloro-N- {4-[(5-methyl-thiazol- 2-ylamino)-methyl]-cyclohexyl}-5- trifluoromethyl- benzamide 432.3  2.6

Trans-2-Chloro-N- {4-[(4,6-dimethyl- pyridin-2-ylamino)-methyl]-cyclohexyl}- 5-trifluoromethyl- benzamide 440.36 2.7

Trans-2-Chloro-N- {4-[(6-methoxy- pyridin-3-ylamino)-methyl]-cyclohexyl}- 5-trifluoromethyl- benzamide 442.34 2.8

Trans-2-Chloro-N- {4-[(5-methyl-pyridin- 2-ylamino)-methyl]-cyclohexyl}-5- trifluoromethyl- benzamide 426.32 2.9

Trans-2-Chloro-N- {4-[(6-methyl-pyridin- 2-ylamino)-methyl]-cyclohexyl}-5- trifluoromethyl- benzamide 426.32 2.10

Trans-2-Chloro-N- {4-[(4,6-dimethoxy- pyrimidin-2- ylamino)-methyl]-cyclohexyl}-5- trifluoromethyl- benzamide 473.39 2.11

Trans-2-Chloro-N-[4- (thiazol-2- ylaminomethyl)- cyclohexyl]-5-trifluoromethyl- benzamide 418.26 2.12

Trans-2-Chloro-N- {4-[(5-cyclopropyl- [1,3,4]thiadiazol-2-ylamino)-methyl]- cyclohexyl}-5- trifluoromethyl- benzamide 459.34 2.13

Trans-2-Chloro-N- {4-[(2-fluoro- phenylamino)- methyl]-cyclohexyl}-5-trifluoromethyl- benzamide 429.3  2.14

Trans-2-Chloro-N- {4-[(2,4-difluoro- phenylamino)- methyl]-cyclohexyl}-5-trifluoromethyl- benzamide 488.36 (MH + MeCN)+ 2.15

Trans-2-Chloro-N- {4-[(2-fluoro-5- methyl- phenylamino)-methyl]-cyclohexyl}- 5-trifluoromethyl- benzamide 443.34 2.16

Trans-2-Chloro-N- {4-[(2-chloro-5- methyl- phenylamino)-methyl]-cyclohexyl}- 5-trifluoromethyl- benzamide 459.34 2.17

Trans-2-Chloro-N- {4-[(2-methoxy- phenylamino)- methyl]-cyclohexyl}-5-trifluoromethyl- benzamide 441.34 2.18

Trans-2-Chloro-N- {4-[(3-cyano- phenylamino)- methyl]-cyclohexyl}-5-trifluoromethyl- benzamide 436.33 2.19

Trans-2-Chloro-N- {4-[(2-sulfamoyl- phenylamino)- methyl]-cyclohexyl}-5-trifluoromethyl- benzamide 489.11 2.20

Trans-2-Chloro-N- {4-[(3-chloro- phenylamino)- methyl]-cyclohexyl}-5-trifluoromethyl- benzamide 445.29 2.21

Trans-2-Chloro-5- trifluoromethyl-N-{4-[(3- trifluoromethyl-phenylamino)- methyl]-cyclohexyl}- benzamide 479.34 2.22

Trans-2-Chloro-N- {4-[(3,4-dimethyl- phenylamino)- methyl]-cyclohexyl}-5-trifluoromethyl- benzamide 439.36 2.23

Trans-2-Chloro-N- {4-[(3,5-dimethyl- phenylamino)- methyl]-cyclohexyl}-5-trifluoromethyl- benzamide 439.36 2.24

Trans-2-Chloro-N- {4-[(4-methoxy- phenylamino)- methyl]-cyclohexyl}-5-trifluoromethyl- benzamide 441.35 2.25

Trans-2-Chloro-N- {4-[(4-ethoxy- phenylamino)- methyl]-cyclohexyl}-5-trifluoromethyl- benzamide 455.35 2.26

Trans-2-Chloro-N- {4-[(2-chloro- phenylamino)- methyl]-cyclohexyl}-5-trifluoromethyl- benzamide 445.3  2.27

Trans-2-Chloro-N- {4-[(3-isopropoxy- phenylamino)- methyl]-cyclohexyl}-5-trifluoromethyl- benzamide 469.39 2.28

Trans-2-Chloro-N- {4-[(1H-indol-5- ylamino-methyl]- cyclohexyl}-5-trifluoromethyl- benzamide 450.34 2.29

Trans-N-[4- (Benzo[1,3]dioxol-5- ylaminomethyl)- cyclohexyl]-2-chloro-5-trifluoromethyl- benzamide 455.32 2.30

Trans-2-Chloro-N-[4- (quinolin-6- ylaminomethyl)- cyclohexyl]-5-trifluoromethyl- benzamide 462.36 2.31

Trans-2-Chloro-N- {4-[(4- trifluoromethoxy- phenylamino)-methyl]-cyclohexyl}- 5-trifluoromethyl- benzamide 536.38 (MH + MeCN)+2.32

Trans-2-Chloro-N- {4-[(3- trifluoromethoxy- phenylamino)-methyl]-cyclohexyl}- 5-trifluoromethyl- benzamide 536.38 (MH + MeCN)+2.33

Trans-N-{4-[(2- Benzenesulfonyl- ethylamino)-methyl]-cyclohexyl}-2-chloro- 5-trifluoromethyl- benzamide 503.34 2.34

Trans-N-{4-[(5-tert- Butyl-isoxazol-3- ylamino)-methyl]-cyclohexyl}-2-chloro- 5-trifluoromethyl- benzamide 458.38 2.35

Trans-2-Chloro-N- (4-{[(5-phenyl- isoxazol-3-ylmethyl)- amino]-methyl}-cyclohexyl)-5- trifluoromethyl- benzamide 492.37 2.36

Trans-2-Chloro-N- (4-{[(3-phenyl- [1,2,4]oxadiazol-5- ylmethyl)-amino]-methyl}-cyclohexyl)- 5-trifluoromethyl- benzamide 493.35 2.37

Trans-2-Chloro-N- (4-{[(3-phenyl- isoxazol-5-ylmethyl)- amino]-methyl}-cyclohexyl)-5- trifluoromethyl- benzamide 492.35 2.38

Trans-2-Chloro-N- {4-[(3,5-dimethyl- isoxazol-4-ylamino)-methyl]-cyclohexyl}- 5-trifluoromethyl- benzamide 430.33 2.39

Trans-2-Chloro-N- {4-[(4-fluoro-3- trifluoromethyl- phenylamino)-methyl]-cyclohexyl}- 5-trifluoromethyl- benzamide 538.38 (MH + MeCN)+2.40

Trans-2-Chloro-N- {4-[(6-phenoxy- pyridin-3-ylamino)-methyl]-cyclohexyl}- 5-trifluoromethyl- benzamide 504.36 2.41

Trans-2-Chloro-N- {4-[(8-methyl- quinolin-5-ylamino)-methyl]-cyclohexyl}- 5-trifluoromethyl- benzamide 476.38 2.42

Trans-2-Chloro-N- (4-{[(2,3-dihydro- benzo[1,4]dioxin-2-ylmethyl)-amino]- methyl}-cyclohexyl)- 5-trifluoromethyl- benzamide482.16 2.43

Trans-2-Chloro-N-[4- (quinolin-8- ylaminomethyl)- cyclohexyl]-5-trifluoromethyl- benzamide 461.15 2.44

Trans-2-Chloro-N-[4- (quinolin-6- ylaminomethyl)- cyclohexyl]-5-trifluoromethyl- benzamide 461.15

Example 3Trans-2-chloro-N-{4-[(4,5-dimethyl-thiazol-2-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide

800 mg (2.40 mmol) oftrans-2-chloro-N-(4-formyl-cyclohexyl)-5-trifluoromethyl-benzamide(Example 1 Step 3) and 274 mg (2.40 mmol) of 5-methylthiazol-2-amine areplaced in a flask with 40 mL of DCM. 191 mg (3.60 mmol) of sodiumtriacetoxyborohydride is added and the RM is stirred at room temperatureovernight 1N sodium hydroxide (2 mL) is added and the mixture is stirredat RT for 10 min. The RM is partitioned between DCM and water. Theorganic phase is washed with water and brine, dried over MgSO₄, filteredand the solvent is removed in vacuo. The product is purified by ISCOCombiflash Rf (80 g Si, iso-hexane→EtOAc, default setting). The productcrystallized out on the column and had to be eluted with EtOAc (10%MeOH). The solvent is removed in vacuo and the product is crystallizedfrom EtOAc, filtered and dried for 4 days under vacuum @50° C.

Examples 4.1 to 4.33

The compounds of the following tabulated Examples are prepared using thefollowing general procedure:

A stock solution oftrans-2-chloro-N-(4-formyl-cyclohexyl)-5-trifluoromethyl-benzamide(Example 1 Step 3) (3.102 g) and acetic acid (1.6 mL) is prepared in23.5 mL DMF (peptide grade). Each microwave vial is loaded withMP-triacetoxyborohydride resin (˜100 mg). 267 μl of the aceticacid/aldehyde solution is added to each microwave vial. Each amine issolubilized in 750 μl DMF and added to the microwave vials. The vialsare sealed and heated to 60° C. for 10 minutes in the microwavesynthesizer. The crude reactions are passed onto a 1 g SCX-2 cartridge(Biotage) under gravity, which had been pre-wetted with 1 mL MeOH. Thecartridges are washed with 2×2 mL MeOH, then compounds eluted with 2×2mL 2M ammonia in MeOH. Compounds are analyzed and evaporated in vacuo.Crude mixtures are purified further by prep HPLC (Waters Sunfire C18 5micron column, 19×50 mm, mobile phases 0.1% TFA in water, 0.1% TFA inacetonitrile, 6 minute gradient dependant on retention time fromanalytics). Successful purifications are turned into free-based aminesby passing prep fraction through a SCX-2 cartridge pre-wetted with MeOH,washed with 5 mL MeOH, and eluted with 2×2 mL 3.5M ammonia in MeOH.Compounds are evaporated in vacuo.

TABLE 3 Ex. Structure Name [M + H]⁺ 4.1

Trans-2-Chloro-N- [4- ([1,3,4]thiadiazol- 2-ylaminomethyl)-cyclohexyl]-5- trifluoromethyl- benzamide 419.04 4.2

Trans-2-Chloro-N- {4-[(5-methyl-1H- pyrazol-3- ylamino)-methyl]-cyclohexyl}-5- trifluoromethyl- benzamide 415.33 4.3

Trans-2-Chloro-N- {4-[(4-methyl- thiazol-2-ylamino)- methyl]-cyclohexyl}-5- trifluoromethyl- benzamide 432.29 4.4

Trans-2-Chloro-N- {4-[(1H-pyrazol-3- ylamino)-methyl]- cyclohexyl}-5-trifluoromethyl- benzamide 401.3 4.5

Trans-2-Chloro-N- {4-[(2-methyl-1H- indol-5-ylamino)- methyl]-cyclohexyl}-5- trifluoromethyl- benzamide 464.38 4.6

Trans-2-Chloro-5- trifluoromethyl-N- {4-[(1,3,5-trimethyl- 1H-pyrazol-4-ylamino)-methyl]- cyclohexyl}- benzamide 443.38 4.7

Trans-N-[4- (Benzothiazol-2- ylaminomethyl)- cyclohexyl]-2- chloro-5-trifluoromethyl- benzamide 468.31 4.8

Trans-2-Chloro-N- (4-{[(5-phenyl-4H- [1,2,4]triazol-3- ylmethyl)-amino]-methyl}- cyclohexyl)-5- trifluoromethyl- benzamide 492.39 4.9

Trans-2-Chloro-N- {4-[(1,3-dihydro- isobenzofuran-5- ylamino)-methyl]-cyclohexyl}-5- trifluoromethyl- benzamide 453.35 4.10

Trans-2-Chloro-N- (4-{[(2-phenyl-2H- [1,2,3]triazol-4- ylmethyl)-amino]-methyl}- cyclohexyl)-5- trifluoromethyl- benzamide 492.38 4.11

Trans-2-Chloro-N- (4-{[5-(4-fluoro- phenyl)-2H- pyrazol-3-ylamino]-methyl}- cyclohexyl)-5- trifluoromethyl- benzamide 495.07 4.12

Trans-2-Chloro-N- {4-[(2-methyl-3H- benzoimidazol-5- ylamino)-methyl]-cyclohexyl}-5- trifluoromethyl- benzamide 465.38 4.13

Trans-2-Chloro-N- {4-[(1-methyl-1H- benzoimidazol-2- ylamino)-methyl]-cyclohexyl}-5- trifluoromethyl- benzamide 465.09 4.14

Trans-2-Chloro-N- {4-[(1-methyl-1H- [1,2,4]triazol-3- ylamino)-methyl]-cyclohexyl}-5- trifluoromethyl- benzamide 416.33 4.15

Trans-2-Chloro-N- {4-[(5-propyl-1H- pyrazol-3- ylamino)-methyl]-cyclohexyl}-5- trifluoromethyl- benzamide 443.38 4.16

Trans-2-Chloro-N- {4-[(5-isopropyl- 1H-pyrazol-3- ylamino)-methyl]-cyclohexyl}-5- trifluoromethyl- benzamide 443.38 4.17

Trans-2-Chloro-N- {4-[(2,6-dimethyl quinolin-5- ylamino)-methyl]-cyclohexyl}-5- trifluoromethyl- benzamide 490.38 4.18

Trans-2-Chloro-N- {4-[(5,6-dimethyl 1H-benzoimidazol- 2-ylamino)-methyl]- cyclohexyl}-5- trifluoromethyl- benzamide 479.15 4.19

Trans-N-(4- {[(Benzooxazol-2- ylmethyl)-amino]- methyl}- cyclohexyl)-2-chloro-5- trifluoromethyl- benzamide 466.36 4.20

Trans-N-{4-[(1H- Benzoimidazol-2- ylamino)-methyl]- cyclohexyl}-2-chloro-5- trifluoromethyl- benzamide 451.34 4.21

Trans-2-Chloro-N- [4-(pyridin-3- ylaminomethyl)- cyclohexyl]-5-trifluoromethyl- benzamide 412.33 4.22

Trans-N-{4-[(4-tert- Butyl- phenylamino)- methyl]- cyclohexyl}-2-chloro-5- trifluoromethyl- benzamide 467.13 4.23

Trans-2-Chloro-N- {4-[(3,4-dimethoxy- phenylamino)- methyl]-cyclohexyl}-5- trifluoromethyl- benzamide 471.38 4.24

Trans-N-{4-[(3- Bromo-4-methyl- phenylamino)- methyl]- cyclohexyl}-2-chloro-5- trifluoromethyl- benzamide 505.01 4.25

Trans-2-Chloro-N- (4-{[methyl-(3- phenyl- [1,2,4]oxadiazol-5-ylmethyl)-amino]- methyl}- cyclohexyl)-5- trifluoromethyl- benzamide507.38 4.26

Trans-2-Chloro-N- (4-{[methyl-(4- methyl-thiazol-2- ylmethyl)-amino]-methyl}- cyclohexyl)-5- trifluoromethyl- benzamide 460.33 4.27

Trans-2-Chloro-N- {4-[(methyl-phenyl- amino)-methyl]- cyclohexyl}-5-trifluoromethyl- benzamide 425.33 4.28

Trans-2-Chloro-N- (4-{[methyl-(5- phenyl-1H-pyrazol- 3-ylmethyl)-amino]-methyl}- cyclohexyl)-5- trifluoromethyl- benzamide 505.4 4.29

Trans-2-Chloro-N- (4-{[methyl-(2- methyl-thiazol-4- ylmethyl)-amino]-methyl}- cyclohexyl)-5- trifluoromethyl- benzamide 460.33 4.30

Trans-2-Chloro-N- (4-{[methyl-(3- phenyl-isoxazol-5- ylmethyl)-amino]-methyl}- cyclohexyl)-5- trifluoromethyl- benzamide 506.4 4.31

Trans-2-Chloro-N- {4-[(3-methoxy-4- methyl- phenylamino)- methyl]-cyclohexyl}-5- trifluoromethyl- benzamide 455.38 4.32

Trans-2-Chloro-N- {4-[(6-methyl- quinolin-5- ylamino)-methyl]-cyclohexyl}-5- trifluoromethyl- benzamide 476.38 4.33

Trans-2-Chloro-N- (4- phenylaminomethyl- cyclohexyl)-5- trifluoromethyl-benzamide 411.35

Examples 5.1 to 5.17 Preparation of Intermediate CompoundTrans-(4-Amino-cyclohexylmethyl)phenylamine Step 1 Methyltrans-4-(tert-butoxycarbonylamino)cyclohexanecarboxylate

Methyl trans-4-aminocyclohexanecarboxylate (43 g, 222 mmol) is added toMeOH (500 mL) to give a colourless solution. The solution is cooled to10° C. and triethylamine (46.4 mL, 333 mmol) is added dropwise, followedby a solution of di-tert-butyldicarbonate (53.3 g, 244 mmoL) in MeOH(400 mL) over 20 minutes. The reaction is warmed to room temperature andstirred at room temperature overnight. The mixture is evaporated todryness under reduced pressure. The resulting colourless solid isdissolved in EtOAc (1000 mL) and the solution obtained is washedsuccessively with 10% citric acid solution (100 mL), saturated sodiumbicarbonate solution (2×100 mL) and saturated brine (100 mL); dried(MgSO₄) and evaporated under reduced pressure to give a colourlesssolid.

Step 2 Trans-tert-butyl 4-(hydroxymethyl)cyclohexylcarbamate

Methyl trans-4-(tert-butoxycarbonylamino)cyclohexanecarboxylate (55.5 g,216 mmol) is suspended in ethanol (900 mL) and THF (100 mL) and themixture is cooled to 5° C. Granular calcium chloride (47.9 g, 431 mmol)is added portionwise to give a milky suspension. Sodium borohydride(32.6 g, 863 mmol) is added portionwise over 25 mins at 5° C. Thereaction mixture (white emulsion) is stirred at 5° C. for 1 hour, thewater bath is removed and then the reaction mixture is allowed to warmto room temperature and stirred at room temperature overnight. Thereaction mixture is cooled to 10° C. and 5% potassium carbonate (200 mL)is added dropwise until the pH of the solution is pH 11. A colourlessprecipitate formed which is filtered off. The solid is stirred withethyl acetate (2000 mL) and water (500 mL). The organic layer isseparated and washed with 0.5M HCl (200 mL), then washed with water(2×200 mL) and saturated brine (100 mL). The organic solution is driedover anhydrous MgSO₄, filtered and evaporated to give a white solid Thesolid is dried under high vacuum overnight to constant weight; [MH⁺230].

Step 3 Trans-(4-Formyl-cyclohexyl)carbamic acid tert-butyl ester

To trans-tert-butyl-4-(hydroxymethyl)cyclohexylcarbamate (8.0 g, 34.9mmol) in DCM (180 mL) and DMSO (60 mL) at 0° C. is added DIPEA (24.37mL, 140 mmol) and pyridine sulfur trioxide (22.21 g, 140 mmol) dissolvedin DMSO (60 mL). The mixture is stirred at room temperature for 15minutes and then is partitioned between 1M HCl and diethylether. Theorganic phase is separated and washed with 1M HCl, water then saturatedbrine. The mixture is dried (MgSO₄) and solvent evaporated to give theexpected product; [MH+MeCN]⁺ 269.

Step 4 Trans-(4-Phenylaminomethyl-cyclohexyl)carbamic acid tert-butylester

Trans-(4-Formyl-cyclohexyl)carbamic acid tert-butyl ester (3.27 g, 14.38mmol) and aniline (1.98 mL, 15.81 mmol) are dissolved in dichloromethane(60 mL) at room temperature. Sodium triacetoxyborohydride (4.57 g, 21.57mmol) is added in one portion and the mixture is stirred at roomtemperature for 2.5 hours. 1N sodium hydroxide solution (20 mL) is addedand the mixture is stirred at room temperature for a further 10 minutes.The DCM layer is separated and washed successively with water andsaturated brine, dried (MgSO₄), filtered and evaporated to give acolourless solid. This is slurried with iso-hexane, filtered and driedto give a colourless solid; [MH⁺ 305]

Step 5 Trans-(4-Amino-cyclohexylmethyl)phenylamine

Trans-(4-Phenylaminomethyl-cyclohexyl)carbamic acid tert-butyl ester(4.37 g, 14.35 mmol) is dissolved in dry dichloromethane (200 mL) undera nitrogen atmosphere and trifluoroacetic acid (70 mL) is added dropwiseat room temperature. The reaction mixture is stirred at room temperaturefor 3 hours before the volatiles are removed under reduced pressure. Theresidue is redissolved in DCM and washed with 1N sodium hydroxidesolution. The DCM is then separated, washed sequentially with water andsaturated brine and evaporated under reduced pressure, whereupon a beigesolid is formed; [MH⁺ 205]

The compounds of the following tabulated Examples (Table 4) are preparedaccording from trans-(4-amino-cyclohexylmethyl)phenylamine (Ex. 5.1 step5) according to the following general procedure:

In each reaction: carboxylic acid (0.147 mmol, 1.47 eq),trans-(4-amino-cyclohexylmethyl)phenylamine (Step 5) (0.1 mmol, 1 eq, 21mg), HATU (0.147 mmol, 1.47 eq, 56 mg), PS-DIEA 3.4 mmol/g loading (0.2mmol, 2 eq, 60 mg) are used.

A stock solution of trans-(4-amino-cyclohexylmethyl)phenylamine is madeup in DMF (1.428 g in 13.6 mL). A stock solution of HATU is made up inDMF (3.808 g in 20.4 mL DMF). Ca. 60 mg PS-DIEA is added to eachpre-weighed carboxylic acid. 200 ulTrans-(4-amino-cyclohexylmethyl)phenylamine solution is pipetted intoeach vial, followed by 300 μl of HATU solution. Vials are sealed andshaken at RT for 16 hr. Crude reactions are purified by loading onto a 1g SCX-2 cartridge pre-wetted with MeOH, crude is washed with 3 mL MeOHbefore compounds are eluted with 2×2 mL 2M ammonia in MeOH. Compoundsare analyzed and evaporated in vacuo. Crude mixtures are purifiedfurther by prep HPLC (Waters Sunfire C18 5 micron column, 19×50 mm,mobile phases 0.1% TFA in water, 0.1% TFA in acetonitrile, 6 minutegradient dependant on retention time from analytics). Successfulpurifications are turned into free-based amines by passing prep fractionthrough a SCX-2 cartridge pre-wetted with MeOH, washed with 5 mL MeOH,and eluted with 2×2 mL 3.5M ammonia in MeOH. Compounds are evaporated invacuo.

TABLE 4 Ex. Structure Name [M + H]⁺ 5.1

Trans-2-Chloro-6- methyl-N-(4- phenylaminomethyl- cyclohexyl)-nicotinamide 358.28 5.2

Trans-5-Methyl-N- (4- phenylaminomethyl- cyclohexyl)- nicotinamide324.32 5.3

Trans-3H-Indole-5- carboxylic acid (4- phenylaminomethyl- cyclohexyl)-amide 348.33 5.4

Trans-2-Methyl-N- (4- phenylaminomethyl- cyclohexyl)- nicotinamide323.33 5.5

Trans-2,3- Dimethyl-N-(4- phenylaminomethyl- cyclohexyl)- benzamide337.35 5.6

Trans-3-Chloro-4- methyl-N-(4- phenylaminomethyl- cyclohexyl)- benzamide357.3 5.7

Trans-2,5- Dichloro-N-(4- phenylaminomethyl- cyclohexyl)- benzamide377.26 5.8

Trans-4-Fluoro-N- (4- phenylaminomethyl- cyclohexyl)-3- trifluoromethyl-benzamide 395.32 5.9

Trans-5-Fluoro-N- (4- phenylaminomethyl- cyclohexyl)-2- trifluoromethyl-benzamide 395.32 5.10

Trans-2,5- Dichloro-N-(4- phenylaminomethyl- cyclohexyl)-isonicotinamide 378.24 5.11

Trans-Benzofuran- 5-carboxylic acid- (4- phenylaminomethyl- cyclohexyl)-amide 349.31 5.12

Trans-3-Fluoro-N- (4- phenylaminomethyl- cyclohexyl)- benzamide 327.325.13

Trans-5-Chloro-N- {4-[(4,5-dimethyl- thiazol-2-ylamino)- methyl]-cyclohexyl}-2- methoxy- nicotinamide 409.35 5.14

Trans-5-Chloro-N- {4-[(4,5-dimethyl- thiazol-2-ylamino)- methyl]-cyclohexyl}-2- methyl- nicotinamide 393.31 5.15

Trans-5-Chloro-2- dimethylamino-N- {4-[(4,5-dimethyl-thiazol-2-ylamino)- methyl]- cyclohexyl}- nicotinamide 422.41 5.16

Trans-6-Chloro- benzofuran-5- carboxylic acid {4- [(4,5-dimethyl-thiazol-2-ylamino)- methyl]- cyclohexyl}-amide 418.4 5.17

Trans-N-{4-[(4,5- Dimethyl-thiazol-2- ylamino)-methyl]- cyclohexyl}-5-trifluoromethyl- nicotinamide 413.38

Example 6Trans-2-chloro-N-(4-((3-(2-oxoimidazolidin-1-yl)-1H-pyrazol-1-yl)methyl)cyclohexyl)-5-(trifluoromethyl)benzamide

Step 1 Trans-(4-(2-chloro-5-(trifluoromethyl)benzamido)cyclohexyl)methyl4-methyl benzenesulfonate

Trans-2-chloro-N-(4-hydroxymethyl-cyclohexyl)-5-trifluoromethyl-benzamide(Example 1 step 2) 1.00 g (2.98 mmol) is dissolved in DCM (40 mL) andpyridine (10 mL). Tosyl chloride (0.85 g, 4.47 mmol) is added and thereaction mixture is stirred at RT overnight. The mixture is partitionedbetween DCM and 1M HCl. The organic phase is washed with water andbrine, dried over MgSO₄, filtered and the solvent is removed in vacuo.Trituration of the resulting solid with iso-hexane:EtOAc—4:1 affords thetitle compound; ¹H NMR (400 MHz, DMSO-d₆) δ 8.48 (1H, d), 7.80 (3H, m),7.72 (2H, d), 7.49 (2H, d), 3.85 (2H, d), 3.60 (1H, m), 2.41 (3H, s),1.89 (2H, m), 1.68 (2H, m), 1.53 (1H, m), 1.20 (2H, m), 1.00 (2H, m).

Step 2Trans-2-chloro-N-(4-((3(2-oxoimidazolidin-1-yl)-1H-pyrazol-1-yl)methyl)cyclohexyl)-5-(trifluoromethyl)benzamide

1-(1H-pyrazol-3-yl)imidazolidin-2-one (410 mg, 2.69 mmol) is placed in amicrowave vial with acetonitrile (12 mL). NaH (60%, 108 mg, 2.69 mmol)is added and the reaction mixture is stirred at RT for 30 minutes.Trans-(4-(2-chloro-5-(trifluoromethyl)benzamido)cyclohexyl)methyl4-methylbenzenesulfonate (1.20 g (0.20 mmol) is added and the mixture isheated using microwave radiation at 120° C. for 30 minutes. The mixtureis partitioned between DCM and water. The organic phase is washed withwater and brine, dried over MgSO₄, filtered and the solvent was removedin vacuo. The product is purified by crystallization (EtOAc with a smallamount of MeOH) to afford the title compound.

The compounds of the following tabulated Examples (Table 5), ortautomers thereof, are prepared by a similar method to that of Example 6by replacing 1-(1H-pyrazol-3-yl)imidazolidin-2-one with the appropriateintermediate. One such intermediate is1-(5-Methyl-1H-pyrazol-3-yl)-imidazolidin-2-one, the preparation ofwhich is described as follows:

Step 1 3-[3-(2-Chloro-ethyl)-ureido]-5-methyl-pyrazole-1-carboxylic acid(2-chloro-ethyl)-amide

To a solution of 5-Methyl-1H-pyrazol-3-ylamine (7.5 g, 77.2 mmol) in THF(150 mL) at 0° C. was added 2-chloroethylisocyanate (25 g, 236.9 mmol)and then the reaction mixture was stirred at RT for 18 h. Hexane wasadded to the reaction mixture, cooled to 0° C. and stirred for ˜2 h. Thewhite solid precipitated out was collected by filtration, washed withdiethylether and dried.

Step 2 1-(5-Methyl-1H-pyrazol-3-yl)-imidazolidin-2-one

To a solution of3-[3-(2-Chloro-ethyl)-ureido]-5-methyl-pyrazole-1-carboxylic acid(2-chloro-ethyl)-amide (14.5 g, 47.05 mmol) in THF (100 mL) was addedsodium ethoxide solution prepared from sodium (2.2 g, 95.65 mmol) andethanol (100 mL) and then the reaction mixture was stirred at RT for 20h. Precipitation of white solid was observed. The reaction mixture wascooled to 0° C. and stirred for ˜2 h. The precipitated solid wascollected by filtration, washed with ethanol and water, and dried undervacuum.

TABLE 5 Ex. Structure Name [M + H]⁺ 6.1

Trans-N-{4-[3-(2- Oxo-imidazolidin-1- yl)-pyrazol-1- ylmethyl]-cyclohexyl}-3- trifluoromethyl- benzamide 436.37 6.2

Trans-N-{4-[(4- Methoxy- phenylamino)- methyl]-cyclohexyl}-3-trifluoromethyl- benzamide 407.43 6.3

Trans-N-(4- Phenylaminomethyl- cyclohexyl)-3- trifluoromethyl- benzamide377.32 6.4

Trans-2,5-Dichloro- N-{4-{3-(2-oxo- imidazolidin-1-yl)-pyrazol-1-ylmethyl]- cyclohexyl}- benzamide 436.33 6.5

Trans-2,5-Dichloro- N-{4-[5-methyl-3-(2- oxo-imidazolidin-1-yl)-pyrazol-1- ylmethyl]- cyclohexyl}- benzamide 450.36

Example 7.0Trans-2-chloro-N-[4-(3,5-dimethyl-pyrazol-1-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide

Step 1 Trans-(4-(2-chloro-5-(trifluoromethyl)benzamido)cyclohexyl)methyltrifluoro methanesulfonate

Trans-2-chloro-N-(4-hydroxymethyl-cyclohexyl)-5-trifluoromethyl-benzamide(1.00 g, 2.98 mmol) in 25 mL of DCM is treated with pyridine (0.28 g,3.57 mmol) and the reaction mixture is cooled to 0° C.Trifluoromethanesulfonic anhydride (0.92 g, 3.28 mmol) of is slowlyadded and the reaction mixture is stirred at 0° C. for 1 hour. Thereaction is quenched by the addition of sat. NH₄Cl at 0° C. and thenextracted with DCM (3×10 mL). The DCM extracts are combined, washed withsat. brine (10 mL), dried (MgSO4), filtered and evaporated to afford thetitle compound as a pale yellow solid; ¹H NMR (400 MHz, DMSO-d₆) δ 8.50(1H, d), 7.80 (1H, m) 7.72 (2H, m), 4.11 (2H, d), 3.68 (1H, m), 1.95(2H, m), 1.78 (2H, m), 1.65 (1H, m), 1.25 (2H, m), 1.11 (2H, m).

Step 2Trans-2-chloro-N-[4-(3,5-dimethyl-pyrazol-1-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide

A solution of 3,5-dimethyl pyrazole (51.4 mg, 0.534 mmol) in MeCN (2 ml)is treated with sodium hydride (14.11 mg, 0.588 mmol) and the reactionmixture is stirred 10 minutes.Trans-4-(2-Chloro-5-(trifluoromethyl)benzamido)cyclohexyl)methyltrifluoromethanesulfonate (250 mg, 0.534 mmol) is added and the mixtureis stirred at RT for 2 hrs.

The resulting mixture is diluted with DCM and washed NaHCO₃. The organicportion is separated and concentrated in vacuo. Purification of thecrude product by chromatography on silica eluting with iso-hexane/EtOAcaffords a white solid. The solid is triturated with 9:1 iso-hexane:EtOAcand the resulting white solid is filtered off and dried to give thetitle compound. [MH+ 414.4]. NMR: δH (400 MHz, DMSO) 8.49 (1H, d), 7.73(3H, m), 5.77 (1H, s), 3.76 (2H, d), 3.68 (1H, m), 2.18 (3H, s), 2.08(3H, s), 1.91 (2H, m), 1.73 (1H, m), 1.58 (2H, m), 1.16 (4H, m).

The compounds of the following tabulated Examples (Table 6), ortautomers thereof, are prepared fromtrans4-(2-chloro-5-(trifluoromethyl)benzamido)cyclohexyl)methyltrifluoromethanesulfonate by a similar method to that of Example 7.0using the appropriate azole.

TABLE 7 Ex. Structure Name [M + H]⁺ 7.1

Trans-2-Chloro-N-[4-(3- methyl-5-trifluoromethyl- pyrazol-1-ylmethyl)-cyclohexyl]-5- trifluoromethyl-benzamide 368.3 7.2

Trans-2-Chloro-N-[4-(5- methyl-3-trifluoromethyl- pyrazol-1-ylmethyl)-cyclohexyl]-5- trifluoromethyl-benzamide 368.3 7.3

Trans-2-Chloro-N-[4-(2- methyl-4-trifluoromethyl- imidazol-1-ylmethyl)-cyclohexyl]-5- trifluoromethyl-benzamide 468.33 7.4

Trans-2-Chloro-N-(4- imidazol-1-ylmethyl- cyclohexyl)-5-trifluoromethyl-benzamide 386.30 7.5

Trans-2-Chloro-N-[4-(2- methyl-imidazol-1- ylmethyl)- cyclohexyl]-5-trifluoromethyl-benzamide 400.38 7.6

Trans-2-Chloro-N-[4-(3,5- di-(d3)-methyl-pyrazol-1- ylmethyl)-cyclohexyl]-5- trifluoromethyl-benzamide 420.45 7.7

Trans-2-Chloro-N-[4-(5- methyl-pyrazol-1- ylmethyl)- cyclohexyl]-5-trifluoromethyl-benzamide 400.35 7.8

Trans-2-Chloro-N-[4-(3- methyl-pyrazol-1- ylmethyl)- cyclohexyl]-5-trifluoromethyl-benzamide 400.35 7.9

Trans-2-Chloro-N-{4-[5-(4- methoxy-phenyl)-pyrazol-1-ylmethyl]-cyclohexyl}-5- trifluoromethyl-benzamide 492.32 7.10

Trans-2-Chloro-N-{4-[3-(4- methoxy-phenyl)-pyrazol-1-ylmethyl]-cyclohexyl}-5- trifluoromethyl-benzamide 492.34

Example 8Trans-2-Chloro-N-{4-[(5-cyclopropyl-2H-pyrazol-3-ylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide

To a 25 mL round-bottomed flask is addedtrans-2-chloro-N-(4-formyl-cyclohexyl)-5-trifluoromethyl-benzamide (100mg, 0.300 mmol) and 3-cyclopropyl-1H-pyrazol-5-amine (24.60 mg, 0.200mmol) in DCM (8 mL) to give a colorless solution. Acetic acid (0.046 mL,0.799 mmol) and sodium triacetoxyborohydride (127 mg, 0.599 mmol) areadded and the mixture is stirred at room temp for 90 minutes.

1M sodium hydroxide solution (2 mL) is added and the mixture is stirredat room temp for 10 minutes. The mixture is passed through a phaseseparator and evaporated to give a colourless oil. The crude mixture isre-dissolved in the minimum amount of DCM, applied to a prepacked 12 gsilica gel column and eluted with 0-100% EtOAc/isohexane gradientelution over 6 minutes, then 100% EtOAc for 8 minutes. Pure product isrecovered as a colourless oil. The oil is dissolved in the minimumamount of DCM and triturated/sonicated With 9:1 isohexane/EtOAc to givea colourless solid, 31 mg, [MH+ 441.36].

Example 9Trans-2-Chloro-N-{4-[(3-fluoro-phenylamino)-methyl]-cyclohexyl}-5-trifluoromethyl-benzamide

To a 50 mL round-bottomed flask containingtrans-2-chloro-N-(4-formyl-cyclohexyl)-5-trifluoromethyl-benzamide (Ex.1 step 3) (1.0 g, 3.0 mmol) and 3-fluoroaniline (0.29 mL, 3.0 mmol) indry DCM (25 mL) is added sodium triacetoxyborohydride (953 mg, 4.49mmol) in three portions over 1-2 minutes. The suspension is stirred atRT for 1 hour. 1N sodium hydroxide (25 mL) is added and the mixture isstirred at RT for 20 min. The mixture is then diluted with DCM (50 mL)and the DCM layer separated and washed with 1M HCl (25 mL) and brine (15mL), dried (MgSO₄), filtered and evaporated to give a colourless solid.The crude product is redissolved in DCM, absorbed directly onto silicagel and columned on silica gel using a 50 g pre-packed column and elutedwith 30% EtOAc/isohexane. Product is isolated as a colourless oil whichis triturated with diether ether-isohexane to afford the title compoundas colourless crystals. [MH+ 429.24].

Example 10Trans-2-chloro-N-(4-((5-methylpyridin-3-ylamino)methyl)-cyclohexyl)-5-(trifluoromethyl)benzamide

To a 50 mL round-bottomed flask containingtrans-2-chloro-N-(4-formyl-cyclohexyl)-5-trifluoromethyl-benzamide (Ex.1 step 3) (100 mg, 0.3 mmol) and 3-amino-5-methylpyridine (36 mg, 0.3mmol) in dry DCM (5 mL) is added sodium triacetoxyborohydride (106 mg,0.45 mmol) in one portion. The suspension is stirred at RT for 4 hours.The mixture is partitioned between DCM and saturated sodium bicarbonate,passed through a phase separator to recover the DCM layer and evaporatedto give a colourless solid. The crude product is redissolved in DCM,absorbed directly onto silica gel and columned on silica gel using a 12g pre-packed column and isohexane/EtOAc gradient elution (0% to 100%EtOAc). Product-containing fractions are combined and evaporated and theproduct is isolated as a colourless solid after trituration with 20%EtOAclisohexane, 55 mg, [MH+ 426.40].

Example 11Trans-2,5-Dichloro-N-(4-{[methyl-(5-phenyl-2H-pyrazol-3-ylmethyl)amino]-methyl}-cyclohexyl)-benzamide

To a 25 mL round-bottomed flask is addedtrans-2,5-dichloro-N-(4-formylcyclohexyl)benzamide (200 mg, 0.666 mmol)and N-methyl-1-(3-phenyl-1H-pyrazol-5-yl)methanamine oxalate (277 mg,0.999 mmol) in DCM (15 mL) to give a colorless solution. Acetic acid(0.153 mL, 2.67 mmol) and sodium triacetoxyborohydride (424 mg, 1.999mmol) are added and the mixture stirred at room temp for 90 minutes. 1Msodium hydroxide solution (4 mL) is added and the mixture is stirred atroom temp for 10 minutes. The mixture is passed through a phaseseparator and evaporated to give a colourless oil. The crude mixture isre-dissolved in the minimum amount of DCM and applied to a pre-packed 12g silica gel column and eluted with 0-100% EtOAc/isohexane over 6minutes then 100% EtOAc for 8 minutes. Pure product is recovered as acolourless oil. The oil is dissolved in the minimum amount of DCM andtriturated/sonicated with 9:1 isohexane/EtOAc to give a colourless solid124 mg, [MH+ 471.30].

Example 12 Trans-3-Chloro-N-(4-phenylaminomethyl-cyclohexyl)-benzamide

To a 7 mL vial equipped with magnetic stirrer bar is added(4-Amino-cyclohexylmethyl)-phenyl-amine (41 mg, 0.2 mmol),3-chlorobenzoyl chloride (20 mg, 0.16 mmol) and DCM (2 mL) followed bytrethylamine (42 μL, 0.3 mmol). The mixture is stirred at roomtemperature under nitrogen atmosphere for 3 hours. The mixture was thenevaporated to dryness and purified directly by preparative HPLC,[MH+343.19].

The compounds of the following tabulated Examples (Table 7), ortautomers thereof, are prepared by a similar method to that of Example12 using the appropriate acid chloride.

TABLE 7 Ex. Structure Name [M + H]⁺ 12.1

Trans-3-Methyl-N- (4- phenylaminomethyl- cyclohexyl)- benzamide 323.3312.2

Trans-N-(4- Phenylaminomethyl- cyclohexyl)-2- trifluoromethyl- benzamide377.2 12.3

Trans-3-Cyano-N-(4- phenylaminomethyl- cyclohexyl)- benzamide 334.2412.4

Trans-3-Methoxy-N- (4- phenylaminomethyl- cyclohexyl)- benzamide 339.2312.5

Trans-3-Chloro-2- fluoro-N-(4- phenylaminomethyl- cyclohexyl)-6-trifluoromethyl- benzamide 429.27

Example 13Trans-N-[4-(Quinolin-5-ylaminomethyl)-cyclohexyl]-3-trifluoromethyl-benzamide

To a solution oftrans-N-(4-formyl-cyclohexyl)-3-trifluoromethyl-benzamide (preparedanalogously totrans-2-chloro-N-(4-formyl-cyclohexyl)-5-trifluoromethyl-benzamide (Ex.1 step 3) from the appropriate starting compounds) (100 mg, 0.33 mmol)and 5-aminoquinoline (48 mg, 0.33 mmol) in dry 1,2-dichloroethane (2 mL)in a 2-5 mL capacity microwave tube, is added acetic acid (0.06 mL, 1.0mmol) and sodium triacetoxyborohydride (178 mg, 0.84 mmol). The tube issealed with a septum and the mixture is heated at 140° C. for 10 minutesin a Biotage Initiator microwave. After cooling to room temperature, thesolvents are removed under reduced pressure and the residue is purifiedby chromatography on a pre-packed reverse phase column. [MH+428.45].

The compounds of the following tabulated Examples (Table 8) are preparedby a similar method to that of Example 13 using the appropriate amine.

TABLE 8 Ex. Structure Name [M + H]⁺ 13.1

Trans-N-{4-[(4- Chloro- phenylamino)- methyl]-cyclohexyl}-3-trifluoromethyl- benzamide 411.36 13.2

Trans-N-[4-(p- Tolylamino-methyl)- cyclohexyl]-3- trifluoromethyl-benzamide 391.37 13.3

Trans-N-{4-[(3- Chloro-4-methoxy- phenylamino)- methyl]-cyclohexyl}-3-trifluoromethyl- benzamide 441.38 13.4

Trans-N-{4-[(4- Isopropyl- phenylamino)- methyl]-cyclohexyl}-3-trifluoromethyl- benzamide 419.48 13.5

Trans-N-{4-[(4- Fluoro- phenylamino)- methyl]-cyclohexyl}-3-trifluoromethyl- benzamide 395.37 13.6

Trans-3- Trifluoromethyl-N-{4- [(4-trifluoromethyl- phenylamino)-methyl]-cyclohexyl}- benzamide 445.37 13.7

Trans-N-{4-[(4- Cyano- phenylamino)- methyl]-cyclohexyl}-3-trifluoromethyl- benzamide 402.35 13.8

Trans-N-{4-[(3- Chloro-4-cyano- phenylamino)- methyl]-cyclohexyl}-3-trifluoromethyl- benzamide 477.42 (MH + MeCN)+ 13.9

Trans-N-[4- (Naphthalen-1- ylaminomethyl)- cyclohexyl]-3-trifluoromethyl- benzamide 427.44 13.10

Trans-N-{4-[(3- Cyano- phenylamino)- methyl]-cyclohexyl}-3-trifluoromethyl- benzamide 402.37 13.11

Trans-N-{4-[(3- Methoxy- phenylamino)- methyl]-cyclohexyl}-3-trifluoromethyl- benzamide 407.4  13.12

Trans-N-[4- (Quinolin-6- ylaminomethyl)- cyclohexyl]-3- trifluoromethyl-benzamide 428.45 13.13

Trans-N-{4-[(4- Cyano-3- trifluoromethyl phenylamino)-methyl]-cyclohexyl}- 3-trifluoromethyl- benzamide 511.33 (MH + MeCN)+13.14

Trans-N-{4-[(4- Morpholin-4-yl- phenylamino)- methyl]-cyclohexyl}-3-trifluoromethyl- benzamide 462.42

Example 14Cis-2-Chloro-N-(4-{[5-(4-fluoro-phenyl)-2H-pyrazol-3-ylamino]-methyl}-cyclohexyl)-5-trifluoromethyl-benzamide

Step 1Cis-2-chloro-N-(4-(hydroxymethyl)cyclohexyl)-5-(trifluoromethyl)-benzamide

To a solution of cis-(4-Amino-cyclohexyl)-methanol (Tetrahedron Lett.,1970, 11, 4285-4288) (0.75 g, 5.80 mmol) in THF (10 ml) is added water(1.8 mL), triethylamine (2.023 mL, 14.51 mmol) and2-chloro-5-(trifluoromethyl)benzoyl chloride (1.411 g, 5.80 mmol). TheRM is stirred at RT for 1 hour. The reaction mixture is partitionedbetween EtOAc and water. The organic phase is washed successively withwater, saturated sodium bicarbarbonate and saturated brine, dried overMgSO₄, filtered and the solvent removed in vacuo. Purification bychromatography on a pre-packed silica gel column using 0-100% EtOAc inisohexane gradient elution gave the desired product as a colourlesssolid.

Step 2 Cis-2-Chloro-N-(4-formyl-cyclohexyl)-5-trifluoromethyl-benzamide

To a solution ofCis-2-chloro-N-(-4-(hydroxymethyl)cyclohexyl)-5-(trifluoromethyl)-benzamide(1 g, 2.98 mmol) in DCM (18 mL) is added DIPEA (2.081 mL, 11.91 mmol).The reaction mixture is cooled to 0° C. and pyridine-sulfur trioxide(1.896 g, 11.91 mmol) in DMSO (6 mL) is added. The reaction mixture isstirred at this temperature for 30 mins. The reaction mixture ispartitioned between water and DCM and passed through a phase separator.The DCM layer was collected and concentrated under reduced pressure togive a colourless oil. Purification by chromatography on a pre-packedsilica gel column using 0-100% EtOAc in isohexane gradient elution gavethe desired product as a colourless solid.

Step 3Cis-2-chloro-N-(4-((3-(4-fluorophenyl)-1H-pyrazol-5-ylamino)methyl)cyclohexyl)-5-(trifluoromethyl)benzamide

To a solution ofCis-2-Chloro-N-(4-formyl-cyclohexyl)-5-trifluoromethyl-benzamide (100mg, 0.300 mmol) in DCM (3 mL) is added3-(4-fluorophenyl)-1H-pyrazol-5-amine (58.4 mg, 0.330 mmol) to give apale orange solution. This is stirred for 10 mins at room temperaturebefore sodium triacetoxyborohydride (102 mg, 0.479 mmol) is added. Thereaction mixture is stirred at room temperature for 1 hour. The reactionmixture is quenched by the addition of saturated sodium bicarbonate. TheDCM layer is separated and further washed with water. The aqueousextracts are combined and re-extracted with DCM. The combined organicextracts are then dried over MgSO4, filtered and concentrated undervacuum. Purification by chromatography on a pre-packed 12 g silica gelcolumn using 0-100% EtOAc in isohexane (gradient elution) gave thedesired product as a colourless solid. [MH+495.29].

Example 14.1Cis-2-chloro-N-((1s,4s)-4-((4-methylpyridin-3-ylamino)methyl)cyclohexyl)-5-(trifluoromethyl)benzamide

The title compound is prepared analogously to Example 14 using theappropriate amine in step 3; [MH+426.39].

Example 15Trans-2-Chloro-N-[4-(1RS-phenylamino-ethyl)-cyclohexyl]-5-trifluoromethyl-benzamide

Step 1Trans-2-chloro-N-(-4-((S)-1-hydroxyethyl)-cyclohexyl)-5-(trifluoromethyl)benzamide

To a solution oftrans-2-chloro-N-(4-formylcyclohexyl)-5-(trifluoromethyl)-benzamide(1.00 g, 3.00 mmol) in THF (50 mL) is added methylmagnesium bromide 2.5mL of a 3M solution in THF, 7.49 mmol,) and the reaction mixture isstirred at room temperature for 1 hour. The reaction mixture is quenchedwith water and partitioned between EtOAc and water. The organic phase iswashed with water and brine, dried over MgSO4, filtered and the solventis removed in vacuo. The mixture is used directly in step 2 withoutfurther purification.

Step 2Trans-N-(4-acetylcyclohexyl)-2-chloro-5-(trifluoromethyl)benzamide

To a solution ofTrans-2-chloro-N-(-4-((S)-1-hydroxyethyl)-cyclohexyl)-5-(trifluoromethyl)benzamide(1.00 g, 2.86 mmol) in DCM (20 mL) is added DIPEA (1.48 g, 11.4 mmol) ofDIPEA. The reaction mixture is cooled to 0° C. and then a solution ofsulfur trioxide-pyridine complex (1.82 g, 11.4 mmol) in DMSO (5 mL) isadded. The reaction mixture is stirred at 0° C. for 10 min and thenpartitioned between DCM and water. The organic phase was washed withwater and brine, dried over MgSO4, filtered and the solvent was removedin vacuo. Purification by chromatography on a pre-packed 40 g silica gelcolumn using 0-100% EtOAc in isohexane (gradient elution) gave thedesired product as a colourless solid.

Step 3Trans-2-chloro-N-(-4-(1-(phenylamino)ethyl)-cyclohexyl)-5-(trifluoromethyl)benzamide

To a solution ofTrans-N-(4-acetylcyclohexyl)-2-chloro-5-(trifluoromethyl)-benzamide (200mg, 0.57 mmol) and aniline (54 mg, 0.57 mmol) in DCM (10 mL) is addedDMF (0.1 mL) followed by trichlorosilane (78 mg, 0.57 mmol). Afterstirring at room temperature for 1 hour, further trichlorosilane (5×78mg, 5×0.57 mmol) is added at 1 hour intervals for the next 5 hours.Further DMF (0.1 mL) was then added and the mixture is stirred at roomtemperature overnight. The colourless solid that is formed is recoveredby filtration, washed successively with water and then EtOAc and dried.[MH+ 425.38]. The racemic mixture was separated by supercritical fluidchromatography on chiral stationary phase analogously to that reportedfor Example 1.37.

Example 162-Chloro-N-(2RS-methyl-4-phenylaminomethyl-cyclohexyl)-5-trifluoromethyl-benzamide

Step 1 3-Methyl-4-oxo-cyclohexanecarboxylic acid ethyl ester

Ethyl 4-oxocyclohexane carboxylate (10.0 g, 58.8 mmol) and pyrrolidine(5.87 g, 82.7 mmol) in toluene (100 mL) and molecular sieves (40 g of 4Å sieves) are heated to reflux overnight using Dean Stark apparatus. Themixture is filtered and the excess pyrrolidine is removed in vacuo. Theresulting mixture is diluted with toluene (50 mL) and treated withmethyl iodide (8.96 g, 63.1 mmol). After heating at reflux for 15 hours,the mixture is allowed to cool to RT and silica (3 g) and water (30 mL)are added. The mixture is stirred at RT for 3 hours and partitionedbetween water and diethyl ether. The organic portion is separated andwashed with water, brine, dried (MgSO₄) and concentrated in vacuo.Purification by chromatography on silica eluting with iso-hexane: EtOAc(19:1 increasing to 9:1) affords the title compound. ¹H NMR (400 MHz,DMSO-d₆) δ 4.15 (2H, q), 2.89 (1H, m), 2.51 (1H, m), 2.38 (1H, m), 2.21(3H, m), 1.89 (1H, m), 1.62 (1H, m), 1.22 (3H, t), 0.95 (3H, d).

Step 2 4-Benzylamino-3-methyl-cyclohexanecarboxylic acid ethyl ester

A mixture comprising 3-methyl-4-oxo-cyclohexanecarboxylic acid ethylester (1.00 g, 5.43 mmol) and benzylamine (0.58 g, 5.43 mmol) in DCE (50mL) is treated with sodium triacetoxyborohydride (2.30 g, 10.9 mmol) andstirred at RT for 2 hours. The mixture is partitioned between DCM andwater and the organic portion is separated, dried (MgSO₄) andconcentrated in vacuo. Purification by chromatography on silica elutingwith iso-hexane: EtOAc (4:1 increasing to 1:1) affords the titlecompound. ¹H NMR (400 MHz, DMSO-d₆) δ 7.32 (4H, m), 7.20 (1H, m) 4.04(2H, q), 3.72 (2H, m), 2.50-1.30 (9H, m), 1.19 (4H, m), 0.89 (3H, d).

Step 3 (4Benzylamino-3-methyl-cyclohexyl)-methanol

A cooled (0° C.) mixture comprising4-benzylamino-3-methyl-cyclohexanecarboxylic acid ethyl ester (0.90 g,3.27 mmol) in THF (50 mL) is treated with LiAlH₄ (4.09 mL, 8.08 mmol ofa 2M solution in THF) and the reaction mixture is stirred at RT for 2hours. The reaction is quenched with water (5 mL), NaOH (5 mL) followedby water (20 mL). The resulting precipitate is removed by filtration andwashed with EtOAc. The organic phase is washed with water, brine, dried(MgSO₄) and concentrated in vacuo to afford the title compound which isused in the next step without further purification. ¹H NMR (400 MHz,DMSO-d₆) δ 7.30 (4H, m), 7.19 (1H, m) 4.31 (1H, t), 3.68 (2H, m), 3.29(0.4H, t), 3.15 (1.6H, t), 2.45 (1H, m), 2.18 (0.2H, m), 2.06 (0.8H, m),1.69 (2H, m), 1.52 (3H, m), 1.27 (2H, m), 1.03 (1H, m), 0.90 (0.6H, d),0.88 (2.4H, d), 0.80 (1H, m).

Step 4 Toluene-4-sulfonic acid 4-benzylamino-3-methyl-cyclohexylmethylester

(4-Benzylamino-3-methyl-cyclohexyl)-methanol (0.1 g, 3.00 mmol) in DCM(30 mL) and pyridine (3 mL) is treated with TsCl (0.86 g, 4.50 mmol) andthe resulting mixture is stirred at RT overnight. The reaction mixtureis partitioned between DCM and water and the organic portion isseparated, dried (MgSO₄) and concentrated in vacuo. Purification bychromatography on silica eluting with iso-hexane:EtOAc (1:2 increasingto 1:4) affords the title compound. ¹H NMR (400 MHz, DMSO-d₆) δ 7.78(2H, d), 7.50 (2H, d), 7.30 (4H, m), 7.20 (1H, m), 3.80 (2H, d), 3.63(2H, q), 2.41 (4H, m), 2.01 (1H, m), 1.72 (2H, m), 1.58 (1H, m), 1.49(2H, m), 1.20 (1H, m), 1.02 (1H, m), 0.85 (1H, m), 0.81 (3H, d).

Step 5 (4-Benzylamino-3-methyl-cyclohexylmethyl)-phenyl-amine

A mixture comprising toluene-4-sulfonic acid4-benzylamino-3-methyl-cyclohexylmethyl ester (350 mg, 0.90 mmol),aniline (126, mg, 1.35 mmol) and potassium carbonate (250 mg, 1.80 mmol)in MeCN (1 mL) is heated using microwave radiation at 180° C. for 1hour. The reaction mixture is partitioned between DCM and water andpassed through a phase separator. The solvent is removed in vacuo andpurification of the crude residue by chromatography on silica elutingwith iso-hexane: EtOAc (25:1 increasing to 10:1) affords the titlecompound. [MH+ 309.34].

Step 6 (4-Amino-3-methyl-cyclohexylmethyl)-phenyl-amine

(4-Benzylamino-3-methyl-cyclohexylmethyl)-phenyl-amine (160 mg, 0.52mmol) and ammonium formate (164 mg, 2.60 mmol) in EtOH (5 mL) is treatedwith 10% Pd/C (30 mg) and heated at reflux for 2 hours. The Pd/C isremoved by filtration and washed with MeOH. The filtrate is concentratedin vacuo to afford the title compound which is used without furtherpurification.

Step 72-Chloro-N-(2-methyl-4-phenylaminomethyl-cyclohexyl)-5-trifluoromethyl-benzamide

(4-Amino-3-methyl-cyclohexylmethyl)-phenyl-amine (113 mg, 0.52 mmol) indry THF (5 mL) and TEA (105 mg, 1.04 mmol) is treated with2-chloro-5-(trifluoromethyl)benzoyl chloride (139 mg, 0.57 mmol). Afterstirring at RT for 2 hours, the solvent is removed in vacuo and theresidue is partitioned between water and DCM. The mixture is passedthrough a phase separator and the organic portion is concentrated invacuo. Purification of the crude residue by chromatography on silicaeluting with iso-hexane: EtOAc (9:1 increasing to 2:1) affords the titlecompound. ¹H NMR (400 MHz, DMSO-d₆) δ 8.47 (1H, d), 7.82 (1H, d), 7.73(2H, m), 7.07 (2H, t), 6.56 (2H, d), 6.49 (1H, t), 5.55 (1H, m), 3.93(1H, m), 2.86 (2H, m), 2.23 (1H, m), 1.88 (1H, m), 1.78 (1H, m), 1.70(1H, m), 1.59 (2H, m), 1.31 (1H, m), 1.11 (1H, m), 0.92 (3H,d).

Step 8 2-Chloro-N-2-methyl-4-phenylaminomethyl-cyclohexyl)-5-trifluoromethyl-benzamide

The racemate is separated into the component enantiomers by chiralchromatography on a Daicel Chiralpak AS column, 250 mm×20 mm (serialnumber AS00CJ-DD004)

The method used is hexane 95%, ethanol 5% (no modifier) at 20 ml/min for23 minutes. UV trigger at 210 nm.

Example 17Trans-5-Chloro-N-[4-(4-chloro-3,5-dimethyl-pyrazol-1-ylmethyl)-cyclohexyl]-2-methyl-nicotinamide

Step 1 5-chloro-2-methylnicotinoyl chloride

5-Chloro-2-methyl-nicotinic acid (4.15 g, 24.2 mmol) is placed in aflask with DCM (100 mL) and oxalyl chloride (3.68 g, 29 mmol). DMF (200μL) is added and the reaction mixture is stirred at r.t. for 1 hour (gasevolution). The mixture is filtered and the solvent is removed in vacuoto afford the title product which is used in the next step withoutfurther purification.

Step 2Trans-4-[(5-Chloro-2-methyl-pyridine-3-carbonyl)-amino]-cyclohexanecarboxylic acid methyl ester

Trans-4-Amino-cyclohexanecarboxylic acid methyl ester (2.14 g, 11.05mmol) is suspended in THF (50 mL) and Et₃N (2.79 g, 27.6 mmol) andcooled to 0° C. 5-chloro-2-methylnicotinoyl chloride (step 1)(2.20 g,11.05 mmol) is slowly added portionwise and the RM is stirred at r.t.for 2 hours. LCMS showed mainly product. The reaction mixture ispartitioned between EtOAc and 1M HCl. The organic phase is washed withwater and brine, dried over MgSO₄, filtered and the solvent is removedin vacuo to afford the title product which is used in the next stepwithout further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 8.53 (1H, d),7.42 (1H, 5), 7.80 (1H, d), 3.70 (1H, m), 3.60 (3H, s), 2.49 (3H, s),2.29 (1H, m), 1.95 (4H, m), 1.42 (2H, m), 1.29 (2H, m); [MH]⁺ 311.26.

Step 3Trans-5-Chloro-N-(4-hydroxymethyl-cyclohexyl)-2-methyl-nicotinamide

Trans-4-[(5-Chloro-2-methyl-pyridine-3-carbonyl)-amino]-cyclohexanecarboxylicacid methyl ester (step 2) (2.20 g, 7.08 mmol) is placed in a flask withdry THF (100 mL). This is cooled to 0° C. and lithium aluminum hydride(0.537 g, 14.16 mmol) is added. The reaction mixture is stirred at r.t.for 2 hours and then quenched with water (0.5 mL), 2M NaOH (0.5 mL) andthen water again (1.5 mL). The solids are filtered off through Celite®(filter material) and the filtrate is partitioned between EtOAc andwater. The organic phase is washed with water and brine, dried overMgSO₄, filtered and the solvent is removed in vacuo to afford the titleproduct which is used in the next step without further purification. ¹HNMR (400 MHz, DMSO-d₆) δ 8.53 (1H, d), 8.38 *1H, d), 7.79 (1H, d), 4.40(1H, t), 3.66 (1H, m), 3.21 (2H, t), 2.47 (3H, s), 1.92 (2H, m), 1.78(2H, m), 1.31 (1H, m), 1.22 (2H, m), 0.98 (2H, m). [MH]⁺ 283.30.

Step 4 Trans-Methanesulfonic acid4-[(5-chloro-2-methyl-pyridine-3-carbonyl)-amino]-cyclohexylmethyl ester

A solution ofTrans-5-chloro-N-(hydroxymethyl-cyclohexyl)-2-methyl-nicotinamide(step 1) (100 mg, 0.354 mmol) and pyridine (3.6 ml) in dry DCM (3.5 ml)under nitrogen is cooled to approx. 0° C. using an ice-water bath.Methanesulfonyl chloride (0.030 ml, 0.389 mmol) is added dropwise. Thereaction mixture is allowed to warm to room temp and stirred at thistemp for 4 hours. The reaction is quenched by the addition of sat. NH₄Clat room temp and then extracted with diethyl ether (3×20 ml). The Et₂Oextracts are combined, washed with sat brine (20 mL), dried (MgSO₄),filtered and evaporated to give the title compound as a colourlesssolid.

MS m/z 361.2/363.2 [M+H]+. ¹H NMR (400 MHz, CDCl₃) δ 8.52 (1H, d), 7.65(1H, d), 5.68 (1H, br d), 4.09 (2H, d), 3.96 (1H, m), 3.04 (3H, s), 2.65(3H, s), 2.21 (2H, m), 1.96 (2H, m), 1.79 (1H, m), 1.27 (4H, m).

Step 5a 4-Chloro-3,5-dimethyl-1H-pyrazole

3,5-Dimethyl-1H-pyrazole (1.00 g, 10.4 mmol) is dissolved in chloroform(10 mL). N-Chlorosuccinimide (1.39 g, 10.4 mmol) is added and thereaction mixture is stirred at RT for 1 hour. The mixture is partitionedbetween chloroform and water. The organic phase is washed with water andbrine, dried over MgSO₄, filtered and the solvent is removed in vacuo toafford the title product; ¹H NMR (400 MHz, DMSO-d₆) δ 12.5 (1H, broad),2.12 (6H, s).

Step 5bTrans-5-Chloro-N-[4-(4-chloro-3,5-dimethyl-pyrazol-1-ylmethyl)-cyclohexyl]-2-methyl-nicotinamide

To a solution of 4-chloro-3,5-dimethyl-1H-pyrazole (step 5a)(37 mg,0.283 mmol) in dry acetonitrile (4.5 mL) at room temp is added sodiumhydride (14 mg of a 60% dispersion in mineral oil, 0.353 mmol). Themixture is stirred at room temp for 10 minutes beforetrans-methanesulfonic acid4-[(5-chloro-2-methyl-pyridine-3-carbonyl)-amino]-cyclohexylmethyl ester(step 4) (85 mg, 0.236 mmol) is added in one portion. The mixture isheated at 120° C. for 30 minutes using microwave radiation. Aftercooling to RT, the reaction mixture is diluted with water (10 mL) andextracted with EtOAc (3×10 mL). The EtOAc extracts are combined, washedwith saturated brine (10 mL), dried (MgSO₄), filtered and evaporated togive a colourless foam. Purification by chromatography on silica gelusing a 12 g pre-packed column eluting with 0-100% EtOAc affords thetitle compound as a colourless solid. MS m/z 395.3/397.3 [M+H]⁺. ¹H NMR(400 MHz, DMSO-d₆) δ 8.53 (1H, d), 8.39 (1H, d), 7.78 (1H, d), 3.83 (2H,d), 3.67 (1H, m), 2.47 (3H, s), 2.20 (3H, s), 2.09 (3H, s), 1.89 (2H,m), 1.73 (1H, m), 1.57 (2H, m), 1.16 (4H, m).

Example 18Trans-5-Chloro-2-methyl-N-[4-(3,4,5-trimethyl-pyrazol-1-ylmethyl)-cyclohexyl]-nicotinamide

Step 1 Trans-Trifluoro-methanesulfonic acid4-tert-butoxycarbonylamino-cyclohexylmethyl ester

To a stirred solution of trans-tert-butyl4-(hydroxymethyl)cyclohexylcarbamate (Ex 5.1 step 2) (1 g, 4.36 mmol)and dry pyridine (0.423 mL, 5.23 mmol) in dry DCM (45 mL) at 0° C. isadded trifluoromethanesulfonic anhydride (0.81 mL, 4.8 mmol). Themixture is stirred at 0° C. for 1 hour and then allowed to warm to roomtemp. TLC analysis (isohexane:EtOAc, 1:2; stained with phosphomolybdicacid in EtOH) shows that the starting alcohol had been consumed and anew, less polar product had been formed. The reaction is quenched withsaturated ammonium chloride solution (30 mL) and the DCM layer isseparated using a phase separator, dried (MgSO4), filtered andevaporated to give the title compound as a pale yellow solid. This isused in the next step without further purification; ¹H NMR (400 MHz,CDCl₃) δ 4.40 (1H, m), 4.35 (2H, d), 3.41 (1H, m), 2.12 (2H, m), 1.89(2H, m), 1.80 (1H, m), 1.46 (9H, s), 1.16 (4H, m).

Step 2Trans-[4-(3,4,5-Trimethyl-pyrazol-1-ylmethyl)-cyclohexyl]-carbamic acidtert-butyl ester

To a stirred solution of 3,4,5-trimethyl-1H-pyrazole (84 mg, 0.761 mmol)in dry acetonitrile (4 mL) at room temp is added sodium hydride (33 mgof a 60% dispersion on mineral oil, 0.83 mmol). The mixture is stirredat room temp for 10 minutes and then treated with a solution oftrans-trifluoro-methanesulfonic acid4-tert-butoxycarbonylamino-cyclohexylmethyl ester (step 1) (250 mg,0.692 mmol) in dry acetonitrile (3 mL). The reaction mixture is stirredat room temp for 17 hours. The mixture is diluted with water (20 mL) andextracted with EtOAc (3×10 mL). The EtOAc extracts are combined, washedwith brine (20 mL), dried (MgSO4), filtered and evaporated to give thetitle compound as a colourless oil. This is used in the next stepwithout further purification; MS m/z 322.4 [M+H]⁺.

Step 3 Trans-4-(3,4,5-Trimethyl-pyrazol-1-ylmethyl)-cyclohexylamine

To a stirred solution oftrans-[4-(3,4,5-trimethyl-pyrazol-1-ylmethyl)-cyclohexyl]-carbamic acidtert-butyl ester (step 2)(215 mg, 0.669 mmol) in methanol (3 mL) at roomtemp is added a solution of 4M HCl in dioxane (3 mL). The mixture isstirred at room temp for 1 hour and then concentrated in vacuo. Theresulting gum is dried under vacuum overnight to afford the titlecompound which is used without further purification. ¹H NMR (400 MHz,CDCl₃) δ 8.16 (3H, br s), 4.10 (2H, d), 2.90 (1H, m), 2.29 (3H, s), 2.27(3H, s), 2.01-1.90 (5H, m including 3H, s), 1.83 (1H, s), 1.54 (2H, m),1.30 (2H, m), 1.12 (2H, m). (NMR shows contamination with side productsand solvents.)

Step 4Trans-5-Chloro-2-methyl-N-[4-(3,4,5-trimethyl-pyrazol-1-ylmethyl)-cyclohexyl]-nicotinamide

To a suspension of 5-chloro-2-methylnicotinoyl chloride (Ex. 17 step 1)and trans-4-(3,4,5-trimethyl-pyrazol-1-ylmethyl)-cyclohexylamine (step3) (197 mg, ca. 0.67 mmol) in dry DCM (6.5 mL) is added triethylamine(0.37 mL, 2.68 mmol). The mixture is stirred at room temp for 45minutes. Water (20 mL) is added and the mixture is extracted with EtOAc(3×20 mL). The EtOAc extracts are combined, washed with saturated brine(20 mL), dried (MgSO4), filtered and evaporated to give a pale yellowgum. The mixture is purified by chromatography on silica gel elutingwith 0-100% EtOAc to give a colourless solid which was triturated withEt₂O to afford the title product. MS m/z 375.3/377.3 [M+H]⁺ ¹H NMR (400MHz, DMSO-d₆) δ 8.54 (1H, d), 8.39 (1H, d), 7.79 (1H, d), 3.74 (2H, d),3.67 (1H, m), 2.47 (3H, s), 2.10 (3H, s), 2.02 (3H, s), 1.88 (2H, m),1.83 (3H, m), 1.70 (1H, m), 1.57 (2H, m), 1.14 (4H, m).

Examples 22.6 and 22.7Trans-5-Chloro-2-methyl-N-[4-(3-methyl-5-trifluoromethyl-pyrazol-1-ylmethyl)-cyclohexyl]-nicotinamide(22.6) andTrans-5-Chloro-2-methyl-N-[4-(5-methyl-3-trifluoromethyl-pyrazol-1-ylmethyl)-cyclohexyl]-nicotinamide(22.7)

Step 1Trans-tert-butyl-4-((3-methyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)methyl)cyclohexylcarbamateandtrans-tert-butyl-4-((5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)methyl)cyclohexylcarbamate

To a stirred solution of 5-methyl-3-(trifluoromethyl)-1H-pyrazole (199mg, 1.328 mmol) in dry acetonitrile (7 mL) at room temp is added sodiumhydride (63 mg of a 60% dispersion on mineral oil, 2.66 mmol). Themixture is stirred at room temp for 10 mins after which the initialeffervescence had subsided to leave a colourless solution. A solution oftrans-trifluoro-methanesulfonic acid4-tert-butoxycarbonylamino-cyclohexylmethyl ester (Ex. 18 step 1) (400mg, 1.107 mmol) in dry acetonitrile (4 mL) is then added and the mixtureis stirred at room temp for 17 hours. The crude mixture is diluted withwater (20 mL) and extracted with EtOAc (3×15 mL). The EtOAc extracts arecombined, washed with sat. brine (30 mL), dried (MgSO4), filtered andevaporated to give a mixture of the title compounds as a pale yellowgum. This is used in the next step without further purification.

Step 2Trans-4-((3-methyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)methyl)cyclohexanamineandTrans-4-((5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)methyl)cyclohexanamine

A crude mixture of step 1 (0.8 g, approx 1.1 mmol) in dry methanol (4mL) at RT is treated with a solution of 4M HCl in dioxane (4 mL) stirredat RT for 1 hour.

The solvents are evaporated under reduced pressure and the pale yellowgum obtained is placed under high vacuum for 18 hours to ensure completeremoval of excess HCl. Due to polar nature of products, no purificationis undertaken—crude product is used in the next step without furthermanipulation or characterization.

Step 3Trans-5-Chloro-2-methyl-N-[4-(3-methyl-5-trifluoromethyl-pyrazol-1-ylmethyl)-cyclohexyl]-nicotinamideandTrans-5-Chloro-2-methyl-N-[4-(5-methyl-3-trifluoromethyl-pyrazol-1-ylmethyl)-cyclohexyl]-nicotinamide

A crude mixture of step 1 (approx. 0.55 mmol of each compound) issuspended in dry DCM (25 mL) at RT. Triethylamine (0.38 mL, 2.75 mmol)is added followed by portionwise addition of 5-chloro-2-methylnicotinoylchloride (Ex. 17 step 1)(0.274 g, 1.21 mmol). The mixture is stirred atRT for 3 hours and then quenched with water (50 mL) and extracted withEtOAc (3×25 mL). The EtOAc extracts are combined, washed with sat. brine(25 mL), dried (MgSO₄), filtered and evaporated to give a pale yellowgum. The compounds are purified and separated by chromatography onsilica gel using ISCO 40 g pre-packed silica column and 0-100% EtOAc iniso-hexane as eluant to afford the title compounds (see Table 12 forcharacterizing data).

The compounds of the following tabulated Examples (Table 9) are preparedby a similar method to that of Example 1 using the appropriate benzamideor pyrazole starting materials (prepared analogously totrans-2-chloro-N-(4-formyl-cyclohexyl)-5-trifluoromethyl-benzamide fromtrans-4-amino-cyclohexylcarboxylic acid methyl ester hydrochloride andthe appropriate benzoly chloride) and the appropriate amine.

TABLE 9 Ex. Structure IUPAC Name [M + H]+ NMR Data 19.1

Trans-2-chloro- N-(4-((5- fluoropyridin-3- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 430.36 δH (400 MHz, DMSO);8.50 (1 H, d), 7.82 (2 H, m) 7.73 (2 H, m), 7.53 (1 H, s), 6.73 (1 H,m), 6.31 (1 H, t), 3.70 (1 H, m), 2.91 (2 H, t), 1.95 (2 H, m), 1.86 (2H, m), 1.50 (1 H, m), 1.25 (2 H, m), 1.09 (2 H, m). 19.2

Trans-2-chloro- N-(4-((5- fluoropyridin-2- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 430.37 δH (400 MHz, DMSO)8.48 (1 H, d), 7.90 (1 H, d), 7.81 (1 H, m), 7.73 (2 H, m), 7.31 (1 H,m), 6.53 (1 H, t), 6.49 (1 H, d of d), 3.70 (1 H, m), 3.08 (2 H, t),1.92 (2 H, m), 1.81 (2 H, m), 1.50 (1 H, m), 1.22 (2 H, m), 1.04 (2 H,m). 19.3

Trans-2-chloro- N-(4-((3,5- difluoro pyridin- 2-ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 448.33 δH (400 MHz, DMSO);8.48 (1 H, d), 7.88 (1 H, d), 7.80 (1 H, m), 7.73 (2 H, m), 7.58 (1 H,m), 6.62 (1 H, t), 3.70 (1 H, m, 3.18 (2 H, t), 1.92 (2 H, m), 1.81 (2H, m), 1.59 (1 H, m), 1.22 (2 H, m), 1.04 (2 H, m). 19.4

Trans-2-chloro- 5- (trifluoromethyl)- N-(4-((4- (trifluoromethyl)pyridin-2- ylamino) methyl) cyclohexyl) benzamide 480.32 δH (400 MHz,DMSO); 8.50 (1 H, d), 8.17 (1 H, d), 7.80 (1 H, m), 7.73 (2 H, m), 7.11(1 H, t), 6.78 (1 H, s), 6.68 (1 H, d), 3.70 (1 H, m), 3.18 (2 H, t),1.93 (2 H, m), 1.82 (2 H, m), 1.51 (1 H, m), 1.23 (2 H, m), 1.07 (2 H,m). 19.5

Trans-2-chloro- 5- (trifluoromethyl)- N-(4-((5- (trifluoromethyl)pyridin-3- ylamino) methyl) cyclohexyl) benzamide 480.33 δH (400 MHz,DMSO); 8.50 (1 H, d), 8.22 (1 H, s), 8.02 (1 H, s), 7.80 (1 H, m), 7.72(2 H, m), 7.11 (1 H, s), 6.43 (1 H, t), 3.70 (1 H, m), 2.98 (2 H, t),1.91 (4 H, m), 1.51 (1 H, m), 1.29 (2 H, m), 1.10 (2 H, m). 19.6

Trans-2-chloro- N-(4-((2- methoxypyridin- 3- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 442.42 δH (400 MHz, DMSO);8.50 (1 H, d), 7.80 (1 H, m), 7.72 (2 H, m), 7.31 (1 H, d), 6.75 (2 H,m), 5.10 (1 H, t), 3.87 (3 H, s), 3.70 (1 H, m), 2.92 (2 H, t), 1.94 (2H, m), 1.82 (2 H, m), 1.57 (1 H, m), 1.22 (2 H, m), 1.04 (2 H, m). 19.7

Trans-2-chloro- N-(4-((5- chloropyridin- 3- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 446.38 δH (400 MHz, DMSO);8.49 (1 H, d), 8.17 (1 H, d), 7.91 (1 H, d), 7.80 (1 H, m), 7.73 (2 H,m), 6.83 (1 H, m), 6.51 (2 H, m), 3.70 (1 H, m), 3.10 (2 H, t), 1.92 (2H, m), 1.81 (2 H, m), 1.49 (1 H, m), 1.22 (2 H, m), 1.05 (2 H, m). 19.8

Trans-2-chloro- N-(4-((4- methylpyrimidin- 2- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 427.41 δH (400 MHz, DMSO);8.48 (1 H, d), 8.10 (1 H, d), 7.81 (1 H, m) 7.73 (2 H, m), 7.02 (1 H,m), 6.41 (1 H, d), 3.69 (1 H, m), 3.11 (2 H, t), 2.21 (3 H, s), 1.91 (2H, m), 1.79 (2 H, m), 1.50 (1 H, m), 1.21 (2 H, m), 1.02 (2 H, m). 19.9

Trans-2-chloro- N-(4-((4,6- dimethylpyrimidin- 2-ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 441.42 δH (400 MHz, DMSO);8.48 (1 H, d), 7.80 (1 H, m) 7.73 (2 H, m), 6.88 (1 H, m), 6.30 (1 H,s), 3.68 (1 H, m), 3.11 (2 H, t), 2.18 (6 H, s), 1.91 (2 H, m), 1.80 (2H, m), 1.50 (1 H, m), 1.21 (2 H, m), 1.02 (2 H, m). 19.10

Trans-2,5- dichloro-N-(4- ((5- fluoropyridin-3- ylamino) methyl)cyclohexyl) benzamide 396.27 δH (400 MHz, DMSO); 8.40 (1 H, d), 7.82 (1H, s) 7.63 (1 H, d), 7.50 (3 H, m), 6.72 (1 H, d), 6.31 (1 H, t), 3.70(1 H, m), 2.901 (2 H, t), 1.89 (4 H, m), 1.50 (1 H, m), 1.22 (2 H, m),1.08 (2 H, m). 19.11

Trans-2,5- dichloro-N-(4- ((5- fluoropyridin-2- ylamino) methyl)cyclohexyl) benzamide 396.25 δH (400 MHz, DMSO); 8.39 (1 H, d), 7.90 (1H, d) 7.50 (3 H, m), 7.30 (1 H, m), 6.50 (2 H, m), 3.68 (1 H, m), 3.04(2 H, t), 1.90 (2 H, m), 1.80 (2 H, m), 1.50 (1 H, m), 1.21 (2 H, m),1.02 (2 H, m). 19.12

Trans-2,5- dichloro-N-(4- ((3,5- difluoro pyridin-2- ylamino) methyl)cyclohexyl) benzamide 414.31 δH (400 MHz, DMSO); 8.39 (1 H, d), 7.88 (1H, d) 7.51 (4 H, m), 6.61 (1 H, t), 3.66 (1 H, m), 3.18 (2 H, t), 1.90(2 H, m), 1.79 (2 H, m), 1.57 (1 H, m), 1.20 (2 H, m), 1.01 (2 H, m).19.13

Trans-2-chloro- N-(4-((6- (dimethylamino) pyridin- 3- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 455.37 δH (400 MHz, DMSO);8.48 (1 H, d), 7.80 (1 H, m) 7.73 (2 H, m), 7.56 (1 H, s), 6.93 (1 H,m), 6.52 (1 H, d), 4.92 (1 H, m), 3.70 (1 H, m), 2.87 (6 H, s), 2.81 (2H, t), 1.93 (2 H, m), 1.88 (2 H, m), 1.48 (1 H, m), 1.22 (2 H, m), 1.05(2 H, m). 19.14

Trans-2-chloro- N-(4-((5- (dimethylamino) pyridin- 2- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 455.37 δH (400 MHz, DMSO);8.48 (1 H, d), 7.80 (1 H, m) 7.72 (2 H, m), 7.55 (1 H, d), 7.08 (1 H, dof d), 6.41 (1 H, d), 5.90 (1 H, t), 3.70 (1 H, m), 3.01 (2 H, t), 2.69(6 H, s), 1.91 (2 H, m), 1.82 (2 H, m), 1.50 (1 H, m), 1.22 (2 H, m),1.02 (2 H, m). 19.15

6-{[4-(2- Chloro-5- rifluoromethyl- benzoylamino)- cyclohexylmethyl]-amino}- nicotinic acid methyl ester 470.36 δH (400 MHz, DMSO); 8.55 (1H, d), 8.48 (1 H, d), 7.80 (2 H, m) 7.74 (2 H, m), 7.45 (1 H, m), 6.50(1 H, d), 3.77 (3 H, s), 3.70 (1 H, m), 3.20 (2 H, m), 1.93 (2 H, m),1.82 (2 H, m), 1.52 (1 H, m), 1.22 (2 H, m), 1.07 (2 H, m). 19.16

2-chloro-N-(4- ((5-(4- fluorophenyl)- 1H-pyrazol-3- ylamino)methyl)- 3-methylcyclohexyl)- 5- (trifluoromethyl) benazmide 509.4 NO NMR data19.17

Trans-2-chloro- N-(-(4-((S)-1- (phenylamino) ethyl) cyclohexyl)-5-(trifluoro methyl) benzamide 425.46 δH (400 MHz, DMSO); 8.48 (1 H, d),7.80 (1 H, m), 7.73 (2 H, m), 7.02 (2 H, t), 6.53 (2 H, d), 6.43 (1 H,t), 5.29 (1 H, d), 3.68 (1 H, m), 3.30 (3 H, s), 3.25 (1 H, m), 1.91 (3H, m), 1.78 (1 H, m), 1.40 (1 H, m), 1.20 (4 H, m), 1.03 (3 H, d). 19.18

Trans-2-chloro- N-(4-((R)-1- (phenylamino) ethyl) cyclohexyl)-5-(trifluoro methyl) benzamide 425.47 δH (400 MHz, DMSO); 8.48 (1 H, d),7.80 (1 H, m), 7.73 (2 H, m), 7.02 (2 H, t), 6.53 (2 H, d), 6.43 (1 H,t), 5.29 (1 H, d), 3.68 (1 H, m), 3.30 (3 H, s), 3.25 (1 H, m), 1.91 (3H, m), 1.78 (1 H, m), 1.40 (1 H, m), 1.20 (4 H, m), 1.03 (3 H, d). 19.19

Trans-2-chloro- N-(4-((3,5- dimethylpyrazin- 2- ylamino) methyl)cyclohexyl)-5- (trifluoro methyl) benzamide 441.41 δH (400 MHz, DMSO);8.47 (1 H, d, J 8.0 Hz), 7.82-7.68 (4 H, m), 6.18 (1 H, br t, J 5.5Hz),3.70 (1 H, m), 3.16 (2 H, t, J 6.2 Hz), 2.27 (3 H, s), 2.21 (3 H, s),1.92 (2 H, m), 1.82 (2 H, m), 1.59 (1 H, m), 1.23 (2 H, m), 1.06 (2 H,m). 19.20

Trans-2-chloro- N-(4-((5- (hydroxymethyl) pyridin-2- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 442.42 δH (400 MHz, DMSO);8.47 (1 H, d), 7.86 (1 H, d) 7.80 (1 H, m), 7.72 (2 H, m), 7.30 (1 H, dof d), 6.43 (2 H, d), 4.85 (1 H, t), 4.26 (2 H, d), 3.68 (1 H, m), 3.10(2 H, t), 1.93 (2 H, m), 1.81 (2 H, m), 1.50 (1 H, m), 1.22 (2 H, m),1.03 (2 H, m). 19.21

Trans-5-chloro- N-(4-((3- cyclopropyl-1H- pyrazol-5- ylamino) methyl)cyclohexyl)-2- methyl- nicotinamide 388.36 δH (400 MHz, DMSO); 11.1 (1H, br s), 8.52 (1 H, s), 8.38 91 H, d), 7.80 (1 H, s), 5.10 (1 H, br s),3.68 (1 H, m), 2.80 (2 H, m), 2.45 (3 H, s), 1.90 (2 H, m), 1.80 (2 H,m), 1.72 (1 H, m), 1.45 (1 H, m), 1.22 (2 H, m), 1.00 (2 H, m), 0.80 (2H, m), 0.55 (2 H, m) 19.22

Trans-2,5- dichloro-N-(4- ((3,5-dimethyl- 1H-pyrazol-4- ylamino) methyl)cyclohexyl) benzamide 395.27 δH (400 MHz, DMSO); 11.59 (1 H, br s), 8.38(1 H, d, J 7.9 Hz), 7.88-7.38 (3 H, m), 3.66 (1 H, m), 3.17 (1 H, br s),2.60 (2 H, d, J 6.4 Hz), 2.04 (6 H, s), 1.90 (4 H, m), 1.29-1.18 (3 H,m), 1.04-0.95 (2 H, m). 19.23

Trans-2,5- dichloro-N-(4- ((3- cyclopropyl-1- methyl-1H- pyrazol-5-ylamino) methyl) cyclohexyl) benzamide 421.44 δH (400 MHz, DMSO); 11.25(1 H, br s), 8.39 (1 H, d, J 7.9 Hz), 7.53-7.45 (3 H, m), 5.22 (1 H, brs), 3.64 (1 H, m), 2.91 (2 H, d, J 7.0 Hz), 2.72 (3 H, s), 1.90-1.59 (6H, m), 1.23 (2 H, m), 0.99 (2 H, m), 0.83 (2 H, m), 0.61 (2 H, m). 19.24

Trans-2,5- dichloro-N-(4- ((1-propyl-1H- pyrazol-4- ylamino) methyl)cyclohexyl) benzamide 409.4 δH (400 MHz, DMSO); 8.39 (1 H, d, J 8.0 Hz),7.54-7.46 (3 H, m), 7.03 (1 H, s), 6.92 (1 H, s), 4.27 (1 H, t, J 6.3Hz), 3.87 (2 H, t, J 6.9 Hz), 3.66 (1 H, m), 2.67 (2 H, t, J 6.4 Hz),1.87 (4 H, m), 1.70 (2 H, m), 1.44 (1 H, m), 1.21 (2 H, m), 1.04 (2 H,m), 0.80 (3 H, t, J 7.4 Hz). 19.25

Trans-N-(4- ((6-bromo pyridin-2- ylamino) methyl) cyclohexyl)2-chloro-5- (trifluoro methyl) benzamide 492.19 δH (400 MHz, DMSO); 8.48(1 H, d), 7.81 (1 H, m), 7.73 (2 H, m), 7.27 (1 H, t), 6.97 (1 H, m),6.60 (1 H, d), 6.45 (1 H, d), 3.70 (1 H, m), 3.04 (2 H, m), 1.93 (2 H,m), 1.81 (2 H, m), 1.49 (1 H, m), 1.24 (2 H, m), 1.09 (2 H, m). 19.26

Trans-2-chloro- N-(4-((5- fluoro-4-methyl pyridin-2- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 444.36 δH (400 MHz, DMSO);8.48 (1 H, d), 7.80 (2 H, m), 7.72 (2 H, m), 6.39 (1 H, m), 6.36 (1 H,m), 3.69 (1 H, m), 3.03 (2 H, m), 2.11 (3 H, s), 1.92 (2 H, m), 1.81 (2H, m), 1.49 (1 H, m), 1.22 (2 H, m), 1.03 (2 H, m). 19.27

Trans-5-chloro- 2-methyl-N-(4- ((5- methylpyridin- 3- ylamino) methyl)cyclohexyl) nicotinamide 373 NO NMR data 19.28

Trans-5-chloro- N-(4-((4,6- dimethylpyridin- 2- ylamino) methyl)cyclohexyl)-2- methyl- nicotinamide 387.1 NO NMR data 19.29

Trans-5-chloro- N-(4-((5- fluoropyridin- 3- ylamino) methyl)cyclohexyl)-2- methyl- nicotinamide 377 NO NMR data 19.30

Trans-5-chloro- 2-methyl-N-(4- ((3-methyl pyridin-2- ylamino) methyl)cyclohexyl) nicotinamide 373 NO NMR data 19.31

Trans-5-chloro- 2-methyl-N-(4- ((1-methyl-1H- benzo [d]imidazol-2-ylamino) methyl) cyclohexyl) nicotinamide 412.1 NO NMR data 19.32

Trans-5-chloro- 2-methyl-N-(4- ((pyrimidin-2- ylamino) methyl)cyclohexyl) nicotinamide 360 NO NMR data 19.33

Trans-5-chloro- 2- (dimethylamino)- N-(4-((5- methylpyridin- 3-ylamino)methyl) cyclohexyl) nicotinamide 402.1 NO NMR data 19.34

Trans-2- methyl-N-(4- ((5- methylpyridin- 3- ylamino)methyl)cyclohexyl)-5- (trifluoro methyl) nicotinamide 407.1 NO NMR data 19.35

Trans-2,5- dimethyl-N-(4- ((5- methylpyridin- 3- ylamino)methyl)cyclohexyl) nicotinamide 353.1 NO NMR data 19.36

Trans-5-chloro- 2- (dimethylamino)- N-(4-((4,6- dimethyl pyridin-2-ylamino) methyl) cyclohexyl) nicotinamide 416.1 NO NMR data 19.37

Trans-N-(4- ((4,6- dimethylpyridin- 2- ylamino)methyl) cyclohexyl)-2-methyl-5- (trifluoromethyl) nicotinamide 421.1 NO NMR data 19.38

Trans-5-chloro- 2- (dimethylamino)- N-(4-((5- fluoropyridin-3- ylamino)methyl) cyclohexyl) nicotinamide 406.1 NO NMR data 19.39

Trans-N-(4- ((5- fluoropyridin- 3- ylamino)methyl) cyclohexyl)-2-methyl-5- (trifluoromethyl) nicotinamide 411.1 NO NMR data 19.40

Trans-N-(4- ((5- fluoropyridin- 3- ylamino)methyl) cyclohexyl)-2,5-dimethyl nicotinamide 357.1 NO NMR data 19.41

Trans-2,5- dichloro-N-(4- ((3-propyl-1H- 1,2,4-triazol-5- ylamino)methyl) cyclohexyl) benzamide 410.43 δH (400 MHz, DMSO); 12.28 and 11.66(1 H, br s, NH tautomers), 8.39 (1 H, d, J 7.8 Hz), 7.88-7.45 (3 H, m),6.35 and 5.60 (1 H br s NH tautomers), 3.66 (1 H, br m), 2.93 (2 H, brm), 2.39 (2 H, br m), 1.89 (2 H, m), 1.80 (2 H, m), 1.61 (2 H, m), 1.45(1 H, m), 1.21 (2 H, m), 1.00 (2 H, m), 0.89 (3 H, t, J 7.3 Hz). 19.42

Trans-2-chloro- N-(4-(2-(4,6- dimethyl pyridin-2- ylamino) ethyl)cyclohexyl)-5- (trifluoromethyl) benzamide 454.39 δH (400 MHz, DMSO);8.48 (1 H, d), 7.80 (1 H, m), 7.74 (2 H, m), 6.15 (2 H, m), 6.02 (1 H,s), 3.68 (1 H, m), 3.20 (2 H, m), 2.19 (3 H, s), 2.09 (3 H, s), 1.91 (2H, m), 1.80 (2 H, m), 1.41 (2 H, m), 1.30 (1 H, m), 1.23 (2 H, m), 1.02(2 H, m). 19.43

Trans-2-chloro- N-(4-((5- fluoro-6-methyl pyridin-2- ylamino) methyl)cyclohexyl)-5- (trifluoro methyl) benzamide 444.48 δH (400 MHz, DMSO);8.49 (1 H, d), 7.82 (1 H, m), 7.73 (2 H, m), 7.22 (1 H, m), 6.35 (1 H,m), 6.29 (1 H, m), 3.70 (1 H, m), 3.04 (2 H, m), 2.21 (3 H, d), 1.93 (2H, m), 1.83 (2 H, m), 1.49 (1 H, m), 1.22 (2 H, m), 1.08 (2 H, m). 19.44

Trans-2-chloro- N-(4-(2,6- dimethylpyridin- 3- ylamino) methyl)cyclohexyl)-5- (trifluoro methyl) benzamide 440.47 δH (400 MHz, DMSO);8.50 (1 H, d), 7.81 (1 H, m), 7.73 (2 H, m), 6.83 (1 H, d), 6.73 (1 H,d), 4.88 (1 H, m), 3.71 (1 H, m), 2.90 (2 H, m), 2.28 (6 H, d), 1.94 (2H, m), 1.88 (2 H, m), 1.54 (1 H, m), 1.23 (2 H, m), 1.08 (2 H, m). 19.45

Trans-2-chloro- N-(4-((5- (hydroxymethyl) pyridin- 3- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 442.43 δH (400 MHz, DMSO);8.49 (1 H, d), 7.78 (5 H, m), 6.83 (1 H, s), 5.87 (1 H, t), 5.12 (1 H,t), 4.41 (2 H, d), 3.70 (1 H, m), 2.90 (2 H, t), 1.90 (4 H, m), 1.51 (1H, m), 1.24 (2 H, m), 1.09 (2 H, m). 19.46

Trans-2-chloro- N-(4-((2,4- dimethylpyridin- 3- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 440.47 δH (400 MHz, DMSO);8.49 (1 H, d), 7.80 (4 H, m), 6.92 (1 H, d), 3.89 (1 H, m), 3.71 (1 H,m), 2.80 (2 H, m), 2.42 (3 H, s), 2.22 (3 H, s), 1.92 (4 H, m), 1.43 (1H, m), 1.26 (2 H, m), 1.10 (2 H, m). 19.47

Trans-2-chloro- N-(4-((4,6- dimethylpyridin- 3- ylamino) methyl)cyclohexyl)-5- (trifluoro methyl) benzamide 440.46 δH (400 MHz, DMSO);8.50 (1 H, d), 7.81 (1 H, m), 7.75 (1 H, m), 7.70 (2 H, m), 6.81 (1 H,s), 4.80 (1 H, t), 3.71 (1 H, m), 2.97 (2 H, m), 2.28 (3 H, s), 2.08 (3H, s), 1.92 (4 H, m), 1.60 (1 H, m), 1.27 (2 H, m), 1.09 (2 H, m). 19.48

Trans-2-chloro- N-(4-((5- (fluoromethyl) pyridin-3- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 444.45 δH (400 MHz, DMSO);8.50 (1 H, d), 7.98 (1 H, s), 7.78 (4 H, m), 6.91 (1 H, s), 6.05 (1 H,t), 5.34 (2 H, d, 50 Hz), 3.71 (1 H, m), 2.91 (2 H, t), 1.95 (2 H, m),1.89 (2 H, m), 1.51 (1 H, m), 1.24 (2 H, m), 1.09 (2 H, m). 19.49

Trans-2-chloro- N-(4-((4,5,6,7- tetrahydro-1H- indazol-3- ylamino)methyl) cyclohexyl)-5- (trifluoromethyl) benzamide 455.48 δH (400 MHz,DMSO); 10.80 (1 H br), 8.47 (d 1 H), 7.79 (m 1 H), 7.74 (m 2 H), 4.55(br 1 H), 3.70 (br 1 H), 2.89 (t 2 H), 2.41 (m 2 H), 2.33 (m 2 H), 1.91(m 2 H), 1.82 (m 2 H), 1.63 (br m 4 H), 1.52 (br 1 H), 1.22 (m 2 H),0.98 (m 2 H) 19.50

Trans-2-chloro- N-(4-((5- ethylpyridin- 2- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 440.47 δH (400 MHz, DMSO);8.48 (1 H, d, J 7.92 Hz), 7.81-7.73 (4 H, m). 7.22 (1 H, dd, J 2.3, 8.5Hz), 6.41 (1 H, d, J 8.5 Hz), 6.28 (1 H, br t, 5.6 Hz), 3.70 (1 H, m),3.07 (2 H, t, J 6.2 Hz), 2.40 (2 H, q, J 7.5 Hz), 1.93 (2 H, m), 1.83 (2H, m), 1.50 (1 H, m), 1.23 (2 H, m), 1.12-0.83 (5 H, m). 19.51

Trans-N-(4- ((1H-pyrazol-4- ylamino) methyl) cyclohexyl)-2- chloro-5-(trifluoromethyl) benzamide 401.41 δH (400 MHz, DMSO); 11.99 (1 H, s),8.49 (1 H, d), 7.81 (1 H, m), 7.73 (2 H, m), 7.02 (2 H, s), 4.23 (1 H,m), 3.70 (1 H, m), 2.70 (2 H, t), 1.92 (2 H, m), 1.85 (2 H, m), 1.46 (1H, m), 1.25 (2 H, m), 1.03 (2 H, m). 19.52

Trans-N-(4- ((1H-indazol-3- ylamino) methyl) cyclohexyl)-2- chloro-5-(trifluoromethyl) benzamide 541.42 δH (400 MHz, DMSO); 11.30 (1 H, s),8.50 (1 H, d), 7.80 (1 H, m), 7.72 (3 H, m), 7.20 (2 H, m), 6.87 (1 H,m), 5.97 (1 H, t), 3.72 (1 H, m), 3.11 (2 H, t), 1.91 (4 H, m), 1.68 (1H, m), 1.25 (2 H, m), 1.09 (2 H, m). 19.53

Trans-2-chloro- N-(4-((5- ethylpyridin- 3- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 440.45 δH (400 MHz, DMSO);8.49 (1 H, d, J 7.9 Hz), 7.83-7.74 (4 H, m), 7.61 (1 H, d, J 1.5 Hz),6.73 (1 H, s), 5.77 (1 H, t, J 5.6 Hz), 3.71 (1 H, m), 2.89 (2 H, t, J6.0 Hz), 2.49 (2 H, q, partially obscured by residual DMSO), 1.96-1.87(4 H, m), 1.51 (1 H, m), 1.30-1.22 (2 H, m), 1.16 (3 H, t, J 7.6 Hz),1.1-1.04 (2 H, m). 19.54

Trans-5-chloro- N-(4-((5- fluoro-4- methylpyridin- 2- ylamino) methyl)cyclohexyl)-2- methylnicotinamide 391.39 δH (400 MHz, DMSO); 8.52 (d 1H), 8.38 (d 1 H), 7.78 (m 2 H), 6.38 (t 1 H), 6.36 (d 1 H), 3.66 (m 1H), 3.04 (t 2 H), 2.46 (s 3 H), 2.14 (s 3 H), 1.86 (m 4 H), 1.48 (m 1H), 1.16 (m 4 H). 19.55

Trans-5-chloro- 2-methyl-N-(4- ((4,5,6,7- tetrahydro-1H- indazol-3-ylamino) methyl) cyclohexyl) nicotinamide 402.47 δH (400 MHz, DMSO);10.82 (br s 1 H), 8.54 (d 1 H), 8.36 (d 1 H), 7.80 (d 1 H), 4.54, 4.24(2 x br s 1 H), 2.36 (t 2 H), 2.46 (s 3 H), 2.42 (m 2 H), 2.22 (m 2 H),1.88 (m 4 H), 1.64 (m 4 H), 1.54 (m 1 H), 1.22 (m 2 H), 0.98 (m 2 H).19.56

Trans-2-chloro- N-(4-((2- methoxy-5- methylpyridin- 3- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 456.42 δH (400 MHz, DMSO);8.49 (1 H, d), 7.80 (1 H, m), 7.72 (2 H, m), 7.11 (1 H, s), 6.58 (1 H,s), 5.00 (1 H, t), 3.83 (3 H, s), 3.70 (1 H, m), 2.91 (2 H, t), 2.13 (3H, s), 1.92 (2 H, m), 1.82 (2 H, m), 1.58 (1 H, m), 1.25 (2 H, m), 1.07(2 H, m). 19.57

Trans-N-(4- ((1H- pyrazolo[3,4- b]pyridin-3- ylamino) methyl)cyclohexyl)-2- chloro-5- (trifluoro methyl) benzamide 452.39 δH (400MHz, DMSO) 11.9 (1 H, s), 8.49 (1 H, d), 8.33 (1 H, dd), 8.16 (1 H, dd),7.82-7.70 (3 H, m), 6.93 (1 H, dd), 6.21 (1 H, t), 3.71 (1 H, m), 3.12(2 H, t), 1.96-1.88 (4 H, m), 1.52 (1 H, m), 1.30-0.87 (4 H, m). 19.58

Trans-2-chloro- 5-(trifluoro methyl)-N-(4- ((5-trifluoro methyl)-1H-indazol-3-yl amino) methyl) cyclohexyl) benzamide 519.46 δH (400 MHz,DMSO) 11.81 (1 H, br s), 8.48 (1 H, d), 8.28 (1 H, s), 7.82-7.74 (3 H,m), 7.47 (1 H, d), 7.39 (1 H, d), 6.30 (1 H, t), 3.72 (1 H, m), 3.14 (2H, t), 1.97-1.66 (5 H, m), 1.31-1.13 (4 H, m). 19.59

Trans-2-chloro- N-(4-((5- methyl-1H- indazol-3- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 465.44 δH (400 MHz, DMSO)11.14 (1 H, br s), 8.48 (1 H, d), 7.80 (1 H, dd), 7.74 (2 H, m), 7.50 (1H, m), 7.11 (1 H, d), 7.05 (1 H, dd), 5.79 (1 H, t), 3.72 (1 H, m), 3.10(2 H, t), 2.34 (3 H, s), 1.92 (4 H, m), 1.65 (1 H, m), 1.25 (2 H, m),1.08 (2 H, m). 19.60

Trans-2-chloro- N-(4-((5,5- dimethyl- 4,5,6,7- tetrahydro-1H- indazol-3-ylamino) methyl) cyclohexyl)-5- (trifluoromethyl) benzamide 483.41 δH(400 MHz, DMSO) 8.46 (1 H, d), 7.79 (1H d), 7.75 (1 H d), 7.73 (1 H d),4.49 (1 H br), 3.68 (1 H s), 2.88 (2 H t), 2.41 (2 H t), 2.02 (2 H s),1.91 (2 H m), 1.81 (2 H m), 1.54 (1 H br), 1.44 (2 H t), 1.24 (2 H m),1.01 (2 H m), 0.93 (6 H s) 19.61

Trans-2-chloro- N-(4-((6- methyl-1H- indazol-3- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 465.39 δH (400 MHz, DMSO);11.12 (1 H, s), 8.50 (1 H, d), 7.80 (1 H, m), 7.72 (2 H, m), 6.98 (1 H,s), 6.71 (1 H, d), 5.82 (1 H, t), 3.70 (1 H, m), 3.10 (2 H, t), 2.36 (3H, s), 1.91 (4 H, m), 1.62 (1 H, m), 1.22 (2 H, m), 1.08 (2 H, m). 19.62

Trans-2-chloro- N-(4-((5- fluoro-1H- indazol-3- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 469.36 δH (400 MHz, DMSO);11.39 (1 H, br s), 8.48 (1 H, d), 7.80 (1 H, dd), 7.74 (2 H, m), 7.52 (1H, dd), 7.23 (1 H, dd), 7.11 (1 H, dt), 5.89 (1 H, t), 3.72 (1 H, m),3.11 (2 H, t), 1.93 (4 H, m), 1.65 (1 H, m), 1.25 (2 H, m), 1.08 (2 H,m). 19.63

Trans-2-chloro- N-(4-((4- fluoro-1H- indazol-3- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 469.33 δH (400 MHz, DMSO);11.70 (1 H, s), 8.49 (1 H, d), 7.81 (1 H, m), 7.73 (2 H, m), 7.19 (1 H,m), 7.03 (1 H, d), 6.60 (1 H, m), 5.48 (1 H, t), 3.70 (1 H, m), 3.11 (2H, t), 1.91 (4 H, m), 1.70 (1 H, m), 1.23 (2 H, m), 1.08 (2 H, m). 19.64

Trans-2-chloro- N-(4-((4,6- dimethylpyridin- 2- ylamino) methyl)cyclohexyl)-5- isopropyl- nicotinamide 415.44 δH (400 MHz, DMSO); 8.42(1 H, d), 8.35 (1 H, d), 7.72 (1 H, d), 6.20 (1 H, t), 6.15 (1 H, s),6.07 (1 H, s), 3.69 (1 H, m), 3.05 (2 H, t), 2.99 (2 H, t), 2.19 (3 H,s), 2.09 (3 H, s), 1.92 (2 H, m), 1.83 (2 H, m), 1.49 (1 H, m), 1.22 (8H, m), 1.05 (2 H, m). 19.65

Trans-2-chloro- N-(4-((4- methyl-1H- indazol-3- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 465.3 δH (400 MHz, DMSO)11.39 (1 H, br s), 8.49 (1 H, d), 7.81 (1 H, dd), 7.74 (2 H, m), 7.05 (2H, m), 6.60 (1 H, d), 5.12 (1 H, t), 3.72 (1 H, m), 3.11 (2 H, t), 2.61(3 H, s), 1.93 (4 H, m), 1.70 (1 H, m), 1.25 (2 H, m), 1.08 (2 H, m).19.66

Trans-2-chloro- N-(4-((5- chloro-1H- indazol-3- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 485.2 δH (400 MHz, DMSO)11.52 (1 H, s), 8.49 (1 H, d), 7.86-7.74 (4 H, m), 7.24 (2 H, m), 6.02(1 H, t), 3.74 (1 H, m), 3.11 (2 H, t), 1.93 (4 H, m), 1.64 (1 H, m),1.25 (2 H, m), 1.11 (2 H, m). 19.67

Trans-2-chloro- N-(4-((5,6- dimethoxy-1H- indazol-3- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 511.43 δH (400 MHz, DMSO);10.95 (1 H, s), 8.50 (1 H, d), 7.80 (1 H, m), 7.73 (2 H, m), 7.21 (1 H,s), 6.70 (1 H, s), 5.63 (1 H, t), 3.79 (3 H, s) 3.71 (4 H, s + m), 3.09(2 H, t), 1.91 (4 H, m), 1.62 (1 H, m), 1.25 (2 H, m), 1.10 (2 H, m).19.68

Trans-2-chloro- N-(4-((6- methoxy-1H- indazol-3- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 481.36 δH (400 MHz, DMSO);11.10 (1 H, s), 8.49 (1 H, d), 7.80 (1 H, m), 7.71 (2 H, m), 7.58 (1 H,d), 6.62 (1 H, d), 6.50 (1 H, d of d), 5.83 (1 H, t), 3.78 (3 H, s) 3.71(1 H, m), 3.09 (2 H, t), 1.91 (4 H, m), 1.65 (1 H, m), 1.25 (2 H, m),1.09 (2 H, m). 19.69

Trans-2-chloro- N-(4-((5- chloro-4- methylpyridin- 2- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 460.31 δH (400 MHz, DMSO);8.49 (1 H, d), 7.89 (1 H, s), 7.80 (1 H, m), 7.71 (2 H, m), 6.63 (1 H,t), 6.42 (1 H, s), 3.70 (1 H, m), 3.08 (2 H, t), 1.93 (2 H, m), 1.81 (2H, m), 1.49 (1 H, m), 1.21 (2 H, m), 1.04 (2 H, m). 19.70

Trans-2-chloro- N-(4-((1- methyl-1H- indazol-3- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 465.29 δH (400 MHz, DMSO);8.49 (1 H, d), 7.80 (1 H, m), 7.73 (3 H, m), 7.27 (2 H, m), 6.89 (1 H,m), 6.00 (1 H, t), 3.72 (3 H, s and 1 H, m), 3.11 (2 H, t), 1.92 (4 H,m), 1.65 (1 H, m), 1.28 (2 H, m), 1.09 (2 H, m). 19.71

Trans-2-chloro- N-(4-((3- methyl-4- phenyl-1H- pyrazol-5- ylamino)methyl) cyclohexyl)-5- (trifluoromethyl) benzamide 491.29 δH (400 MHz,DMSO); 11.40 (1 H, s), 8.48 (1 H, d), 7.80 (1 H, m), 7.73 (2 H, m), 7.38(4 H, m), 7.20 (1 H, t), 4.49 (1 H, m), 3.68 (1 H, m), 2.92 (2 H, t),2.17 (3 H, s), 1.91 (2 H, m), 1.81 (2 H, m), 1.59 (1 H, m), 1.20 (2 H,m), 1.00 (2 H, m). 19.72

Trans-N-(4- ((5-benzyl- 4,5,6,7- tetrahydro-1H- pyrazolo[4,3-c]pyridin-3- ylamino) methyl) cyclohexyl)-2- chloro-5- (trifluoromethyl)benzamide 546.44 δH (400 MHz, DMSO); 11.20 (1 H, br), 8.48 (1 H, d),7.80 (1 H, m), 7.73 (2 H, m), 7.32 (5 H, m), 7.23 (1 H, m), 4.78 (0.5 H,br), 4.33 (0.5 H, br), 3.65 (3 H, m), 3.18 (2 H, s), 2.82 (1 H, m), 2.64(3 H, m), 1.91 (4 H, m), 1.80 (2 H, m), 1.45 (1 H, m), 1.20 (3 H, m),0.98 (2 H, m). 19.73

Trans-2-chloro- N-(4-((5- chloro-2- methylpyridin- 3- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 460.28 δH (400 MHz, DMSO);8.49 (1 H, d), 7.80 (1 H, m), 7.73 (2 H, m), 7.51 (1 H, d), 6.82 (1 H,d), 5.50 (1 H, t), 3.70 (1 H, m), 2.95 (2 H, t), 2.28 (3 H, s), 1.92 (2H, m), 1.87 (2 H, m), 1.58 (1 H, m), 1.22 (2 H, m), 1.06 (2 H, m). 19.74

Trans-2-chloro- N-(4-((6- methyl-1H- pyrazolo[3,4- b]pyridin-3- ylamino)methyl) cyclohexyl)-5- (trifluoromethyl) benzamide 466.35 δH (400 MHz,DMSO); 11.70 (1 H, s), 8.49 (1 H, d), 8.02 (1 H, d), 7.80 (1 H, m), 7.73(2 H, m), 6.82 (1 H, d), 6.12 (1 H, t), 3.70 (1 H, m), 3.10 (2 H, t),2.50 (3 H, s), 1.91 (4 H, m), 1.62 (1 H, m), 1.25 (2 H, m), 1.10 (2 H,m). 19.75

Trans-2-chloro- N-(4-((5- chloro-6- methylpyridin- 3- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 460.31 δH (400 MHz, DMSO)8.49 (1 H, d), 7.81 (2 H, m), 7.73 (2 H, m), 6.95 (1 H, d), 5.99 (1 H,t), 3.70 (1 H, m), 2.90 (2 H, t), 2.34 (3 H, s), 1.93 (2 H, m), 1.87 (2H, m), 1.49 (1 H, m), 1.23 (2 H, m), 1.08 (2 H, m). 19.76

Trans-N-(4- ((4-bromo-5- propyl-1H- pyrazol-3- ylamino) methyl)cyclohexyl)-2- chloro-5- (trifluoromethyl) benzamide 521.3 δH (400 MHz,DMSO) 8.50 (1 H, d), 7.81 (1 H, m) 7.73 (2 H, m), 6.45 (1 H, v br), 3.70(1 H, m), 3.00 (2 H, d), 2.52 (2 H, m), 1.92 (2 H, m), 1.81 (2 H, m),1.59 (3 H, m), 1.22 (2 H, m), 1.02 (2 H, m), 0.89 (3 H, t). 19.77

Trans-2-chloro- N-(4- ((imidazo[1,2- b]pyridazin-3- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 452.3 δH (400 MHz, DMSO) 8.49(1 H, d), 8.37 (1 H, dd), 7.88 (1 H, dd), 7.81 (1 H, m), 7.75 (2 H, m),7.09 (1 H, s), 6.87 (1 H, dd), 5.63 (1 H, br t), 3.71 (1 H, m), 3.08 (2H, m), 1.92 (4 H, m), 1.64 (1 H, m), 1.26 (2 H, m), 1.09 (2 H, m). 19.78

Trans-2-chloro- N-(4-((4,6- dihydro-1H- thieno[3,4- c]pyrazol-3-ylamino) methyl) cyclohexyl)-5- (trifluoromethyl) benzamide 459.29 δH(400 MHz, DMSO), 11.28 (br 1 H), 8.51 (d 1 H), 7.82 (d 1 H), 7.77 (d 1H), 7.74 (m 2 H), 5.40 (br 1 H), 3.74 (s 2 H), 3.70 (br m 1 H), 3.65 (s2 H), 2.86 (s 2 H), 1.96 (m 2 H), 1.84 (m 2 H), 1.43 (m 1 H), 1.24 (m 2H), 1.0 (m 2 H) 19.79

Trans-2-chloro- N-(4-((4- methyl-5- phenyl-1H- pyrazol-3- ylamino)methyl) cyclohexyl)-5- (trifluoromethyl) benzamide 491.33 δH (400 MHz,DMSO) 11.55 (1 H, br s), 8.5 (1 H, d), 7.82 (1 H, d), 7.75 (2 H, m),7.51 (2 H, m), 7.45 (2 H, m), 7.33 (1 H, m), 4.75 (1 H, br s), 3.72 (1H, m), 2.96 (2 H, m), 1.98 (3 H, s), 1.92 (4 H, m), 1.60 (1 H, m), 1.25(2 H, m), 1.03 (2 H, m). 19.80

Trans-2-chloro- N-(4-((4-(4- chlorophenyl)- 1H-pyrazol-3- ylamino)methyl) cyclohexyl)-5- (trifluoromethyl) benzamide 511.2 1H NMR (400MHz, MeOD). δ 8.6 (~0.5 H, d. Slow exchange of amide proton), 8.0 (1 H,s), 7.7 (3 H, m), 7.5 (4 H, s), 3.8 (1 H, m), 3.2 (2 H, d), 2.1 (2 H,d), 1.9 (2 H, d), 1.7 (1 H, m), 1.4 (2 H, m), 1.2 (2 H, m). 19.81

Trans-N-(4- ((7-bromo- [1,2,4]triazolo [1,5-a]pyridin-2- ylamino)methyl) cyclohexyl)-2- chloro-5- (trifluoromethyl) benzamide 532.1 1HNMR (400 MHz, MeOD). δ 8.4 (1 H, d), 7.7 (3 H, m), 7.6 (1 H, s), 7.1 (1H, d), 3.9 (1 H, m), 3.2 (2 H, d), 2.1 (2 H, d), 2.0 (2 H, d), 1.7 (1 H,m), 1.4 (2 H, m), 1.2 (2 H, m). 19.82

Trans-2-chloro- N-(4-((1- methyl-1H- pyrazolo[3,4- b]pyridin-3- ylamino)methyl) cyclohexyl)-5- (trifluoromethyl) benzamide 466.35 δH (400 MHz,DMSO); 8.50 (1 H, d), 8.38 (1 H, m), 8.17 (1 H, m), 7.80 (1 H, m), 7.75(2 H, m), 6.95 (1 H, m), 6.32 (1 H, t), 3.78 (3 H, s), 3.71 (1 H, m),3.11 (2 H, t), 1.92 (4 H, m), 1.62 (1 H, m), 1.25 (2 H, m), 1.10 (2 H,m). 19.83

Trans-5-chloro- N-(4-((5- chloro-4- methylpyridin- 2- ylamino) methyl)cyclohexyl)-2- methyl- nicotinamide 407.37 δH (400 MHz, DMSO): 8.53 (1H, d), 8.38 (1 H, d), 7.88 (1 H, s), 7.79 (1 H, d), 6.64 (1 H, t), 6.41(1 H, s), 3.68 (1 H, m), 3.05 (2 H, t), 2.45 (3 H, s), 2.17 (3 H, s),1.92 (2 H, m), 1.80 (2 H, m), 1.50 (1 H, m), 1.22 (2 H, m), 1.05 (2 H,m). 19.84

Trans-2-chloro- N-(4- ((pyrazolo[1,5- a]pyridin-3- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 451.4 δH (400 MHz, DMSO) 8.49(1 H, d), 8.34 (1 H, d), 7.81 (1 H, m), 7.75 (2 H, m), 7.62 (1 H, d),7.53 (1 H, s), 6.86 (1 H, m), 6.63 (1 H, m), 4.71 (1 H, t), 3.72 (1 H,m), 2.91 (2 H, t), 1.94 (4 H, m), 1.53 (1 H, m), 1.25 (2 H, m), 1.09 (2H, m). 19.85

Trans-2-chloro- N-(4-((4-(2,4- dichlorophenyl)- 1H-pyrazol-3- ylamino)methyl) cyclohexyl)-5- (trifluoromethyl) benzamide 545.1 1H NMR (400MHz, MeOD). δ 8.6 (0.5 H, d, amide proton slow exchange in MeOD), 8.0 (1H, s), 7.75 (1 H, d), 7.70 (2 H, d), 7.45 (1 H, s), 7.4 (2 H, t), 3.9 (1H, m), (2 H, d), 2.1 (2 H, d), 1.9 (2 H, d), 1.6 (1 H, m), 1.35 (2 H,q), 1.1 (2 H, q). 19.86

Trans-5-chloro- 2-methyl-N-(4- ((4- (trifluoromethyl) pyridin-2-ylamino) methyl) cyclohexyl) nicotinamide 427.4 δH (400 MHz, DMSO); 8.53(1 H, d), 8.40 (1 H, d), 8.18 (1 H, d), 7.80 6.77 (1 H, s), 6.69 (1 H,d), 3.70 (1 H, m), 3.18 (2 H, t), 2.48 (3 H, s), 1.92 (2 H, m), 1.81 (2H, m), 1.51 (1 H, m), 1.24 (2 H, m), 1.08 (2 H, m). 19.87

Trans-5-chloro- 2-methyl-N-(4- ((5- (trifluoromethyl) pyridin-3-ylamino) methyl) cyclohexyl) nicotinamide 427.4 δH (400 MHz, DMSO); 8.54(1 H, d), 8.40 (1 H, d), 8.22 (1 H, d), 8.02 (1 H, d), 7.80 (1 H, d),7.11 (1 H, s), 6.45 (1 H, t), 3.70 (1 H, m), 2.98 (2 H, t), 2.48 (3 H,s), 1.91 (4 H, m), 1.51 (1 H, m), 1.28 (2 H, m), 1.10 (2 H, m). 19.88

Trans-2-chloro- N-(4-((3- phenyl-1H- propyl-1H- pyrazol-5- ylamino)methyl) cyclohexyl)-5- (trifluoromethyl) benzamide 519.43 δH (400 MHz,DMSO); 11.50 (1 H, s), 8.50 (1 H, d), 7.81 (1 H, m), 7.73 (2 H, m), 7.45(4 H, m), 7.32 (1 H, m), 4.70 (1 H, m), 3.71 (1 H, m), 2.99 (2 H, t),2.40 (2 H, t), 1.91 (4 H, m), 1.61 (1 H, m), 1.43 (2 H, m), 1.24 (2 H,m), 1.02 (2 H, m). 19.89

Trans-N-(4- ((6-bromo- [1,2,4]triazolo [1,5-a]pyridin-2- ylamino)methyl) cyclohexyl)-2- chloro-5- (trifluoromethyl) benzamide 530.1 1HNMR (400 MHz, DMSO-d6). δ 9.0 (1 H, s), 8.5 (1 H, d), 7.8 (1 H, d), 7.75(2 H, d), 7.6 (1 H, d), 7.4 (1 H, d), 6.8 (1 H, t), 3.7 (1 H, m), 3.1 (2H, t), 2.0 (2 H, d), 1.9 (2 H, d), 1.6 (1 H, m), 1.2 (2 H, q), 1.0 (2 H,q). 19.90

Trans-2-chloro- N-(4-((4,6- dimethyl-1H- pyrazolo[3,4- b]pyridin-3-ylamino) methyl) cyclohexyl)-5- (trifluoromethyl) benzamide 480.2 NO NMRDATA 19.91

Trans-2-chloro- N-(4-((4-(4- chlorophenyl)- 5-methyl-1H- pyrazol-3-ylamino) methyl) cyclohexyl)-5- (trifluoromethyl) benzamide 527.54 δH(400 MHz, DMSO), 11.48 (1 H s), 8.47 ( 1H d), 7.82 (1 H d), 7.76 (d,7.72) 1 H (s, 7.43) 2 H (d, 7.34) 2 H (d, 4.61) 1 H (br s), 3.69 (1 Hm), 2.94 (2 H t), 2.17 (3 H s), 1.94 (2 H m), 1.82 (2 H m), 1.59 (1 Hm), 1.22 (2 H m), 0.99 (2 H m). 19.92

Trans-2-chloro- N-(4-((5- chloro-3-(4- hydroxy- cyclohexyl)-3H-imidazo[4,5- b]pyridin-2- ylamino) methyl) cyclohexyl)-5-(trifluoromethyl) benzamide 584.2 δH (400 MHz, MeOD), 8.6 (~1 H, d, NHslow exchange), 7.7 (4 H, m), 7.3 (1 H, d), 4.4 (1 H, m), 3.9 (1 H, m),3.8 (1 H, m), 3.4 (2 H, d), 2.7 (2 H, q), 2.2 (4 H, d), 2.0 (4 H, q),1.8 (1 H, m), 1.5 (4 H, m), 1.3 (2 H, q). 19.93

Trans-N-(4- ((1H-pyrazolo [4,3- b]pyridin-3- ylamino) methyl)cyclohexyl)-2- chloro-5- (trifluoromethyl) benzamide 452.2 δH (400 MHz,MeOD), 8.6 (~1 H, d, NH slow exchange), 8.4 (1 H, d), 7.9 (1 H, d), 7.7(3 H, m), 7.5 (1 H, m), 3.9 (1 H, m), 2.1 (4 H, dd), 1.8 (1 H, m), 1.3(4 H, m). 19.94

Trans-2-chloro- N-(4-((4- phenyl-1H- pyrazol-3- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 477.2 δH (400 MHz, MeOD). 8.6(~1 H, d, NH slow exchange), 7.9 (1 H, s), 7.7 (3 H, m), 7.5 (4 H, m),7.3 (1 H, m, 3.9 (1 H, m), 3.1 (2 H, d), 2.1 (2 H, d), 1.95 (2 H, d),1.7 (1 H, m), 1.4 (2 H, q), 1.2 (2 H, q). 19.95

Trans-2-chloro- N-(4-((6- fluoro-1H- pyrazolo[4,3- b]pyridin-3- ylamino)methyl) cyclohexyl)-5- (trifluoromethyl) benzamide 470.2 δH (400 MHz,MeOD). δ 8.6 (1 H, d, NH slow exchange), 8.2 (1 H, s), 7.7 (3 H, m), 7.5(1 H, d), 3.9 (1 H, m), 3.3 (2 H, d), 2.1 (4 H, dd), 1.7 (1 H, m), 1.3(4 H, m). 19.96

Trans-2-chloro- 2-methyl-N-(4- ((3-methyl-4- phenyl-1H- pyrazol-5-ylamino) methyl) cyclohexyl) nicotinamide 438.47 δH (400 MHz, DMSO);11.10 (1 H, br), 8.53 (1 H, d), 8.40 (1 H, d), 7.80 (1 H, d), 7.36 (4 H,m), 7.19 (1 H, m), 4.59 (1 H, t), 3.68 (1 H, m), 2.95 (2 H, t), 2.50 (3H, s), 2.14 (3 H, s), 1.90 (2 H, m), 1.80 (2 H, m), 1.58 (1 H, m), 1.21(2 H, m), 0.99 (2 H, m). 19.97

Trans-2-chloro- N-(4-((3- (pyridin-3-yl)- 1H-pyrazol-5- ylamino) methyl)cyclohexyl)-5- (trifluoromethyl) benzamide 478.3 δH (400 MHz, DMSO);11.90 (1 H, br d), 8.90 (1 H, s), 8.48 (2 H, m), 8.03 (1 H, m), 7.81 (1H, m), 7.74 (2 H, m), 7.40 (1 H, m), 3.70 (3 H, s), 2.91 (2 H, t), 1.95(2 H, m), 1.88 (2 H, m), 1.51 (1 H, m), 1.23 (2 H, m), 1.08 (2 H, m).19.98

Trans-2- Chloro-N-{4- [(3-chloro-6- methoxy- pyridin-2- ylamino)-methyl]- cyclohexyl}-5- trifluoromethyl- benzamide 476.25 δH (400 MHz,DMSO); 8.49 (1 H, d), 7.80 (1 H, m), 7.73 (2 H, m), 7.42 (1 H, d), 6.47(1 H, t), 5.91 (1 H, d), 3.79 (3 H, s), 3.70 (1 H, m), 3.22 (2 H, t),1.93 (2 H, m), 1.80 (2 H, m), 1.62 (1 H, m), 1.22 (2 H, m), 1.07 (2 H,m). 19.99

Trans-2- Chloro-N-{4- [(5-chloro-6- methoxy- pyridin-2- ylamino)-methyl]- cyclohexyl}-5- trifluoromethyl- benzamide 476.24 δH (400 MHz,DMSO); 8.49 (1 H, d), 7.81 (1 H, m), 7.73 (2 H, m), 7.33 (1 H, d), 6.78(1 H, t), 6.03 (1 H, d), 3.83 (3 H, s), 3.70 (1 H, m), 3.10 (2 H, t),1.95 (2 H, m), 1.81 (2 H, m), 1.51 (1 H, m), 1.22 (2 H, m), 1.08 (2 H,m). 19.100

Trans-2- Chloro-N-{4- [(1-phenyl-1H- tetrazol-5- ylamino)- methyl]-cyclohexyl}-5- trifluoromethyl- benzamide 479.2 δH (400 MHz, MeOD); 7.6(8 H, m), 4.4 (1 H, m), 3.25 (2 H, d), 2.1 (2 H, d), 1.9 (2 H, d), 1.2(1 H, m), 1.4 (2 H, q), 1.2 (2 H, q). (Tab; NMR product. Hardcopy;av43563). 19.101

Trans-2- Chloro-N-{4- [(1-methyl-4- phenyl-1H- pyrazol-3- ylamino)-methyl]- cyclohexyl}-5- trifluoromethyl- benzamide 491.2 δH (400 MHz,MeOD); 8.6 (~1 H, d, NH slow exchange), 7.9 (1 H, s), 7.7 (4 H, m), 7.4(4 H, m), 7.3 (1 H, m, 3.8 (1 H, m), 3.1 (2 H, d), 2.1 (2 H, d), 1.95 (2H, d), 1.7 (1 H, m), 1.4 (2 H, q), 1.2 (2 H, q). 19.102

Trans-2- Chloro-N-{4- [(3,4-dimethyl- isoxazol-5- ylamino)- methyl]-cyclohexyl}-5- trifluoromethyl- benzamide 430.38 δH (400 MHz, DMSO);8.50 (1 H, d), 7.80 (1 H, m), 7.73 (2 H, m), 7.42 (1 H, d), 6.60 (1 H,t), 3.70 (1 H, m), 3.02 (2 H, t), 1.96 (3 H, s), 1.92 (2 H, m), 1.80 (2H, m), 1.70 (3 H, s), 1.43 (1 H, m), 1.22 (2 H, m), 1.04 (2 H, m).19.103

Trans-2- Chloro-N-{4- [(4-pyridin-3-yl- 2H-pyrazol-3- ylamino)- methyl]-cyclohexyl}-5- trifluoromethyl- benzamide 478.31 δH (400 MHz, DMSO);11.90 (1 H, br d), 8.72 (1 H, s), 8.49 (1 H, d), 8.31 (1 H, m), 7.77 (5H, m), 7.32 (1 H, m), 3.70 (3 H, s), 3.00 (2 H, t), 1.90 (4 H, m), 1.61(1 H, m), 1.21 (2 H, m), 1.03 (2 H, m). 19.104

Trans-2- Chloro-N-{4- [(5-chloro-6- d3-methyl- pyridin-3- ylamino)-methyl]- cyclohexyl}-5- trifluoromethyl- benzamide 463.3 δH (400 MHz,DMSO); 8.49 (1 H, d), 7.81 (2 H, m), 7.73 (2 H, m), 6.95 (1 H, d), 5.99(1 H, t), 3.70 (1 H, m), 2.90 (2 H, t), 1.93 (2 H, m), 1.87 (2 H, m),1.49 (1 H, m), 1.23 (2 H, m), 1.08 (2 H, m). 19.105

Trans-2- Chloro-N-(4- {[4-(4-fluoro- phenyl)-5- methyl-1H- pyrazol-3-ylamino]- methyl}- cyclohexyl)-5- trifluoromethyl- benzamide 509.4 δH(400 MHz, DMSO); 8.48 (1 H, d), 7.82 (1 H, m), 7.72 (2 H, m), 7.36 (2 H,m), 7.25 (2 H, m), 3.67 (1 H br), 2.65 (2 H, d), 2.17 (2 H, m), 1.80 (2H, m), 1.56 (1 H, br), 1.24 (2 H, m), 1.02 (2 H, m). 19.106

Trans-2- Chloro-N-{4- [(1H- pyrazolo[3,4- b]pyrazin-3- ylamino)-methyl]- cyclohexyl}-5- trifluoromethyl- benzamide 453.29 δH (400 MHz,DMSO); 12.33 (1 H, s), 8.50 (1 H, d), 8.41 (1 H, s), 8.32 (1 H, s), 7.81(1 H, m), 7.72 (2 H, m), 6.38 (1 H, t), 3.70 (1 H, m), 3.20 (2 H, t),1.91 (4 H, m), 1.70 (1 H, m), 1.23 (2 H, m), 1.10 (2 H, m). 19.107

Trans-5- Chloro-2- methyl-N-{4- [(5- trifluoromethyl- 2H-pyrazol-3-ylamino)- methyl]- cyclohexyl}- nicotinamide 416.4 δH (400 MHz, DMSO);1.0 (2 H, m), 1.2 (2 H, m), 1.45 (1 H, m), 1.82 (2 H, m), 1.95 (2 H, m),2.45 (3 H, s), 2.88 (2 H, t), 3.68 (1 H, m), 5.58 (1 H, s), 5.95 (1 H,t), 7.79 (1 H, s), 8.38 (1 H, d), 8.55 (1 H, d), 12.2 (1 H, s). 19.108

Trans-5- Chloro-N-{4- [(5-fluoro- pyridin-2- ylamino)- methyl]-cyclohexyl}-2- methyl- nicotinamide 377.32 δH (400 MHz, DMSO); 8.52 (1H, d), 8.39 (1 H, d), 7.90 (1 H, d), 7.79 (1 H, d), 7.31 (1 H, m), 6.52(1 H, t), 6.49 (1 H, d of d), 3.69 (1 H, m), 3.08 (2 H, t), 2.49 (3 H,s), 1.91 (2 H, m), 1.82 (2 H, m), 1.49 (1 H, m), 1.23 (2 H, m), 1.03 (2H, m). 19.109

Trans-2- Chloro-N-{4- [(5-chloro-6- methoxy- pyridin-3- ylamino)-methyl]- cyclohexyl}-5- trifluoromethyl- benzamide 476.31 δH (400 MHz,DMSO); 8.50 (1 H, d), 7.81 (1 H, m), 7.75 (2 H, m), 7.48 (1 H, d), 7.19(1 H, d), 5.58 (1 H, t), 3.80 (3 H, s), 3.70 (1 H, m), 2.87 (2 H, t),1.97 (2 H, m), 1.87 (2 H, m), 1.49 (1 H, m), 1.26 (2 H, m), 1.09 (2 H,m). 19.110

Trans-2- Chloro-2 methyl-N-{4- [(5-propyl-1H- pyrazol-3- ylamino)-methyl]- cyclohexyl}- nicotinamide 390.41 δH (400 MHz, DMSO); 11.02 (1H, s), 8.52 (1 H, d), 8.39 (1 H, d), 7.80 (1 H, d), 5.20 (1 H, s), 3.68(1 H, m), 2.81 (2 H, t), 2.48 (3 H, s), 2.39 (2 H, m), 1.90 (2 H, m),1.81 (2 H, m), 1.53 (2 H, m), 1.46 (1 H, m), 1.21 (2 H, m), 1.00 (2 H,m), 0.89 (3 H, t). 19.111

Trans-2- Chloro-N-(4- {[(4-chloro- phenyl)-3- methyl- isoxazol-5-ylamino]- methyl}- cyclohexyl)-5- trifluoromethyl- benzamide 526.2 δH(400 MHz, MeOD); 8.60 (1 H, d), 7.72 (3 H, m), 7.43 (2 H, d), 7.31 (2 H,d), 3.84 (1 H, m), 3.16 (2 H, d), 2.15 (3 H, s), 2.09 (2 H, d), 1.88 (2H, d), 1.60 (1 H, m), 1.34 (2 H, q), 1.13 (2 H, q) 19.112

Trans-2- Chloro-N-{4- [(5- methoxymethyl- 4H- [1,2,4]triazol-3-ylamino)- methyl]- cyclohexyl}-5- trifluoromethyl- benzamide 446.2 δH(400 MHz, MeOD); 7.73 (3 H, m), 4.47 (3 H, s), 3.86 (1 H, m), 3.43 (2 H,s), 3.21 (2 H, d), 2.13 (2 H, d), 1.96 (2 H, d), 1.65 (1 H, m), 1.39 (2H, q), 1.22 (2 H, q) 19.113

Trans-2- Chloro-N-{4- [(5-chloro-2- methoxy- pyridin-3- ylamino)-methyl]- cyclohexyl}-5- trifluoromethyl- benzamide 476.31 δH (400 MHz,DMSO); 8.49 (1 H, d), 7.80 (1 H, m), 7.72 (2 H, m), 7.29 (1 H, d), 6.76(1 H, d), 5.53 (1 H, t), 3.88 (3 H, s), 3.69 (1 H, m), 2.94 (2 H, t),1.92 (2 H, m), 1.80 (2 H, m), 1.56 (1 H, m), 1.22 (2 H, m), 1.03 (2 H,m). 19.114

Trans-2- Chloro-N-{4- [(4-chloro-5- methyl-2H- pyrazol-3- ylamino)-methyl]- cyclohexyl}-5- trifluoromethyl- benzamide 449.2 δH (400 MHz,MeOD); 7.72 (3 H, m), 3.85 (1 H, m), 3.07 (2 H, d), 2.16 (3 H, s), 2.09(2 H, d), 1.96 (2 H, d), 1.63 (1 H, m), 1.35 (2 H, q), 1.16 (2 H, q)19.115

Trans-2- Chloro-N-{4- [(4-cyano-5- methyl-2H- pyrazol-3- ylamino)-methyl]- cyclohexyl}-5- trifluoromethyl- benzamide 440.2 δH (400 MHz,MeOD); 8.61 (1 H, d), 7.72 (3 H, m), 3.86 (1 H, m), 3.10 (2 H, d), 2.26(3 H, s), 2.10 (2 H, d), 1.96 (2 H, d), 1.63 (1 H, m), 1.36 (2 H, q),1.15 (2 H, q) 19.116

Trans-2- Chloro-N-(4- {[2-(4-chloro- phenyl)-5- methyl-2H- pyrazol-3-ylamino]- methyl}- cyclohexyl)-5- trifluoromethyl- benzamide 525.2 δH(400 MHz, MeOD); 8.61 (1 H, d), 7.56-7.76 (7 H, m), 3.84 (1 H, m), 3.07(2 H, d), 2.33 (3 H, s), 2.10 (2 H, d), 1.90 (2 H, d), 1.63 (1 H, m),1.34 (2 H, q), 1.15 (2 H, q) 19.117

Trans-2- Chloro-N-{4- [(5-ethyl-4- methyl-1H- pyrazol-3- ylamino)-methyl]- cyclohexyl}-5- trifluoromethyl- benzamide 443.43 δH (400 MHz,DMSO); 10.87 (1 H, s), 8.49 (1 H, d), 7.80 (1 H, m), 7.72 (2 H, m), 4.47(1 H, m), 3.69 (1 H, m), 2.90 (2 H, t), 2.40 (2 H, q), 1.92 (2 H, m),1.83 (2 H, m), 1.72 (3 H, s), 1.53 (1 H, m), 1.22 (2 H, m), 1.10 (3 H,t), 1.00 (2 H, m). 19.118

Trans-2- Chloro-N-{4- [(1-methyl-1H- pyrazolo[4,3- b]pyridin-3-ylamino)- methyl]- cyclohexyl}-5- trifluoromethyl- benzamide 466.2 δH(400 MHz, MeOD); 8.3 (1 H, d), 7.8 (1 H, d), 7.7 (3 H, m), 7.4 (1 H, m),3.9 (1 H, m), 3.8 (3 H, s), 3.3 (2 H, m), 2.1 (2 H, d), 2.05 (2 H, d),1.75 (1 H, m), 1.4 (2 H, q), 1.25 (2 H, q). 19.119

Trans-2- Chloro-N-[4- ([1,2,4]triazolo [4,3-a]pyridin-3- ylaminomethyl)-cyclohexyl]-5- trifluoromethyl- benzamide 452.2 δH (400 MHz, MeOD); 1.2(2 H, m), 1.4 (2 H, m), 1.80 (1 H, m), 2.0 (2 H, m), 2.12 (2 H, m), 3.90(1 H, m), 6.80 (1 H, t), 7.25 (1 H, dd), 7.45 (1 H, d), 7.6 (3 H, m),8.05 (1 H, d). 19.120

Trans-2- Chloro-N-{4- [(5,7-dimethyl- pyrazolo[1,5- a]pyrimidin-3-ylamino)- methyl]- cyclohexyl}-5- trifluoromethyl- benzamide 480.3 δH(400 MHz, CDCl3) 1.3 (4 H, m), 1.80 (1 H, m), 2.12 (2 H, m), 2.22 (2 H,m), 2.55 (3 H, s), 2.70 (3 H, s), 3.25 (2 H, m), 4.0 (1 H, m), 6.02 (1H, d), 6.50 (1 H, s), 7.50 (1 H, d), 7.62 (1 H, d), 7.88 (1 H, s), 8.0(1 H, m) 19.121

Trans-5- Chloro-N-{4- [(Trans-5- Chloro-2- methoxy- pyridin-3- ylamino)-methyl]- cyclohexyl}-2- methyl- nicotinamide 423.4 δH (d6-DMSO, 400MHz); 8.53 (1 H, d), 8.40 (1 H, d), 7.80 (1 H, m), 7.30 (1 H, d), 6.77(1 H, d), 5.55 (1 H, t), 3.89 (3 H, s), 3.69 (1 H, m), 2.95 (2 H, t),2.49 (3 H, s), 1.91 (2 H, m), 1.80 (2 H, m), 1.57 (1 H, m), 1.25 (2 H,m), 1.06 (2 H, m). 19.122

Trans-2- Chloro-N-(4- {[4-(3,4- dimethoxy- phenyl)-2,5- dimethyl-2H-pyrazol-3- ylamino]- methyl}- cyclohexyl)-5- trifluoromethyl- benzamide565.3 δH (CDCl3, 400 MHz) 7.89 (1 H, s), 7.62 (1 H, d), 7.54 (1 H, d),6.93 (1 H, d), 6.80 (2 H, d), 5.99 (1 H, d), 3.93 (3 H, s), 3.90 (3 H,s), 3.73 (3 H, s), 3.30 (1 H, br), 2.79 (2 H, d), 2.20 (3 H, s), 2.12 (2H, d), 1.73 (2 H, d), 1.33 (1 H, m), 1.15 (2 H, q), 1.05 (2 H, q) 19.123

Trans-2- Chloro-N-(4- {[4-(Trans-2- Chloro- phenyl)-1H- pyrazol-3-ylamino]- methyl}- cyclohexyl)-5- trifluoromethyl- benzamide 511.29 δH(400 MHz, MeOD). 7.8 (3 H, m), 7.5 (3 H, m), 7.4 (2 H, m), 3.8 (1 H, m),3.0 (2 H, d), 2.1 (2 H, d), 1.9 (2 H, d), 1.6 (1 H, m), 1.3 (2 H, m),1.1 (2 H, m). 19.124

Trans-2- Chloro-N-(4- {[1-(4-chloro- benzyl-1H- tetrazol-5- ylamino]-methyl}- cyclohexyl)-5- trifluoromethyl- benzamide 527.4 δH (400 MHz,DMSO-d6). 8.5 (1 H, d), 7.8 (1 H, d), 7.7 (2 H, d), δ7.4 (2 H, d), 7.2(2 H, m), 7.0 (1 H, m), 5.4 (2 H, m + DCM), 3.7 (1 H, m), 3.1 (2 H, t),1.9 (2 H, d), 1.7 (2 H, d), 1.5 (1 H, m), 1.2 (2 H, m), 1.0 (2 H, m).19.125

Trans-2- Chloro-N-{4- [(4-chloro-5- methoxy- pyridin-2- ylamino)-methyl]- cyclohexyl}-5- trifluoromethyl- benzamide 476.3 δH (d6-DMSO,400 MHz); 8.49 (1 H, d), 7.81 (2 H, m), 7.74 (2 H, m), 6.68 (1 H, t),6.17 (1 H, s), 3.81 (3 H, s), 3.69 (1 H, m), 3.09 (2 H, t), 1.92 (2 H,m), 1.80 (2 H, m), 1.50 (1 H, m), 1.23 (2 H, m), 1.03 (2 H, m).

The compounds of the following tabulated Examples (Table 10) areprepared according from trans-(4-amino-cyclohexylmethyl)phenylamine (Ex.5.1 step 5) according to the following general procedure:

In each reaction: carboxylic acid (0.147 mmol, 1.47 eq),trans-(4-amino-cyclohexylmethyl)phenylamine (Step 5) (0.1 mmol, 1 eq, 21mg), HATU (0.147 mmol, 1.47 eq, 56 mg), PS-DIEA 3.4 mmol/g loading (0.2mmol, 2 eq, 60 mg) are used.

A stock solution of trans-(4-amino-cyclohexylmethyl)phenylamine is madeup in DMF (1.428 g in 13.6 mL). A stock solution of HATU is made up inDMF (3.808 g in 20.4 mL DMF). Ca. 60 mg PS-DIEA is added to eachpre-weighed carboxylic acid. 200 ulTrans-(4-amino-cyclohexylmethyl)phenylamine solution is pipetted intoeach vial, followed by 300 μl of HATU solution. Vials are sealed andshaken at RT for 16 hr. Crude reactions are purified by loading onto a 1g SCX-2 cartridge pre-wetted with MeOH, crude is washed with 3 mL MeOHbefore compounds are eluted with 2×2 mL 2M ammonia in MeOH. Compoundsare analyzed and evaporated in vacuo. Crude mixtures are purifiedfurther by prep HPLC (Waters Sunfire C18 5 micron column, 19×50 mm,mobile phases 0.1% TFA in water, 0.1% TFA in acetonitrile, 6 minutegradient dependant on retention time from analytics). Successfulpurifications are turned into free-based amines by passing prep fractionthrough a SCX-2 cartridge pre-wetted with MeOH, washed with 5 mL MeOH,and eluted with 2×2 mL 3.5M ammonia in MeOH. Compounds are evaporated invacuo.

TABLE 10 Ex. Structure IUPAC Name [M + H]+ NMR Data 20.1

5-chloro-2- (dimethylamino)- N-(4-((4,5- dimethylthiazol-2-ylamino)methyl) cyclohexyl) benzamide 421.47 δH (400 MHz, DMSO); 8.75 (d1H), 7.47 (d 1H), 7.43 (dd 1H), 7.24 (t 1H), 7.13 (d 1H), 3.74 (m 1H),3.03 (t 2H), 2.78 (s 6 H), 2.17 (s 3H), 2.04 (s 3H), 1.96 (m 2H), 1.86(m 2H), 1.49 (m 1H), 1.30(m 2H), 1.20 (m 2H) 20.2

2- (dimethylamino)- N-(4-((4,5- dimethylthiazol-2- ylamino)methyl)cyclohexyl)-5- (trifluoromethyl) nicotinamide 456.42 δH (400 MHz, DMSO);8.42 (2H, m), 7.64 (1H, s), 7.18 (1H, t), 3.63 (1H, m), 3.04 (6 H, s),3.01 (2H, t), 2.10 (3H, s), 1.98 (3H, s), 1.90 (2H, m), 1.80 (2H, m),1.51 (1H, m), 1.23 (2H, m), 1.02 (2H, m) 20.3

2- (dimethylamino)- N-{-4-((4,6- dimethylpyridin-2- ylamino)methyl)cyclohexyl}-5- (trifluoromethyl) nicotinamide 450.58 δH (400 MHz, DMSO);8.42 (2H, m), 7.64 (1H, s), 6.30 (1H, br s), 6.20 (1H, s), 6.12 (1H, brs), 3.63 (1H, m), 3.05 (2H, m), 2.20 (3H, s), 2.11 93H, s), 1.92 (2H,m), 1.82 (2H, m), 1.48 (1H, m), 1.23 (2H, m), 1.05 (2H, m)

The compounds of the following tabulated Examples (Table 11), ortautomers thereof, are prepared by a similar method to that of Example 6by replacing 1-(1H-pyrazol-3-yl)imidazolidin-2-one with the appropriateintermediate.

TABLE 11 Ex. Structure IUPAC Name [M + H]+ NMR Data 21.1

N-(4-((1H-indazol-1- yl)methyl)cyclohexyl)- 2-chloro-5-(trifluoromethyl) benzamide 436.26 δH (400 MHz, DMSO) 8.48 (1H, d), 8.07(1H, s), 7.30 (5 H, m), 7.39 (1H, t), 7.11 (1H, t), 4.29 (2H, d), 3.69(1H, m), 1.88 (3H, m), 1.55 (2H, m), 1.20 (4H, m) 21.2

2-Chloro-N-(4- indazol-2-ylmethyl- cyclohexyl)-5- trifluorometnyl-benzamide 436.29 δH (400 MHz, DMSO) 8.50 (1H, d), 8.34 (1H, s), 7.80(1H, m) 7.71 (3H, m), 7.60 (1H, m), 7.21 (1H, t), 7.02 (1H, t), 4.30(2H, d), 3.70 (1H, m), 1.93 (3H, m), 1.58 (2H, m), 1.20 (4H, m). 21.3

N-[4-(3-Amino-4- chloro-indazol-1-yl methyl)-cyclohexyl]- 2-chloro-5-trifluoromethyl- benzamide 485.2 δH (400 MHz, DMSO) 8.48 (1H, d), 7.80(1H, m), 7.73 (2H, m), 7.38 (1H, d), 7.21 (1H, m), 6.90 (1H, d), 5.27(2H, br s), 3.98 (2H, d), 3.67 (1H, m), 1.89 (2H, m(, 1.81 (1H, m), 1.56(2H, m), 1.16 (4H, m). 21.4

2-Chloro-N-[4-(3,5- dimethyl-[1,2,4] triazol-1-ylmethyl)- cyclohexyl]-5-trifluoromethyl- benzamide 415.4 δH (400 Mhz, DMSO) 8.50 (1H, d), 7.81(1H, m), 7.74 (2H, m), 3.84 (2H, d), 3.69 (1H, m), 2.32 (3H, s), 2.16(3H, s), 1.91 (2H, m), 1.74 (1H, m), 1.59 (2H, m), 1.18 (4H, m). 21.5

2-Chloro-N-{4-[5- methyl-3-(2-oxo- imidazolidin-1-yl)-pyrazol-1-ylmethyl]- cyclohexyl}-5- trifluoromethyl- benzamide 484.26 δH(400 MHz, DMSO) 8.50 (1H, d), 7.81 (1H, m), 7.73 (2H, m), 6.75 (1H, s),6.22 (1H, s), 3.73 (4H, m), 3.70 (1H, m), 2.20 (3H, s), 1.90 (2H, d),1.75 (1H, m), 1.58 (2H, m), 1.15 (4H, m). 21.6

2-Chloro-N-[4-(5- methyl-tetrazol-2- ylmethyl)- cyclohexyl]-5-trifluoromethyl- benzamide 402.1 δH (400 MHz, MeOD) 7.7 (3H, m), 4.5(2H, d), 3.9 (1H, m), 2.5 (3H, s), 2.1 (3H, m), 1.7 (2H, d), 1.3 (4H,m). 21.7

2-Chloro-N-[4-(5- cyclopropyl- tetrazol-2- ylmethyl)- cyclohexyl]-5-trifluoromethyl- benzamide 428.2 δH (400 MHz, MeOD) 8.6 (~0.5 H, d, NHslow exchange), 7.7 (3H, m), 4.5 (2H, d), 3.85 (1H, m), 2.2 (1H, m), 2.0(3H, m), 1.7 (2H, d), 1.3 (4H, m), 1.1 (2H, m), 1.0 (2H, m). 21.8

2-Chloro-N-[4-(4- chloro-3,5- dimethyl-pyrazol- 1-ylmethyl)-cyclohexyl]-5- trifluoromethyl- benzamide 448.33 δH (400 MHz, DMSO) 8.50(1H, d), 7.80 (1H, m), 7.72 (2H, m), 3.82 (2H, d), 3.70 (1H, m), 2.20(3H, s), 2.10 (3H, s), 1.91 (2H, m), 1.72 (1H, m), 1.58 (2H, m), 1.18(4H, m). 21.9

2-Chloro-N-[4-(3- ethoxy-5-methyl- [1,2,4]triazol-1- ylmethyl)-cyclohexyl]-5- trifluoromethyl- benzamide 445.4 δH (400 MHz, DMSO) 8.50(1H, d), 7.81 (1H, m), 7.74 (2H, m), 4.15 (2H, q), 3.78 (2H, d), 3.69(1H, m), 2.30 (3H, s), 1.92 (2H, m), 1.74 (1H, m), 1.60 (2H, m), 1.28(3H, t), 1.18 (4H, m). 21.10

2-Chloro-N-[4-(5- ethoxy-3-methyl- [1,2,4]triazol-1- ylmethyl)-cyclohexyl]-5- trifluoromethyl- benzamide 445.4 δH (400 MHz, DMSO) 8.49(1H, d), 7.81 (1H, m), 7.74 (2H, m), 4.36 (2H, q), 3.69 (1H, m), 3.64(2H, d), 2.12 (3H, s), 1.91 (2H, m), 1.69 (1H, m), 1.60 (2H, m), 1.33(3H, t), 1.22 (2H, m), 1.08 (2H, m). 21.11

2-Chloro-5- trifluoromethyl-N- [4-(3,4,5- trimethyl-pyrazol-1-ylmethyl)- cyclohexyl]- benzamide 428.44 δH (400 MHZ, DMSO) 8.48 (1H,d), 7.80 (1H, m), 7.72 (2H, m), 3.75 (2H, d), 3.69 (1H, m), 2.10 (3H,s), 2.01 (3H, s), 1.90 (2H, m), 1.82 (3H, s), 1.70 (1H, m), 1.58 (2H,m), 1.20 (2H, m), 1.10 (2H, m). 21.12

2-Chloro-5- trifluoromethyl-N- [4-(3- trifluoromethyl- pyrazol-1-ylmethyl)- cyclohexyl]- benzamide 454.35 δH (400 MHZ, DMSO) 8.50 (1H,d), 7.98 (1H, s), 7.80 (1H, m), 7.72 (2H, m), 6.70 (1H, d), 4.09 (2H,d), 3.68 (1H, m), 1.91 (2H, m), 1.80 (1H, m), 1.55 (2H, m), 1.22 (2H,m), 1.11 (2H, m).

The compounds of the following tabulated Examples (Table 12), ortautomers thereof, are prepared by a similar method to that of Example12 using the appropriate acid chloride.

TABLE 12 Ex. Structure IUPAC Name [M + H]+ NMR Data 22.1

5-Chloro-N-{4- [(1H-indazol-3- ylamino)- methyl]- cyclohexyl}-2- methyl-nicotinamide 398.35 δH (400 MHz, DMSO) 11.30 (1H, s), 8.52 (1H, d), 8.40(1H, d), 8.22 (1H, d), 7.80 (1H, d), 7.72 (1H, d), 7.21 (2H, m), 6.89(1H, m), 5.93 (1H, t), 3.72 (1H, m), 3.11 (2H, t), 2.48 (3H, s), 1.92(4H, m), 1.68 (1H, m), 1.26 (2H, m), 1.10 (2H, m). 22.2

5-Chloro-2- methyl-N-{4- [(1H-pyrazolo [3,4-b]pyridin-3-ylamino)-methyl]- cyclohexyl}- nicotinamide 399.38 δH (400 MHz, DMSO)11.90 (1H, s), 8.53 (1H, d), 8.40 (1H, d), 8.32 (1H, d), 8.18 (1H, d),7.80 (1H, d), 6.93 (1H, m), 6.21 (1H, t), 3.72 (1H, m), 3.12 (2H, t),2.48 (3H, s), 1.91 (4H, m), 1.67 (1H, m), 1.25 (2H, m), 1.11 (2H, m).22.3

2-Chloro-N-[4- (3-phenyl- pyrazol-1- ylmethyl)- cyclohexyl]-5-trifluoromethyl- benzamide 462.34 δH (400 MHz, DMSO) 8.50 (1H, d), 7.78(6 H, m), 7.40 (2H, t), 7.29 (1H, t), 4.01 (2H, d), 3.70 (1H, m), 1.93(2H, m), 1.72 (1H, m), 1.62 (2H, m), 1.20 (4H, m). 22.4

5-Chloro-N-[4- (3,5-dimethyl- pyrazol-1- ylmethyl)- cyclohexyl]-2-methyl- nicotinamide 361.3 δH (400 MHz, CDCl3) 8.50 (1H, d), 7.62 (1H,d), 5.82 (1H, s), 5.70 (1H, s), 3.94 (1H, m), 3.86 (2H, d), 2.62 (3H,s), 2.27 (3H, s), 2.25 (3H, s), 2.14 (2H, m), 2.02 (1H, m), 1.76 (2H,m), 1.23 (4H, m). 22.5

2-Chloro-N-[4- (4-phenyl- pyrazol-1- ylmethyl)- cyclohexyl]-5-trifluoromethyl- benzamide 462.33 δH (400 MHz, DMSO) 8.50 (1H, d), 8.17(1H, s), 7.90 (1H, s), 7.80 (1H, m), 7.72 (2H, m), 7.58 (2H, d), 7.35(2H, t), 7.19 (1H, t), 4.00 (2H, d), 3.70 (1H, m), 1.91 (2H, m), 1.81(1H, m), 1.62 (2H, m), 1.23 (2H, m), 1.12 (2H, m). 22.6

Trans-5- Chloro-2- methyl-N-[4- (3-methyl-5- trifluoromethyl- pyrazol-1-ylmethyl)- cyclohexyl]- nicotinamide 415.4 δH (400 MHz, CDCl3) 8.48 (1H,d), 7.62 (1H, d), 6.36 (1H, s), 5.64 (1H, br d), 3.98 (2H, d), 3.93 (1H,m), 2.61 (3H, s), 2.28 (3H, s), 2.13 (2H, m), 2.02 (1H, m), 1.72 (2H,m), 1.22 (4H, m). 22.7

Trans-5- Chloro-2- methyl-N-[4- (5-methyl-3- trifluoromethyl- pyrazol-1-ylmethyl)- cyclohexyl]- nicotinamide 415.4 δH (400 MHz, CDCl3) 8.48 (1H,d), 7.63 (1H, d), 6.26 (1H, s), 5.67 (1H, br), 3.93 (1H, m), 3.91 (2H,d), 2.62 (3H, s), 2.30 (3H, s), 2.13 (2H, m), 1.99 (1H, m), 1.72 (2H,m), 1.22 (4H, m). 22.8

Trans-N-{4- [(4,5-Dimethyl- thiazol-2- ylamino)-methyl]- cyclohexyl}-2-fluoro-5- trifluoromethyl- benzamide 430.4 No Data 22.9

Trans-5- Chloro-N-{4- [(4,5-Dimethyl- thiazol-2- ylamino)- methyl]-cyclohexyl}-2- fluoro- benzamide 393.3 No Data

TABLE 13 CRF-1 IC₅₀ data and ¹H NMR data for representative compounds ofthe invention Exam- IC₅₀ ple (micro NMR data (400 MHz, DMSO unlessstated No. molar) otherwise)  1 0.038 8.48 (1H, d), 7.85-7.73 (4H, m),7.18 (1H, d), 6.40 (1H, dd), 5.82 (1H, t), 3.70 (1H, m), 3.20 (2H, t),2.04 (3H, s), 1.93 (2H, m), 1.83 (2H, m), 1.61 (1H, m), 1.21 (2H, m),1.05 (2H, m).  1.13 0.019 8.50 (1H, d), 7.81 (1H, d), 7.73 (2H, m), 7.64(1H, d), 6.98 (1H, m), 6.80 (1H, m), 5.11 (1H, t), 3.70 (1H, m), 2.93(2H, m), 2.30 (3H, s), 1.90 (4H, m), 1.60 (1H, m), 1.25 (2H, m), 1.06(2H, m).  1.18 0.031 8.57 (1H, s), 8.52 (1H, d), 8.09 (1H, s), 7.18 (1H,t), 3.65 (1H, m), 3.00 (2H, t), 2.10 (3H, s), 1.98 (3H, s), 1.92 (2H,m), 1.79 (2H, m), 1.50 (1H, m), 1.20 (2H, m), 1.02 (2H, m).  1.33 6.42512.29 (1H, s), 8.53 (1H, d), 8.48 (1H, d), 7.78 (4H, m) 7.35 (1H, m),6.50 (1H, d), 3.71 (1H, m), 3.19 (2H, m), 1.96 (2H, m), 1.83 (2H, m),1.52 (1H, m), 1.23 (2H, m), 1.08 (2H, m).  1.34 1.241 11.75 (1H, s),8.51 (1H, d), 8.10 (1H, s), 7.92 (1H, br), 7.80 (1H, m), 7.81 (1H, m),7.74 (2H, m), 7.05 (1H, br s), 4.20 (2H, m), 3.71 (1H, m), 3.27 (2H, m),2.70 (6H, d), 1.92 (4H, m), 1.59 (1H, m), 1.28 (2H, m), 1.12 (2H, m). 1.35a{circumflex over ( )} 0.199 11.81 (1H, br s), 8.42 (1H, d), 7.80(1H, m), 7.71 (4H, m), 7.20 (2H, m), 5.78 (1H, br s), 5.27 (1H, br),3.96 (1H, m), 2.91 (2H, m), 2.12 (1H, m), 1.94 (1H, m), 1.74 (1H, m),1.61 (1H, m), 1.45 (1H, m), 1.24 (3H, m), 0.92 (3H, d).  2.5 0.036 8.49(1H, d), 7.81 (1H, d), 7.75 (2H, d), 7.30 (1H, t), 6.61 (1H, s), 3.69(1H, m), 3.02 (2H, t), 2.19 (3H, s), 1.92 (2H, m), 1.79 (2H, m), 1.51(1H, m), 1.22 (2H, m), 1.03 (2H, m).  2.6 0.215 8.48 (1H, d), 7.80 (1H,m), 7.72 (2H, m), 6.20 (1H, t), 6.14 (1H, s), 6.04 (1H, s), 3.69 (1H,m), 3.03 (2H, m), 2.19 (3H, s), 2.09 (3H, s), 1.92 (2H, m), 1.81 (2H,m), 1.48 (1H, m), 1.22 (2H, m), 1.03 (2H, m).  2.8 0.066 8.48 (1H, d),7.80 (1H, m), 7.72 (2H, m), 7.18 (1H, d of d), 6.39 (1H, d), 6.23 (1H,t), 3.69 (1H, m), 3.05 (2H, m), 2.06 (3H, s), 1.91 (2H, m), 1.81 (2H,m), 1.49 (1H, m), 1.22 (2H, m), 1.02 (2H, m).  2.9 0.039 8.47 (1H, d),7.80 (1H, m), 7.72 (2H, m), 7.20 (1H, t), 6.30 (2H, m), 6.22 (1H, d),3.68 (1H, m), 3.05 (2H, m), 2.20 (3H, s), 1.92 (2H, m), 1.82 (2H, m),1.49 (1H, m), 1.23 (2H, m), 1.04 (2H, m).  2.26 0.063 8.48 (1H, d),7.82-7.73 (3H, m), 6.91 (1H, t), 6.13-6.04 (3H, m), 5.56 (1H, t), 4.48(1H, m), 3.71 (1H, m), 2.84 (2H, t), 1.95-1.86 (4H, m), 1.49 (1H, m),1.39-1.21 (8H, m), 1.20-1.02 (2H, m).  2.35 0.346 8.47 (1H, d),7.87-7.73 (5H, m), 7.56-7.48 (3H, m), 6.99 (1H, s), 3.75 (2H, s), 3.66(1H, m), 2.39 (2H, d), 2.19 (1H, br s), 1.93-1.83 (4H, m), 1.37 (1H, m),1.28-1.20 (2H, m), 1.04-0.95 (2H, m).  3 0.060 8.47 (1H, d), 7.81 (1H,d), 7.72 (2H, d), 7.18 (1H, t), 3.68 (1H, m), 2.99 (2H, t), 2.09 (3H,s), 1.98 (3H, s), 1.92 (2H, m), 1.79 (2H, m), 1.50 (1H, m), 1.22 (2H,m), 1.03 (2H, m).  4.11 0.061 11.40-12.00 (1H, very broad d), 7.70 (5H,m) 7.20 (2H, m), 5.77 (1H, br), 5.00-5.60 (1H, very broad d), 3.70 (1H,m), 2.90 (2H, m), 1.90 (4H, m), 1.82 (2H, m), 1.49 (1H, m), 1.22 (2H,m), 1.03 (2H, m).  4.15 0.061 11.05 (1H, br s), 8.47 (1H, d), 7.82-7.73(3H, m), 5.20 (1H, br s), 4.89 (1H, br s), 3.70 (1H, m), 2.83 (2H, m),2.39 (2H, t), 1.92 (2H, m), 1.83 (2H, m), 1.59-1.46 (3H, m), 1.22 (2H,m), 1.00 (2H, m), 0.89 (3H, t,).  4.16 0.063 11.06 (1H, br s), 8.48 (1H,d), 7.82-7.73 (3H, m), 5.20 (1H, br s), 4.86 (1H, br s), 3.69 (1H, m),2.83 (2H, t), 2.76 (1H, m), 1.92 (2H, m), 1.83 (2H, m), 1.47 (1H, m),1.24 (2H, m), 1.15 (6H, d), 1.01 (2H, m).  4.21 0.076 8.50 (1H, d), 7.96(1H, d), 7.81 (1H, m), 7.72 (3H, m), 7.03 (1H, m), 6.88 (1H, m), 5.89(1H, t), 3.71 (1H, m), 2.90 (2H, t), 1.90 (4H, m), 1.50 (1H, m), 1.25(2H, m), 1.10 (2H, m).  4.33 0.050 8.50 (1H, d), 7.80 (1H, d), 7.72 (2H,d), 7.05 (2H, t), 6.55 (2H, d), 6.48 (1H, t), 5.58 (1H, m), 3.70 (1H,m), 2.86 (2H, t), 1.90 (4H, m), 1.50 (1H, m), 1.23 (2H, m), 1.07 (2H,m).  5.14 0.066 8.54 (1H, d), 8.38 (1H, d), 7.79 (1H, d), 7.18 (1H, t),3.70 (1H, m), 3.00 (2H, t), 2.47 (3H, s), 2.10 (3H, s), 1.97 (3H, s),1.90 (2H, m), 1.80 (2H, m), 1.50 (1H, m), 1.22 (2H, m), 1.03 (2H, m).  60.090 8.49 (1H, d), 7.81 (1H, d), 7.74 (2H, d), 7.30 (1H, t), 6.80 (1H,s), 6.39 (1H, s), 3.83 (2H, d), 3.79 (2H, t), 3.69 (1H, m), 3.40 (2H,t), 1.91 (2H, m), 1.73 (1H, m), 1.58 (2H, m), 1.21 (2H, m), 1.09 (2H,m).  7 0.022 See Example 7.0  8 0.047 11.08 (1H, br s), 8.47 (1H, d),7.82-7.73 (3H, m), 5.08 (1H, br s), 4.95 (1H, br s), 3.69 (1H, m), 2.80(2H, m), 1.92 (2H, m), 1.82 (2H, m), 1.72 (1H, m), 1.45 (1H, m), 1.23(2H, m), 1.02 (2H, m), 0.81 (2H, m), 0.58 (2H, m).  9 0.050 8.50 (1H,d), 7.81 (1H, m), 7.75 (2H, m), 7.04 (1H, q), 6.38 (1H, d), 6.30 (1H,m), 6.24 (1H, m), 5.98 (1H, m), 3.71 (1H, m), 2.86 (2H, t), 1.91 (4H,m), 1.50 (1H, m), 1.25 (2H, m), 1.08 (2H, m). 10 0.041 8.50 (1H, d),7.78 (4H, m), 7.59 (1H, s), 6.70 (1H, s), 5.79 (1H, t), 3.70 (1H, m),2.89 (2H, m), 2.18 (3H, s), 1.91 (4H, m), 1.51 (1H, m), 1.28 (2H, m),1.09 (2H, m). 11 0.174 12.99-12.68 (1H 2 × br s), 8.40 (1H, d), 7.77(2H, br m), 7.54-7.29 (6H, m), 6.56 (1H, s), 3.63 (1H, m), 3.52 (2H, m),2.15 (3H, s), 2.13 (2H, s), 1.88 (4H, m), 1.46 (1H, m), 1.30-1.21 (2H,m), 0.95-0.87 (2H, m). 12 0.137 8.34 (1H, d), 7.88 (1H, m), 7.80 (1H,m), 7.58 (1H, m), 7.49 (1H, m), 7.05 (2H, m), 6.55 (2H, d), 6.48 (1H,m), 5.58 (1H, t), 3.75 (1H, m), 2.86 (2H, t), 1.89 (4H, m), 1.52 (1H,m), 1.33 (2H, m), 1.07 (2H, m). 13 0.070 8.78 (1H, dd), 8.68 (1H, d),8.51 (1H, d), 8.17 (2H, m), 7.89 (1H, d), 7.71 (1H, m), 7.50 (1H, m),7.38 (1H, dd), 7.19 (1H, d), 6.54 (1H, d), 6.42 (1H, br t), 3.82 (1H,m), 3.10 (2H, t), 1.95 (4H, m), 1.76 (1H, m), 1.37 (2H, m), 1.15 (2H,m). 14 3.225 11.70 (1H, br), 8.50 (1H, d), 7.80 (1H, d), 7.75 (1H, d),7.70 (2H, t), 7.20 (2H, t), 5.75 (1H, br), 5.30 (1H, br), 4.00 (1H, br),2.95 (2H, t), 1.70 (3H, m), 1.55 (4H, m), 1.45 (2H, m). 14.1 2.205 8.51(1H, d), 8.01 (1H, d), 7.94 (1H, s), 7.82 (1H, dd), 7.76 (2H, m), 7.64(1H, d), 6.33 (1H, br t), 4.02 (1H, br m), 3.09 (2H, br t), 2.34 (3H,s), 1.76 (3H, m), 1.59 (4H, m), 1.47 (2H, m). 15^(a) 0.108 7.81 (1H, d),6.94 (1H, m), 6.90 (2H, m), 6.80 (2H, m), 6.72 (1H, m), 6.66 (2H, m),3.05 (1H, m), 2.82 (1H, m), 1.35 (2H, m), 1.10 (2H, m), 0.91 (1H, m),0.60 (4H, m), 0.49 (3H, d). 16^(b) 0.051 8.47 (1H, d), 7.82 (1H, d),7.73 (2H, m), 7.07 (2H, t), 6.56 (2H, d), 6.49 (1H, t), 5.55 (1H, m),3.93 (1H, m), 2.86 (2H, m), 2.23 (1H, m), 1.88 (1H, m), 1.78 (1H, m),1.70 (1H, m), 1.59 (2H, m), 1.31 (1H, m), 1.11 (1H, m), 0.92 (3H, d). 170.070 8.53 (1H, d), 8.39 (1H, d), 7.78 (1H, d), 3.83 (2H, d), 3.67 (1H,m), 2.47 (3H, s), 2.20 (3H, s), 2.09 (3H, s), 1.89 (2H, m), 1.73 (1H,m), 1.57 (2H, m), 1.16 (4H, m) 18 0.577 8.54 (1H, d), 8.39 (1H, d), 7.79(1H, d), 3.74 (2H, d), 3.67 (1H, m), 2.47 (3H, s), 2.10 (3H, s), 2.02(3H, s), 1.88 (2H, m), 1.83 (3H, m), 1.70 (1H, m), 1.57 (2H, m), 1.14(4H, m). 19.1 0.026 See Table 9 19.2 0.023 See Table 9 19.26 0.013 SeeTable 9 19.49 0.031 See Table 9 19.53 0.028 See Table 9 19.54 0.062 SeeTable 9 19.55 0.143 See Table 9 19.56 0.084 See Table 9 19.57 0.088 SeeTable 9 19.59 0.087 See Table 9 19.62 0.09 See Table 9 19.63 0.017 SeeTable 9 19.65 0.053 See Table 9 19.66 0.062 See Table 9 19.68 0.032 SeeTable 9 19.69 0.022 See Table 9 19.70 0.029 See Table 9 19.71 0.14 SeeTable 9 19.73 0.019 See Table 9 19.74 0.054 See Table 9 19.75 0.054 SeeTable 9 19.76 0.078 See Table 9 19.79 0.037 See Table 9 19.80 0.015 SeeTable 9 19.83 0.038 See Table 9 19.91 0.057 See Table 9 19.93 0.069 SeeTable 9 19.94 0.059 See Table 9 19.98 0.052 See Table 9 19.100 0.029 SeeTable 9 19.101 0.069 See Table 9 19.102 0.076 See Table 9 19.103 0.037See Table 9 19.104 0.08 See Table 9 19.107 0.118 See Table 9 19.1080.072 See Table 9 19.110 0.097 See Table 9 19.113 0.153 See Table 919.114 0.034 See Table 9 19.116 0.059 See Table 9 19.117 0.043 See Table9 21.1 0.114 See Table 11 21.2 0.338 See Table 11 21.4 0.299 See Table11 21.5 0.157 See Table 11 21.8 0.113 See Table 11 21.11 0.14 See Table11 22.3 0.234 See Table 12 22.4 0.35 See Table 12 22.7 0.187 See Table12 {circumflex over ( )}Data shown is for most active isomer (retentiontime = 10.48 min from SFC separation) in which the 1,4 substituents areequatorial and methyl substituent is axial.. ^(a)IC₅₀ for racemate; NMRspectrum recorded in d4-MeOH. ^(b)IC₅₀ for racemate; the two separatedenantiomers have a trans-1,4-diequatorial arrangement with the 2-methylsubstituent axial; IC₅₀ of each enantiomer is identical to racemate.

1. A compound of Formula XI;

in which R⁷ is hydrogen or alkyl C1 to 6; R⁸ is phenyl or a heteroaryl,each of which may be optionally substituted by one or more substituentsselected from the group alkyl C1 to 6, haloalkyl C1 to 6, halogen,alkoxy C1 to 6, nitrile and dialkyl amino C1 to 6 or two adjacentsubstituents may together form a saturated or unsaturated carbocyclic orheterocyclic ring; R¹⁸, R¹⁹ and R²⁰, which may be the same or different,are each hydrogen, alkyl C1 to 10, alkoxy C1 to 10, halogen, haloalkylC1 to 10, halogenated alkoxy, morpholinyl, or imidazolinyl, or phenyl orphenoxy that is optionally substituted by one or more substituentsselected from the group carboxy, alkyl C1 to 6, halogen and hydroxy; orR¹⁸ and R¹⁹ or R¹⁹ and R²⁰ may together form a saturated or unsaturatedcarbocyclic or heterocyclic ring; in free form or in salt form.
 2. Apharmaceutical composition comprising a compound of claim 1 in free formor in pharmaceutically acceptable salt form, in association with apharmaceutically acceptable adjuvant, diluent or carrier.
 3. Apharmaceutical composition comprising a compound of claim 1 in free formor in pharmaceutically acceptable salt form, in combination with anothertherapeutically active ingredient.
 4. The compound of claim 1, whereinR⁸ is disubstituted phenyl or disubstituted 3-pyridyl.
 5. The compoundof claim 1, wherein R⁸ is 2,5-disubstituted phenyl or 2,5-disubstituted3-pyridyl.
 6. The compound of claim 1, which is selected from the groupconsisting of:Trans-2-Chloro-N-[4-(3-methyl-5-trifluoromethyl-pyrazol-1-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;Trans-2-Chloro-N-[4-(5-methyl-3-trifluoromethyl-pyrazol-1-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;Trans-2-Chloro-N-[4-(3,5-di-(d3)-methyl-pyrazol-1-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;Trans-2-Chloro-N-[4-(5-methyl-pyrazol-1-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;Trans-2-Chloro-N-[4-(3-methyl-pyrazol-1-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;Trans-2-Chloro-N-{4-[5-(4-methoxy-phenyl)-pyrazol-1-ylmethyl]-cyclohexyl}-5-trifluoromethyl-benzamide;Trans-2-Chloro-N-{4-[3-(4-methoxy-phenyl)-pyrazol-1-ylmethyl]-cyclohexyl}-5-trifluoromethyl-benzamide;N-(4-((1H-indazol-1-yl)methyl)cyclohexyl)-2-chloro-5-(trifluoromethyl)benzamide2-Chloro-N-(4-indazol-2-ylmethyl-cyclohexyl)-5-trifluoromethyl-benzamide;N-[4-(3-Amino-4-chloro-indazol-1-ylmethyl)-cyclohexyl]-2-chloro-5-trifluoromethyl-Benzamide;2-Chloro-N-{4-[5-methyl-3-(2-oxo-imidazolidin-1-yl)-pyrazol-1-ylmethyl]-cyclohexyl}-5-trifluoromethyl-benzamide;2-Chloro-N-[4-(4-chloro-3,5-dimethyl-pyrazol-1-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;2-Chloro-5-trifluoromethyl-N-[4-(3,4,5-trimethyl-pyrazol-1-ylmethyl)-cyclohexyl]-benzamide;2-Chloro-5-trifluoromethyl-N-[4-(3-trifluoromethyl-pyrazol-1-ylmethyl)-cyclohexyl]-benzamide;5-Chloro-N-{4-[(1H-indazol-3-ylamino)-methyl]-cyclohexyl}-2-methyl-nicotinamide;2-Chloro-N-[4-(3-phenyl-pyrazol-1-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;5-Chloro-N-[4-(3,5-dimethyl-pyrazol-1-ylmethyl)-cyclohexyl]-2-methyl-nicotinamide;2-Chloro-N-[4-(4-phenyl-pyrazol-1-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;Trans-5-Chloro-2-methyl-N-[4-(3-methyl-5-trifluoromethyl-pyrazol-1-ylmethyl)-cyclohexyl]-nicotinamide;Trans-5-Chloro-2-methyl-N-[4-(5-methyl-3-trifluoromethyl-pyrazol-1-ylmethyl)-cyclohexyl]-nicotinamide;Trans-5-Chloro-N-[4-(4-chloro-3,5-dimethyl-pyrazol-1-ylmethyl)-cyclohexyl]-2-methyl-nicotinamide;Trans-5-Chloro-2-methyl-N-[4-(3,4,5-trimethyl-pyrazol-1-ylmethyl)-cyclohexyl]-nicotinamide;Trans-5-Chloro-2-methyl-N-[4-(3-methyl-5-trifluoromethyl-pyrazol-1-ylmethyl)-cyclohexyl]-nicotinamide;andTrans-5-Chloro-2-methyl-N-[4-(5-methyl-3-trifluoromethyl-pyrazol-1-ylmethyl)-cyclohexyl]-nicotinamide;or a pharmaceutically acceptable salt thereof.
 7. The compound of claim1, which is selected from the group consisting of:2-Chloro-5-trifluoromethyl-N-[4-(3,4,5-trimethyl-pyrazol-1-ylmethyl)-cyclohexyl]-benzamide;2-Chloro-5-trifluoromethyl-N-[4-(3-trifluoromethyl-pyrazol-1-ylmethyl)-cyclohexyl]-benzamide;2-Chloro-N-[4-(3-phenyl-pyrazol-1-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;5-Chloro-N-[4-(3,5-dimethyl-pyrazol-1-ylmethyl)-cyclohexyl]-2-methyl-nicotinamide;2-Chloro-N-[4-(4-phenyl-pyrazol-1-ylmethyl)-cyclohexyl]-5-trifluoromethyl-benzamide;Trans-5-Chloro-2-methyl-N-[4-(3-methyl-5-trifluoromethyl-pyrazol-1-ylmethyl)-cyclohexyl]-nicotinamide;andTrans-5-Chloro-2-methyl-N-[4-(5-methyl-3-trifluoromethyl-pyrazol-1-ylmethyl)-cyclohexyl]-nicotinamide;and the pharmaceutically acceptable salts thereof.
 8. A pharmaceuticalcomposition comprising a compound of claim 6 in free form or inpharmaceutically acceptable salt form, in combination with anothertherapeutically active ingredient.
 9. A pharmaceutical compositioncomprising a compound of claim 7 in free form or in pharmaceuticallyacceptable salt form, in combination with another therapeutically activeingredient.
 10. The compound of claim 1, wherein R⁷ is H.
 11. Thecompound of claim 4, wherein the substituents for R⁸ are selected fromhalo, haloalkyl 1-10, alkyl C1-6, alkoxy C1-6, trifluoroalkoxy C1-6 anddimethylamino.